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Chapter 1
GENERAL INTRODUCTION
A historical perspective
Already in 200 AD, the famous doctor Claudius 
Galenus from Pergamon (131-201 AD) was the 
first to describe the heart and arteries1. It was 
only in 1628, almost 1500 years later, that the 
circulation of blood was described by William 
Harvey2. It was Leonardo da Vinci however 
with his comprehensive approach who first 
described arteriosclerosis (or atherosclerosis, 
which was the same at that time).  He observed 
that ‘vessels in the elderly restrict the transit 
of blood through thickening of the tunics’3. 
His study consisted of three separate fields of 
research. First of all, he conducted a study of 
hydrodynamics, studying the flow of fluids in an 
experimental setup (shear stress and laminar 
flow). Secondly, he observed the effects of 
age on anatomical structures, in particular 
on blood vessels. Thirdly, he described the 
concept of exercise and nutrition influencing 
the process of thickening of the arterial wall. Figure 1 shows the results of his anatomical 
study, comparing the straightness of the vessels in the young and the tortuosity and thicker 
coats of the vessels in the elderly. He comments that ‘Vessels which by the thickening of their 
coats in the old restrict the transit of the blood, and from this lack of nourishment the old, 
little by little with a slow death destroy their life without any fever; and this happens through 
the lack of exercise since the blood is not warmed’ and ‘The walls of these tortuous blood 
vessels are nourished by the vital humour, the blood which they contain; forming as it were 
the sheath of that moving warm blood they obtain an undue proportion of the nutriment 
contained in the blood. It is this disproportionate nutrition, prolonged over many years, 
that eventually leads to the undue growth in thickness of the walls’4. Interestingly, several 
hundred years later, we are still studying the same topics in the field of cardiovascular disease. 
Figure 1: Leonardo da Vinci depicts the contrast 
between straightness of vessels in the young 
and their tortuosity in the old
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Cardiovascular disease
Cardiovascular diseases (CVD) are the leading cause of mortality worldwide, causing 17 
million deaths per year5. The main underlying pathological process of CVD is atherosclerosis, 
a chronic inflammatory disorder of the arterial vessel wall, which can ultimately result in 
vascular occlusion and subsequent myocardial infarction or stroke. Although previously 
considered a passive cholesterol storage disease of the arterial wall, vascular inflammation is 
now recognized as the major driver of initiation, progression and rupture of the atherosclerotic 
plaque6. Studies in animal models of atherosclerosis, and novel imaging techniques that can 
be used in humans in vivo, such as 18FluoroDeoxyGlucose-Positron Emission Tomography 
(18FDG-PET) scanning have revealed that chronic low-grade inflammation of the arterial 
wall is an important mechanism contributing to the development of atherosclerosis7. 
Currently, large clinical trials are being performed in patients at risk for CVD with anti-
inflammatory agents, including the interleukin-1-receptor antagonist anakinra, the antibody 
against IL-1b canakinumab, and methotrexate6. However, these drugs are inhibiting 
immune pathways rather broadly and can have serious side effects. Therefore, a better 
understanding of the inflammatory mechanisms in atherosclerosis is needed to identify 
novel drug targets that can be used in the prevention and treatment of atherosclerosis. 
The role of monocytes and macrophages in atherosclerosis 
Atherosclerotic plaque formation is initiated by the accumulation of apoB-100 containing 
lipoproteins within the arterial wall. This occurs mainly at those points where the laminar 
flow is disturbed (da Vinci’s first study), which impairs endothelial function and increases 
endothelial permeability for lipoproteins8. These lipoproteins are susceptible to oxidation 
or other modifications in the intimal layer, which also contributes to further activation of 
the overlying endothelium, resulting in an upregulation of adhesion molecules and the 
secretion of chemokines. Subsequently, the intimal layer is infiltrated with various immune 
cells, including monocytes. A pivotal role for monocytes in the initiation of atherosclerosis 
was demonstrated by the observation that atherosclerosis development is reduced in animal 
models by prevention of monocyte entry into the vascular wall9. Once in the intimal layer, 
monocytes mature into macrophages, which promote the development of atherosclerosis 
by several mechanisms (Figure 2). Firstly, macrophages become cholesterol-laden foam 
cells by taking up modified lipoproteins via scavenger receptors. This mechanism has been 
described as a double-edged sword, since initially, clearance of cholesterol by macrophages 
can be viewed as beneficial, cleaning the vessel wall from the overload of lipids. However, 
cholesterol-laden macrophages lose their ability to emigrate out of the plaque, and 
accumulate. Eventually, foam cells die and contribute to the formation of a necrotic core, 
which is a key component of advanced plaques6,10. Secondly, macrophages produce various 
12
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pro-inflammatory cytokines and chemokines in response to pro-inflammatory stimuli in the 
plaque. Modified LDL particles (such as oxidized LDL) can act as Damage Associated Molecular 
Patters (DAMPs), recognized by membrane-bound and intracellular Pattern Recognition 
Receptors (PRRs) on monocytes and macrophages11. For example, oxLDL stimulates secretion 
of interleukin-6 (IL-6), IL-8, monocyte chemo-attractant protein-1 (MCP-1) and tumor necrosis 
factor-α (TNFα) by signaling through CD36, Toll-like Receptor (TLR) 2, -TLR4 and/or TLR6 
pathways12–14. Moreover, intracellular and extracellular cholesterol crystals can activate the 
NLRP3 inflammasome, thereby inducing processing and release of interleukin-1β14. Thirdly, 
macrophages can contribute to destabilization of plaques by the production of many proteases, 
including various matrix metalloproteinases (MMP). By all these mechanisms, macrophages 
contribute to the initiation, progression and destabilization of atherosclerotic plaques15. 
Although the role of monocytes and macrophages in atherosclerosis is well established, it 
is still unknown why the strong inflammatory response in the arterial wall persists and fails 
to resolve. In this thesis I propose that ‘training’ of monocytes can result in a long-term 
pro-inflammatory phenotype, which contributes to the persistent pro-inflammatory state. 
Trained immunity
Recently, the traditional view on the division between the innate and adaptive immune 
system has changed, as cells of the innate immune system also appeared to possess adaptive 
characteristics16. Plants and invertebrate species, which lack adaptive immunity, are able to 
build up an immunological memory and protection against reinfection, suggesting a memory 
function for innate immunity17,18. Recent studies have shown that also in vertebrates, 
innate immune cells display persistent adaptive characteristics leading to a non-specific 
Monocytes
MØoxLDL
LDL
chemokines
Foam cells
Apoptotic
MØ
Crystals
Thrombus
formation
platelets
INITIATION PROGRESSION RUPTURE
Figure 2: the role of monocytes and macrophages in the different stages of atherosclerosis  
(Adapted from Clinical Therapeutics Vol 37(4), Bekkering et al. ‘The epigenetic memory of mono-
cytes and macrophages as a novel drug target in atherosclerosis’, 2014, 914-923, with permission 
from Elsevier)
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immunological memory, which has been termed ‘trained innate immunity’16. A recent 
series of experiments demonstrated the existence of trained innate immunity in rodents 
and humans and provided insight into the underlying molecular and cellular mechanism. In 
isolated human monocytes, brief exposure to various microbial products, including Bacille-
Calmette Guérin (BCG) vaccine, Candida albicans, or its cell-wall component β-glucan induces 
a long-lasting pro-inflammatory macrophage phenotype that is characterized by increased 
production of cytokines and chemokines upon TLR stimulation six days after the initial 
exposure (Figure 3)19,20. Also in healthy humans, BCG-vaccination induces an augmented 
production of pro-inflammatory cytokines (e.g. TNFα and IL-6) when monocytes were 
subsequently exposed to M. tuberculosis ex vivo, but also to various unrelated microbial 
products20. This enhanced pro-inflammatory phenotype of the monocyte can be detected 
even three months after BCG vaccination. The powerful immunological effects of this 
phenomenon are illustrated by the findings that in mice that lack T and B lymphocytes, BCG 
vaccination provides robust protection against a subsequent lethal dose of Candida albicans20. 
It is likely that trained immunity evolved as a primitive form of immune memory, aimed 
to provide additional protection of the host against reinfection, with increased survival, 
especially in the newborn, who lack adaptive immunity. However, there may also be a 
Figure 3: Trained immunity, a schematic overview ©Siroon Bekkering
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dark side to the reprogramming of innate immunity, in which increased inflammatory 
responses towards exogenous or endogenous stimuli could have deleterious effects, 
such as atherosclerosis. Long-term activation of monocytes by exogenous or endogenous 
triggers could lead to an enhanced immune activation, which can accelerate the process 
of atherosclerosis. In patients with chronic inflammatory diseases, such as rheumatoid 
arthritis, there is an increased risk for the development of atherosclerosis, indicating that 
chronic systemic inflammation may accelerate the process of atherosclerosis. The present 
thesis is focused on the potential pro-atherosclerotic effects of trained innate immunity. 
Since several microorganisms and microbial products have been shown to induce trained 
immunity, this phenomenon might explain the potential association between infections and 
atherosclerosis that has been reported in the literature. A variety of microorganisms have 
been linked to an increased risk of cardiovascular disease, carotid plaque thickness and stroke, 
including C. pneumoniae, H. pylori, cytomegalovirus and herpes simplex virus21–23. However, the 
strength of these data associating pathogens with atherosclerosis varies considerably and up 
till now, the mechanism underlying this association is unclear24. In theory, training of monocytes 
by these microorganisms could be an underlying mechanism linking infection to atherogenesis. 
However, it is important to realize that induction of trained immunity does not have 
to be restricted to microbial products. As described earlier, oxLDL and cholesterol 
crystals are able to induce an inflammatory response in monocytes by stimulation of 
various PRRs. Another endogenous compound that is associated with atherosclerosis 
and with systemic inflammation, is lipoprotein (a). We propose that these 
endogenous pro-atherogenic compounds can also induce trained innate immunity. 
Lipoprotein(a)
In the general population, approximately 20% of the people have elevated 
circulating levels of lipoprotein(a) [Lp(a)]. Lp(a) is a plasma lipoprotein composed 
of an LDL particle with an apolipoprotein(a) [apo(a)] moiety covalently bound to 
oxPL
apoB
neutral 
lipids
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1 2 3 4 5 6 7 8 9 10 VIV P
oxPL
IV IV IV IV IV IV IV IV IV
3 to >40
repeats
apo(a)
LBS
Figure 4: Lipoprotein(a) 
consists of an apoB parti-
cle covalently bound to an 
apo(a) particle
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apolipoprotein B-100 (apoB) (Figure 4). Epidemiological studies, including genome-
wide association and Mendelian randomization studies show a strong, independent 
and likely causal relationship between levels of Lp(a) and the occurrence of myocardial 
infarction, stroke, peripheral artery disease and calcific aortic valve stenosis25,26. 
Over the last decade, a large body of in vitro and in vivo evidence has shown that Lp(a) 
is the main carrier of phosphocholine (PC)-containing oxidized phospholipids (OxPL) in 
plasma. This has led to the hypothesis that a major component of the risk mediated by Lp(a) 
is through its content of OxPL. OxPL is recognized as a DAMP by PRRs on innate immune 
cells, similar to oxLDL, leading to a wide range of pro-inflammatory and plaque destabilizing 
processes. Here we further studied the link between Lp(a), its oxPLs and inflammation 
by studying the induction of trained innate immunity by Lp(a) in vivo and in vitro.
Mechanisms of trained immunity
The key mechanisms underlying the phenotype of trained innate immunity are a shift in the 
intracellular metabolism from oxidative phosphorylation towards an increased aerobic glycolysis 
(ie. the Warburg effect) and epigenetic reprogramming at the level of histone methylation27. 
Epigenetic regulation comprises the control of gene expression without altering the DNA 
sequence itself, by posttranslational modifications of the DNA (DNA methylation), of histones, 
or by non-coding RNA. In general, DNA hypermethylation is associated with transcriptional 
silencing of genes, whereas DNA hypomethylation is associated with transcriptional 
activation28. Modifications of histones can either activate or repress gene transcription. 
Histone modifications can directly alter the chromatin structure, thereby facilitating or 
inhibiting the binding of transcription factors. In general, acetylation of histones neutralizes 
the positive charge of the involved lysine-residues, which weakens the association between 
the DNA and the histones, facilitating binding of transcriptional factors and stimulating 
transcriptional activation29. Histone methylation can either lead to transcriptional activation 
or repression, depending on the specific lysine residue that is modified and the amount 
of methyl-groups that is added. For example, monomethylation or trimethylation of lysine 
4 at histone 3 (H3K4Me1/3) leads to transcriptional activation, whereas H3K9me3 and 
H3K27Me3 are associated with gene silencing30 (Figure 5). The different histone modifications 
can influence each other and can also modulate DNA methylation, in part through the 
activities of protein complexes that bind modified histones or methylated cytosine residues31. 
Chromatin immunoprecipitation studies revealed that the trained monocyte is characterized 
by a global increase in H3K27Ac and H3K4me3, mainly on the promoter region of genes 
involved in immune defense, signaling, and metabolism, and by an increase of H3K4me1 
16
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on enhancer regions32. The pro-inflammatory phenotype of b-glucan-trained cells was 
prevented in vitro by co-administration of the nonspecific histone methyltransferase 
inhibitor methylthioadenosine, suggesting that the increase in histone methylation 
is responsible for the observe change in phenotype19. The kinetics of the epigenetic 
process leading to this increased functional state of the monocyte and macrophages 
were recently described by another group33. In terminally differentiated cells, Ostuni 
et al. demonstrated the presence of several regions of the genome that are unbound by 
transcription factors and lack the histone marks characteristic of enhancers but acquire 
these features in response to stimulation, which they named ‘latent enhancers’ 33. 
Another key mechanism involved in the development of trained immunity is cellular 
metabolism of innate immune cells. The metabolic state of immune cells is a topic of high 
interest in the past few years34,35. It has now been established for various cells of the immune 
system, such as T-cells or macrophages, that the immunological phenotype is determined by 
the cellular metabolism. Resting immune cells are mainly relying on the TCA cycle and OXPHOS 
for energy generation35. Upon activation, both T-cells and M1 macrophages immediately 
Figure 5: Chromatin modifications: Several histone marks can lead to either opening of the chro-
matin (euchromatin) or closing of the chromatin (heterochromatin). Histone acetylation by histone 
acetyltransferases always leads to opening of the chromatin, whereas for histone methylation, the 
location and amount of methylgroups direct opening or closing of the chromatin. Several enzymes 
are known for adding or removing acetyl and methylgroups to the histone tails.  © Siroon Bekkering
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switch to aerobic glycolysis, a phenomenon called the ‘Warburg effect’, which was first 
observed in cancer cells. M2 macrophages however, still rely on the OXPHOS upon activation36. 
Recent studies from our laboratory have reported that a similar metabolic shift occurs in the 
context of trained immunity. In trained immunity, (microbial) triggers induce a metabolic shift 
from oxidative phosphorylation to aerobic glycolysis via activation of the mammalian target of 
rapamycin (mTOR) and its effector hypoxia-inducible factor HIF1α27. Pharmacological blockade 
of glycolysis completely prevents trained immunity, suggesting that the shift to glycoysis plays 
a crucial role in the induction of epigenetic reprogramming of the monocyte. The link between 
this metabolic shift and epigenetic reprogramming is most likely explained by the fact that 
many intermediate metabolites function as essential cofactors for epigenetic enzymes27. 
18
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AIM AND OUTLINE OF THIS THESIS
The aim of this thesis was to investigate whether trained innate immunity can also 
be induced by endogenous pro-atherogenic substances, such as oxLDL and lp(a), and 
whether this mechanism plays a role in the process of atherosclerosis (Figure 6). In 
Chapter 2, the hypothesis that trained immunity contributes to the development 
of atherosclerosis and the potential underlying mechanisms are discussed in depth. 
Trained immunity in atherosclerosis in vitro
In Chapter 3, an in vitro model of trained immunity is explored, studying the temporal 
characteristics and kinetics of trained immunity in the laboratory. We exposed isolated 
monocytes from healthy subjects to different stimuli, including β-glucan, BCG and 
oxLDL and characterized the trained immunity phenotype by measuring ex vivo 
cytokine production, ROS production and lactate production as a measurement of 
glycolysis. We investigated the effect of different training duration and resting times on 
the trained immunity phenotype. In Chapter 4, the induction of trained immunity by 
oxidized LDL is explored, studying the effects of brief exposure to a low dose of oxLDL on 
cytokine production, RNA expression, epigenetic remodeling and foam cell formation. 
Also, the intracellular pathways of oxLDL induced trained immunity were explored. 
Trained immunity in atherosclerosis in vivo
In Chapter 5, we studied whether lipoprotein(a) [lp(a)] also induces trained immunity, 
both in vitro as well as in patients with elevated levels of lp(a). In these patients, we 
characterized the phenotype of circulating monocytes, and this was correlated with vascular 
wall inflammation, that was quantified by use of sophisticating imaging modalities.  In 
Chapter 6, we performed a first proof-of-concept study on trained immunity in patients 
with established atherosclerosis. We isolated monocytes to investigate the trained immune 
phenotype in patients with severe symptomatic coronary atherosclerosis and matched 
controls. Furthermore, we explored RNA expression levels of inflammatory mediators and 
intracellular signaling pathways involved in metabolism, and we explored the epigenetic 
landscape of the cytokine TNFα in detail for activating and repressing histone marks. 
Pathways of trained innate immunity
In Chapter 7, we explored the role of the cholesterol synthesis pathway in trained 
immunity. By using statins and other specific pharmacological inhibitors, we unraveled 
a role for mevalonate in the induction of trained immunity, for both b-glucan training as 
well as oxLDL training. Furthermore, we studied monocytes from patients with a defective 
19
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cholesterol synthesis pathway, which accumulate mevalonate. Monocytes from these 
patients showed a trained immunity phenotype by increased cytokine response upon 
stimulation and an increased expression of genes in the glycolysis and mTOR pathway.
In Chapter 8, we integrate the insights we have gained into the role of trained immunity 
in the context of atherosclerosis, and speculate on the potential clinical relevance 
of this mechanism for the diagnosis and treatment of patients with (risk factors 
for) atherosclerosis. Moreover, we propose a hypothesis of diet-induced trained 
immunity as one of the mechanisms of chronic inflammation in atherosclerosis.
Trained
Immunity
Lipoprotein(a)
Oxidized LDL
ATHEROSCLEROSIS
Statins
Chapter 4
Chapter 5
Chapter 7
Chapter 6
Chapter 2,3 & 8
Figure 6: Schematic overview of the thesis
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ABSTRACT
Purpose of the review
Monocytes/macrophages play a decisive role in the development and progression of 
atherosclerosis. It is currently unknown what stimuli initiate and orchestrate the activation 
of these cells in atherogenesis. In this review, we postulate that the novel concept of ‘trained
immunity’ modulates the development and progression of atherosclerosis. 
Recent findings
Recently, results from our laboratory challenged the current paradigm that innate immunity 
is static and does not have an immunological memory. Stimulation by various microbial 
products, including Candida albicans and bacille Calmette-Guérin, appeared to bring 
monocytes into a long-term enhanced functional state, showing a stronger pro-inflammatory 
response to a second stimulus. This ‘trained immunity’ was mediated by increased and stable 
histone methylation. 
Summary
We describe the hypothesis that this functional reprogramming of monocytes, either by 
microbial products or by metabolic products, contributes to atherogenesis and propose 
epigenetic reprogramming of monocytes as a novel pharmacological target for preventing or 
treating atherosclerosis in the future. 
25
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INTRODUCTION
Cardiovascular diseases (CVD) are the leading cause of mortality worldwide, causing 
17 million deaths per year [1]. The main underlying pathological process of CVD is 
atherosclerosis, a chronic disorder of the arterial wall, which can ultimately result in vascular 
occlusion and subsequent myocardial infarction or stroke. Over the past decades, the view 
on the pathogenesis of atherosclerosis has changed from predominantly being a lipid storage 
disease to a chronic inflammatory disease of the vascular wall [2]. Atherosclerotic plaques 
are characterized by an accumulation of lipids and an infiltration with various immune cells, 
macrophages being the most numerous [2]. Recently, it has been reported by our laboratory 
that monocytes/macrophages can build up a long-term memory after microbial stimulation 
via epigenetic reprogramming; this mechanism was termed ‘trained immunity’ [3-5]. In 
the current review, we postulate that trained immunity contributes to atherogenesis and 
describe potential novel therapeutic targets to prevent or treat atherosclerosis based on this 
concept.
The role of monocytes in the pathogenesis of atherosclerosis
therosclerotic inflammation is initiated by accumulation of apolipoprotein B (ApoB) containing 
lipoproteins, including LDL, in the intimal layer at sites of reduced shear stress. Upon enzymatic 
oxidative modification, LDL particles activate the endothelium to express more adhesion 
molecules and enhance the production of chemo-attractants, thereby recruiting monocytes 
[6]. Prevention of monocyte entry by blocking either chemokines or their receptors prevents 
or retards atherogenesis in mouse models [7-9], indicating a pivotal role for monocytes in the 
early development of atherosclerosis. In the intimal layer, the monocytes differentiate into 
macrophages, a process driven by endothelium-derived macrophage colony-stimulating factor 
(M-CSF) [10]. Macrophages in the intimal layer subsequently engulf oxidized LDL particles 
(oxLDL) through scavenger receptors, notably the CD36 and Scavenger Receptor-A (SR-A) and 
accumulate lipid droplets in the cytoplasm to become “foam cells”; the latter cells play a 
central role in the formation of the atherosclerotic plaque [11]. In addition, inflammatory 
activation of lesional macrophages can occur via membrane-bound and intracellular pattern 
recognition receptors (PRRs), which are expressed in macrophages as well as in vascular cells 
[12]. Using gene deficient mice, a pro-atherosclerotic role was found for MyD88, a key adaptor 
protein in the signaling pathways of most Toll-Like Receptors (TLRs) [13] and of interleukin 
(IL)-1β and IL-18, two pro-atherosclerotic cytokines [14]. By binding to membrane-bound 
CD36 and TLR4/6 on macrophages, oxLDL induces cytokine and chemokine production via 
NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells) activation [15]. In 
addition, modified LDL can induce a pro-inflammatory response in macrophages through 
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TLR2 and TLR4 [16]. Furthermore, not only extracellular, but also intracellular PRRs are 
known to be involved in atherosclerotic inflammation. Minute cholesterol crystals have been 
reported to induce inflammation in macrophages by stimulating the caspase-1-activating 
NLRP3 (NACHT, LRR and PYD domains-containing protein 3) inflammasome with subsequent 
IL-1β and IL-18 activation [17]. In advanced atherosclerotic lesions, macrophages contribute 
to changes in plaque morphology, including formation of a necrotic core and thinning of the 
overlying fibrous cap, ultimately leading to ‘vulnerable plaques’, which are prone for rupture 
[18]. For a more detailed overview of the role of monocytes/macrophages in the process of 
atherosclerosis, we refer to recent excellent reviews on this topic [2, 18, 19]. 
The concept of ‘Trained immunity’
Recently, the classic dichotomy that only adaptive immune cells and not innate immune 
cells have an immunological memory was challenged [3]. It has long been known that plants 
and invertebrates, which lack adaptive immunity, are able to build up an immunological 
memory through chromatin modification in cells of their innate immune system [20]. Already 
many years ago, bacille Calmette- Guérin (BCG) vaccine was shown to protect mice not only 
against mycobacteria but also against unrelated pathogens [21, 22]. Along the same line, 
BCG vaccination in children in West Africa was found to decrease morbidity due to infections 
other than tuberculosis [3, 23]. Based on these observations, a memory for cells of the innate 
immune system was suspected, and this has been termed as ‘trained immunity’[3]. In a 
series of recent experiments, we were able to provide a solid basis for the concept of trained 
immunity, as our group demonstrated it in vivo in animals lacking T and B lymphocytes, and 
in humans, as well as in vitro with isolated monocytes [4, 5].
In healthy humans, BCG vaccination induces an augmented monocyte production of pro-
inflammatory cytokines, such as TNFα and IL-6, when exposed to unrelated microbial products 
[4]. This enhanced pro-inflammatory state of monocytes could be detected even beyond 
6 months after vaccination. In mice that are genetically deficient of T- and B-lymphocytes, 
BCG vaccination was able to protect mice against disseminated candidiasis upon reinfection, 
indicating a memory independent of the adaptive arm of the immune system. In addition 
to BCG, ‘trained immunity’ also can be induced by Candida albicans: Quintin et al. showed 
that infection with C. albicans induced a similar reprogramming of monocytes as seen with 
BCG vaccination, resulting in an enhanced cytokine production in vivo and in vitro upon 
re-stimulation with various agents (e.g. TLR2 and TLR4 agonists or unrelated bacterial 
components) [5].
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In these studies, it has also been demonstrated that trained immunity induced by either 
BCG, C. albicans or the fungal cell wall component β-glucan, is mediated via epigenetic 
reprogramming.  Epigenetic regulation refers to the modification of chromatin, resulting 
in differential regulation of gene expression, but without modification of the nucleotide 
sequence of the DNA itself [24]. Currently, there are three different epigenetic modifications 
known: DNA-based modifications, e.g. DNA methylation or hydroxymethylation, which 
silences the gene transcription; RNA-based modifications, which can either repress or activate 
gene transcription and thirdly, posttranslational modifications of histones [25-27]. In the cell 
nucleus, the DNA is wrapped around an octamer of histones: 2 dimers of Histone 2A (H2A) 
and Histone 2B (H2B) and 2 dimers of H3 and H4 [28]. These histones are the primary protein 
content of the chromatin, packaging and ordering the DNA into nucleosomes. They can 
undergo posttranslational modification on the N-terminal tails (“epigenetic modification”), 
by methylation, acetylation and phosphorylation. Modification alters their interaction with 
the DNA and thereby facilitates or represses DNA transcription, depending on the type of 
modification [29]. Acetylation is often associated with transcriptional activation, but histone 
methylation is either repressing or activating, depending on the methylation residue and 
the amount of methyl-groups added, e.g. mono-, di- or tri-methylation [25]. For instance, 
H3K27 trimethylation is a repressive mark, whereas H3K4 mono- or trimethylation is a 
transcriptionally activating mark. 
The pro-inflammatory phenotype of monocytes in BCG vaccinated subjects was shown to be 
associated with an increased trimethylation on histone 3 at lysine 4 (H3K4me3), that is linked 
with enhanced mRNA transcription [29]. Similarly, monocyte training by C. albicans induced 
a genome-wide H3K4 trimethylation profile, suggesting involvement of the chromatin 
modifications as substrate for trained immunity, similarly to the innate memory described in 
plants [20]. Upon C. albicans or β-glucan training, more than 5000 genes displayed increased 
trimethylation at the H3K4 and these genes could be clustered mainly into genes involved 
in immune defense, such as cytokines, C-type lectin receptors and TLRs. Interestingly, also 
structural, metabolic and signaling pathway genes had upregulated H3K4me3. 
Can trained immunity contribute to atherogenesis?
Monocytes/macrophages play a central role in the development of atherosclerosis. As 
microbial products can induce long-lasting epigenetic reprogramming of monocytes, 
leading to an augmented pro-inflammatory response, it is logical to hypothesize that 
these mechanisms may be relevant for atherogenesis. Stimulation of long-term activated 
macrophages by inflammatory stimuli within the vascular wall, including agonists of TLR2 and
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TLR4, might result in an exaggerated inflammatory response, thereby promoting the induction 
or amplification of atherosclerosis (Fig. 1).
It has been previously described that epigenetic modifications can be long-lasting after an 
experimental model of infection in mice [30] or after BCG vaccination in humans [4]. Indeed, 
BCG vaccination exerts a nonspecific protection against infections throughout childhood [31]. 
If the epigenetic reprogramming of monocytes appears to be long-lived and play a role in 
atherosclerosis, we might have to redesign therapeutics. What is the available evidence to 
support our hypothesis? 
Already in 1999, BCG vaccination has been associated with an exaggerated atherosclerosis. 
Lamb et al. reported that administration of BCG in rabbits fed a cholesterol-enriched 
diet augments adherence of mononuclear cells to aorta endothelium [32], attenuates 
endothelium-dependent vasodilation [33], increases aortic intima/media thickness, and 
increases aortic atherosclerotic lesion formation [34]. Also, increased peripheral lymphocyte 
and monocyte activation was shown by enhanced CD11b and CD25 expression [32]. At that 
time, these observations were suggested to be due to BCG-induced antibodies against heat-
Figure 1: Schematic representation of the concept that epigenetic reprogramming of monocytes/
macrophages is involved in the initiation or progression of atherosclerosis. Initial stimulation of 
monocytes by microorganisms or alternative stimuli induces a long-term activated phenotype 
via epigenetic reprogramming. This phenotype facilitates monocyte recruitment and subsequent 
atherogenesis. EC, endothelial cell; M-CSF, monocyte-colony stimulating factor; Mo, monocytes
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shock protein 65, which can also target vascular HSP-60, thus leading to vascular injury [32-
34]. Obviously, a role for the adaptive immune system (like antibody formation) cannot be 
excluded in these experiments, but it is tempting to primarily explain the findings by BCG-
induced epigenetic reprogramming of monocytes. In addition, Cinemre et al. reported a 
positive association between the titer of anti-Saccharomyces cerevisiae antibodies (ASCA), 
which can be induced by C. albicans [35] and the occurrence of an acute myocardial infarction 
[36]. Furthermore, Nagi-Miura et al. described the induction of lethal and severe coronary 
arteritis by a pathogen-associated molecular pattern (PAMP) produced by C. albicans [37]. 
Here too, the exquisite ability of Candida components to induce a trained state of monocytes 
could well explain these observations. 
In addition to the above-mentioned data, trained immunity might explain the association 
between infections and atherosclerosis that have been reported in the literature. A variety of 
microorganisms have been linked to an increased risk of cardiovascular disease [38]. Although 
surrounded by quite some controversy, many studies suggest that C. pneumoniae promotes 
atherogenesis: upon exposure to C. pneumoniae, isolated endothelial cells demonstrate 
an enhanced expression of adhesion molecules [39]; C. pneumoniae stimulates cytokine 
production by monocytes [40] and induces foam cell formation [41], and C. pneumoniae 
induces human vascular smooth muscle cells to proliferate and release prototypical 
atherogenic cytokines [42]. In rabbits and mice, infection with C. pneumoniae can initiate 
atherosclerosis [43]. These preclinical findings have been supported by observational studies 
in humans, which report an association between the burden of prior infections (including 
C. pneumoniae, H. pylori, cytomegalovirus, and herpes simplex viruses) and carotid plaque 
thickness, cardiovascular events, and stroke [44-46]. However, the strength of these data 
associating pathogens with atherosclerosis varies considerably and up till now, the mechanism 
underlying this association is unclear [47]. Theoretically, training of monocytes by these 
microorganisms could be an underlying mechanism linking infection to atherogenesis. To 
take this one step further, the trained immunity concept does not require that the causative 
agent remains present in the host. Some organisms might reprogram the monocyte by a hit-
and-run mechanism. 
It is also important to realize that induction of trained immunity does not have to be restricted 
to microbial products. As described earlier, oxLDL and cholesterol crystals are able to induce 
an inflammatory response in monocytes by stimulation of various PRRs, and therefore they 
might also have the potential to epigenetically reprogram monocytes.
Interestingly, in the past decade, several epigenetic marks such as DNA methylation and 
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histone acetylation have been associated with atherosclerosis [25, 48]. DNA methylation 
is by far the most studied phenomenon and global DNA hypermethylation has been 
reported in atherosclerotic patients [49-51]. However, this would result in decreased gene 
transcription and could not explain the primed status of a trained immune cell. Furthermore, 
histone modifications, in particular histone acetylation, have only been studied in vascular 
smooth muscle cells and endothelial cells in the context of atherosclerosis. N’Guessan et al. 
showed that oxLDL increased global H4 acetylation in isolated endothelial cells resulting in 
upregulated interleukin-8 and Monocyte Chemoattractant Protein-1 production [52]. Live C. 
pneumoniae also induced H4 acetylation in isolated ECs in vitro resulting in upregulation of 
cytokine production [53]. Furthermore, the transcription of the nitric oxicde synthase (NOS)3 
gene, encoding eNOS, is activated in endothelial cells and repressed in vascular smooth 
muscle cells via several epigenetic marks [54]. Environmental stimuli such as hypoxia [55] or 
reduced shear stress [56, 57] reduce the acetylation but also H3K4 methylation on this gene 
in endothelial cells, underlining the importance of histone modifications in the environmental 
risk factors for cardiovascular disease. 
New therapeutic approaches
Epigenetic modifications are known to act as mediators between the environment and 
the genome, leading to modification of gene transcription. Since these are dynamic and 
reversible changes, they become interesting targets for new therapeutics [58-60]. Histone 
methylation processes can be divided into arginine methylation and lysine methylation, as 
well as in mono-, di- and tri-methylation. Interfering with this complex balance might be 
difficult, since the various forms of methylation differ in their effects on transcriptional 
activity. Only recent efforts have begun to focus on the pharmacological modulation of 
specific histone methyltransferases and demethylases and current knowledge is reviewed in 
[61]. The concept that pharmacological modulation of histone modifications can affect the 
process of atherosclerosis has been tested in murine models of atherosclerosis: the histone 
deacetylase (HDAC) inhibitor trichostatin A appeared to exacerbate atherosclerosis in LDL 
receptor -/- mice [62]. 
Since it is well known that epigenetic changes contribute to the development of cancer 
[63], it is not surprising that various small molecules that reverse epigenetic (in)activation 
are already undergoing clinical trials. Promising histone methyltransferase inhibitors studied 
are S-adenosylmethionine (SAMe) and its metabolite methyl thioadenosine. The latter 
reduced inflammation-induced colonic cancer and inhibited several pathways important 
in carcinogenesis [64]. Histone methylation is also known to be involved in immunological 
responses, as it regulates antigen-driven T-cell response and genes important in survival, 
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proliferation and differentiation [65, 66]. Inhibition of histone methylation by DZNep was 
shown to arrest ongoing graft-versus-host disease (GVHD) in mice after allogenic bone 
marrow transplantation. Besides DZNep, BIX-01294 is also known to be a specific inhibitor of 
lysine methyltransferases [67]. 
Conclusion
In conclusion, the studies summarized above demonstrate that epigenetic changes at the 
histone level are amenable to pharmacological modulation. Further elucidation of the role of 
epigenetic reprogramming of monocytes in atherogenesis is likely to provide novel targets to 
combat the development and progression of atherosclerosis.
Considering the breadth of evidence in the literature linking epigenetic reprogramming of 
innate immune cells with long-term inflammatory profiles on the one hand, and inflammation 
and epigenetic changes with atherosclerosis on the other hand, it is rational to hypothesize 
that the concept of trained immunity has an important role in atherosclerosis. This concept 
could explain some of the current controversies concerning the variable association of 
pathogens with atherosclerosis. Studying the role of trained immunity in atherosclerosis 
might give insight in the disease mechanism and has great potential to reveal new drug 
targets. 
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PART I 
TRAINED IMMUNITY AND 
ATHEROSCLEROSIS IN VITRO
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ABSTRACT
Background
Innate immune memory or ‘trained immunity’ has been recently described as an important 
property of cells of the innate immune system. Due to the increased interest in this important 
new field of immunological investigation we sought to determine the optimal conditions for 
an in-vitro experimental protocol of monocyte training using three of the most commonly 
used training stimuli from the literature: β-glucan, the Bacille Calmette-Guerin (BCG) vaccine, 
and oxidized LDL (oxLDL). 
Methods
We investigated and optimized a protocol of monocyte trained immunity induced by an initial 
training period with b-glucan, BCG or oxLDL, followed by washing and resting of the cells, 
and thereafter restimualtion with secondary bacterial stimuli. The training and resting time 
intervals varied to identify the optimal setting for long-term induction of trained immunity. 
Trained immunity was assessed in terms of secondary cytokine response, production of 
reactive oxygen species, cell morphology and induction of glycolysis. 
Results
Monocytes primed with b-glucan, BCG and oxLDL showed increased pro- and anti-
inflammatory cytokine responses upon restimulation with non-related stimuli. Also, all three 
stimuli induced a switch to glycolysis (Warburg effect). These effects were most pronounced 
when training interval was 24h training and resting time interval was 6 days. BCG and oxLDL 
training also led to increased production of reactive oxygen species, whereas b-glucan 
training showed a decrease in reactive oxygen species production.
Conclusion
We describe the optimal conditions for an in vitro experimental model in human primary 
monocytes to study the induction of trained innate immunity by microbial and metabolic 
stimuli. 
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INTRODUCTION
The immune response is a complex system of cellular and humoral components, which have 
the ability to detect ‘non-self’ structures and confer protection against invading pathogens, 
playing a crucial role in survival of multicellular organisms. Traditionally the immune response 
has been divided into the innate immune system and the adaptive immune system. Adaptive 
immunity, with T- and B-cells as cellular effectors, develops over several weeks after birth, 
is highly specific and builds a specific immunological memory, leading to protection against 
reinfection. The innate immune system on the other hand is classically thought to act rapidly 
in a non-specific and identical manner every time it encounters a pathogen, without having 
the ability to build an immunological memory. 
Recently, the concept that innate immunity is non-specific and completely lacks immunological 
memory has been challenged. First, the discovery of Pattern Recognition Receptors (PRRs) 
confers some specificity to innate immunity and secondly, a growing body of literature shows 
that innate immunity can adapt its function after a first insult (1, 2). Several studies have 
shown that plants and invertebrates, organisms which lack an adaptive immune system, 
show enhanced immune responses upon reinfection (3).  This phenomenon has recently 
been confirmed in higher vertebrates and humans, and has been named ‘trained immunity’ 
or ‘innate immune memory’. Trained immunity is dependent on epigenetic remodelling 
and on rewiring of intracellular metabolic pathways, which in turn lead to a long-term pro-
inflammatory phenotype that is characterized by increased cytokine responses (4, 5). 
A series of recent in vitro and in vivo experiments have revealed that the phenomenon 
of trained immunity is induced both by Pathogen Associated Molecular Patterns (PAMPs) 
and a number of Danger Associated Molecular Patterns (DAMPs). First, in mice, a single 
dose of C. albicans confers protection against reinfection with S. aureus . In vitro studies 
showed that the C. albicans cell wall component β-glucan induces epigenetic remodelling 
and functional reprograming through a dectin-1/Raf1-dependent pathway (6, 7) . Second, 
BCG vaccination of healthy human volunteers resulted in non-specific upregulation of ex 
vivo cytokine production of isolated monocytes that persisted for at least 3 months after 
vaccination. This effect is dependent on NOD2 signalling, autophagy and epigenetic changes 
in histone methylation leading to increased transcription, and likely explains, at least in part, 
the observed non-specific effects of BCG on overall mortality (8–10). Thirdly, the atherogenic 
lipid oxidized LDL (oxLDL) induces long-term pro-atherogenic changes in monocytes in vitro 
leading to increased pro-atherogenic cytokine expression, increased scavenger receptor 
expression and decreased cholesterol efflux transporter expression and ultimately in 
increased foam cell formation. This effect is dependent on TLR4/TLR2 and subsequent PI3K 
and ERK activation, epigenetic changes in histone methylation (e.g. H3K4me3, H3K9me3 and 
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H3K27me3) resulting in increased transcription (11, 12). 
In recent years, there is an increased interest in immunological research to the study of trained 
immunity, with studies assessing different organisms and diseases (13–17). Therefore, we 
sought to determine the optimal conditions for an in-vitro experimental protocol of monocyte 
training using three of the most commonly used training stimuli from the literature: β-glucan, 
BCG vaccine, and oxLDL. 
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METHODS
Reagents
β-1,3-(D)-glucan was kindly provided by Professor David Williams (TN, USA), Bacille Calmette-
Guérin (BCG vaccine SSI) was obtained from the Netherlands Vaccine Institute. Oxidized 
LDL (oxLDL) was prepared as described before (18). Escherichia coli LPS (serotype 055:B5, 
Sigma-Aldrich) was further purified as described (19), Pam3Cys was obtained from EMC 
microcollections (L2000). Luminol and zymosan (from S. cerevisiae) were purchased from 
Sigma-Aldrich.
PBMC and monocyte isolation
Buffy coats from healthy donors were obtained after written informed consent (Sanquin 
blood bank, Nijmegen, The Netherlands). PBMC isolation was performed by dilution of blood 
in sterile PBS and density centrifugation over Ficoll-Paque (GE healthcare, UK). Cells were 
washed three times in cold PBS. Percoll isolation of monocytes was performed as described 
(20). Briefly, 150-200·106 PBMCs were layered on top of a hyper-osmotic Percoll solution 
(48,5% Percoll (Sigma-Aldrich, St Louis, MO, USA), 41,5% sterile H2O, 0.16M filter sterilized 
NaCl) and centrifuged for 15 minutes at 580xg. The interphase layer was isolated and cells 
were washed with cold PBS. Cells were resuspended in dutch modified RPMI culture medium 
(Roswell Park Memorial Institute medium; Invitrogen, CA, USA) supplemented with 10μg/ml 
gentamicin, 10mM Glutamax, and 10mM pyruvate and counted. An extra purification step 
was added by adhering Percoll isolated monocytes to polystyrene flat bottom plates (Corning, 
NY, USA) for 1 hour at 37°C; the cells were washed with warm PBS to obtain maximal purity. 
At this point T-cell contamination as measured by FACS was 5% (Supplementary Figure 1). 
Trained immunity model in human monocytes 
100.000 cells/well were added to flat bottom 96-well plates. After incubation for 1 hour at 
37°C and washing with warm PBS, monocytes were incubated with culture medium only as a 
negative control or 5 μg/ml β-glucan, 10 μg/ml BCG or 10 μg/ml oxLDL for 2, 4 or 24h (in 200 
μL/well RPMI + 10% pooled human serum) (Figure 1). After the indicated incubation time, the 
cells were washed once with 200μl warm PBS and incubated for 24h, 3 or 6 days in culture 
medium with 10% serum and medium was changed once at day 3 for cells resting 6 days. 
Cells were re-stimulated with 200μl RPMI, 10 ng/ml LPS, or 10μg/ml Pam3Cys. After 24h, 
supernatants were collected and stored at -20oC until cytokine measurement. Supernatants 
before re-stimulation were stored at -20oC for lactate measurements. 
For production of reactive oxygen species (ROS) and for cell counting experiments, 5x106 
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monocytes were trained in vitro in 10cm petridishes (Greiner) in 5 ml medium volumes for 
24h as described above with a 6 day resting period. At day 6, cells were detached from the 
plate with versene (Life Technologies) and counted. 25.000 cells/well were restimulated as 
described above. 100.000 cells/well were used for ROS measurement, as described below.
Microscopy
Cell morphology was studied by conventional light microscopy during incubation each day. 
Pictures were taken before restimulation at 4x and 20x magnification. Cell size was quantified 
using Leica LAS EZ software (Leica Microsystems).
Reactive oxygen species measurements
For measurement of reactive oxygen species production a luminol – enhanced luminescence 
assay was used. After detachment and counting of trained monocytes, a total of 1x105 cells 
were added per well of a white 96-well assay plate (Corning) in a volume of 200 µl. Cells were 
left either unstimulated or stimulated with serum opsonised zymosan in a concentration of 1 
mg/ml. Luminol (145 µg/mL) was added and chemiluminescence was measured every 142 s 
for 1h. All measurements were performed at least in duplicate depending on the number of 
cells available. Opsonized zymosan particles were prepared by incubation of zymosan derived 
from Saccharomyces cerevisiae (Sigma, St. Louis) in pooled human serum for 30 minutes at 
37ºC, after which particles were washed twice in PBS and suspended in PBS.
Cytokine and lactate measurements 
Cytokine production was determined in supernatants using commercial ELISA kits for TNF-α, 
IL-1Ra (R&D systems, MN, USA) and IL-6 and IL-10 (Sanquin, Amsterdam, The Netherlands) 
Figure 1: Schematic overview of trained immunity methodology. Monocytes were trained 
for 2 hours (TRIM1), 4 hours (TRIM2) or 24 hours (TRIM3). After washing away the 
training stimulus, cells were rested for 24 hours (TRIM#.1), 3 days (TRIM#.2) or 6 days 
(TRIM#.3), after which the cells were restimulated with RPMI, LPS or Pam3Cys for 24 hours. 
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following instructions of the manufacturer. Lactate concentration was measured using a 
Lactate Fluorometric Assay Kit (Biovision, CA, USA).
Statistics 
In vitro monocyte experiments were performed at least 6 times and analysed using a Wilcoxon 
matched pairs signed-rank test, comparing fold change or raw cytokine values to the RPMI 
control . A two-sided P-value below 0.05 was considered statistically significant. All data were 
analyzed using Graphpad prism 5.0 (La Jolla, CA, USA). ^ = p = 0.06, * = p < 0.05, ** = p < 0.01. 
Data are shown as means ± SEM.
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RESULTS
Training induces an increase in pro-inflammatory cytokine production, which is 
dependent on both training and resting time
As was shown previously, 24 hour incubation with β-glucan, BCG, or oxLDL induces a trained 
immune phenotype characterized by increased production of pro-inflammatory cytokines 
upon restimulation at day 7 with heterologous stimuli. Here we aimed to investigate how 
temporal changes in duration of the first stimulus and the timing of the second stimulus impact 
upon the development of the trained immunity phenotype. (Figure 2A-B and Supplementary 
Figure 2). Training with β-glucan induced the strongest increase in cytokine production upon 
restimulation, whereas the effects of BCG and oxLDL were less pronounced, although still 
approximately associated with a 4-5 fold higher production of cytokines. For β-glucan and 
oxLDL training, the fold increase of IL-6 and TNFa production was comparable, while priming 
with BCG led to a greater amplification of IL-6 (Fig 2A) compared to TNFa (Fig 2B) production. 
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Figure 2: Increased pro-inflammatory cytokine production is dependent on both training interval 
and resting time. (A) IL-6 production after re-stimulation; cells were trained for 2h, 4h or 24h with 
βglucan (upper panel), BCG (middle panel) or oxLDL (lower panel), and rested for 24h, 3d or 6d. (B) 
TNFα production after re-stimulation; cells were trained for 2h, 4h or 24h with βglucan (upper panel), 
BCG (middle panel) or oxLDL (lower panel), and rested for 24h, 3d or 6d. Shown are fold changes 
compared to the RPMI control (n=6, ^p=0.06, * p<0.05, ** p<0.01 compared to RPMI control). . 
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For all three stimuli, priming for either 2 hours, 4 hours or 24 hours induced training, when 
the cells were rested for three or six days. However, the fold increase in cytokine production 
was highest with 24h training time interval. When comparing the different time periods 
between stimulation and restimulation, it follows that the trained phenotype developed only 
after at least three days, with a maximum response after 6 days.
Training associated morphological changes
Upon training, the monocytes not only changed their response to secondary stimuli and 
subsequently their cytokine production, but also changed their morphology. Just before 
restimulation, we analyzed cell morphology and cell size by using light microscopy at two 
different magnifications (Fig 3A and supplementary figure 3). When cells were trained for 24 
hours and rested for 6 days, β-glucan induced most remarkable changes in cell morphology: 
the cells were bigger than non-trained cells. BCG and oxLDL training only induced minor 
changes in cell morphology, with a slight increase in cell-size compared to the untrained 
control cells (Fig 3B). We also analyzed cell numbers at the end of the most optimal protocol 
of trained immunity induction (24h training, 6 days rest) by culturing cells in Petri dishes, 
detaching them on day 6 before restimulation, and reseeding corrected cell numbers for each 
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Figure 3: Trained immunity effects on cell morphology and numbers. (A) Cell morphology 
of cells from TRIM3.3 trained with RPMI (negative control) βglucan, BCG or oxLDL. Pictures 
were taken before re-stimulation at day 6 (20x). (B) Relative cell counts before re-stimulation 
at day 6 n=6, * p<0.05, compared to RPMI control).. (C) IL-6 and TNFα production after re-
stimulation for corrected cell counts. (n=6, * p<0.05, ** p<0.01 compared to RPMI control).
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condition. Counting experiments showed that β-glucan training induced a small increase in 
cell numbers compared to the RPMI control (Figure 3C), whereas BCG or oxLDL training did 
not induce this increase in numbers. However, after correcting for cell numbers, the cytokine 
production upon restimulation was still significantly increased, indicating that the increase in 
cytokines was not due to an increased cell number, but is mainly dependent on the production 
of cytokines per cell (Figure 3D).
The production of anti-inflammatory cytokines IL-10 and IL-1Ra is increased in 
trained cells
Previously we have shown that β-glucan training increases not only pro-inflammatory cytokine 
production, but also anti-inflammatory cytokine production. Therefore, we measured the 
production of two anti-inflammatory cytokines IL-10 and IL-Ra upon restimulation for all 
three training stimuli and all training protocols. Training was associated with increased LPS-
induced IL-10 production depending on training time interval and resting time (Figure 4A 
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Figure 4: Anti-inflammatory cytokine production is increased in trained monocytes. (A) IL-10 
production after re-stimulation; cells were trained for 24h with βglucan, BCG or oxLDL and 
rested for 6d. Production of the anti-inflammatory cytokine IL-10 increases upon training. (B). 
IL-1Ra production; cells were trained for 24h with βglucan, BCG or oxLDL and rested for 6d. 
Production of the anti-inflammatory cytokine IL-1Ra increases upon training, not only after 
restimulation, but also on baseline. (n=6, ^p=0.06, * p<0.05, ** p<0.01 compared to RPMI control). 
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and Supplementary Figure 3A), but this only reached statistical significance for training with 
β-glucan. The production of IL-1Ra was increased for all three training stimuli even without 
re-stimulation (Figure 4B), and this was dependent on training duration and resting time 
(Supplementary Figure 3B).
ROS production is increased upon BCG and oxLDL training, but not upon β-glucan 
training
To further characterize the functional phenotype of trained monocytes we measured another 
innate immune effector mechanism, the oxidative burst, in the most optimal protocol (24h 
training, 6 days rest). 
Both BCG and oxLDL trained cells showed increased production of reactive oxygen species 
(ROS) compared to RPMI control when cells were stimulated with zymosan, although for 
oxLDL this effect was not statistically significant. Interestingly, β-glucan trained cells showed 
a very different pattern, with a slight, but statistically significant downregulation of ROS 
production. 
The metabolic switch towards increased glycolysis induced upon training is 
dependent on both training and resting time
Previously, we have shown that trained immunity depends on a metabolic shift from oxidative 
phosphorylation towards aerobic glycolysis (Warburg effect) (21). Increased glycolysis results 
in increased lactate production by the cell, which can be easily be measured by analyzing 
the accumulation of lactate in the culture medium. Before the cells were restimulated, the 
culture medium was removed and stored and lactate concentration was measured (Fig 6). 
24h resting time, independent of the training time, did not increase glycolysis and lactate 
production. When cells were rested for 3 days, lactate production was slightly increased for 
2 hour and 24 hour β-glucan trained cells; for BCG training, 2h and 4h training induced a 
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Figure 5: ROS production is a component of trained immunity for some stimuli. ROS 
production is significantly increased for BCG and oxLDL trained monocytes; β-glucan training 
decreases ROS production. (n=6, * p<0.05, *** p<0.001 compared to RPMI control).. 
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slight increase in glycolysis, while for oxLDL training only 4h training period was sufficient to 
induce significant increase in lactate production. When cells were rested for 6 days however, 
all three training durations induced significant increase in lactate production for all three 
stimuli. Interestingly, the lactate production and thus glycolysis was even more increased 
with increasing training duration. 
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Figure 6: Trained immunity induction of glycolysis. Cells were trained for 2h, 4h or 
24h with RPMI (white, negative control) βglucan (light grey), BCG (dark grey) or 
oxLDL (black), and rested for 24h, 3d or 6d. Lactate production was measured in the 
supernatants before re-stimulation. (n=6, * p<0.05, ** p<0.01 compared to RPMI control). 
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DISCUSSION
In the present study we describe the optimal conditions for the induction of trained immunity 
in an in vitro model in primary human monocytes. This model has previously been used to 
investigate several different stimuli, but the optimal parameters necessary to induce trained 
immunity have not been yet characterized. In this model, microbial or endogenous stimuli 
such as β-glucan, BCG, oxidized LDL are added to monocytes for a short period of time 
(training period), after which cells are washed and let to rest in culture medium, followed by 
restimulation with unrelated antigens (6, 8, 11, 22, 23). 
This study provides several new insights in this basic model of trained innate immunity, that 
will aid the design of future studies. Firstly, induction of trained immunity depends on the 
duration of the first stimulation time interval: the ‘training period’, with increasing training 
time leading to increased induction of trained immunity, an effect which was observed for 
all three stimuli. Secondly, the magnitude of the induction of non-related cytokine responses 
increases with the time that trained cells are left to rest, most notably for β-glucan primed 
cells. The importance of resting time to establish trained immunity has recently also been 
demonstrated in a study which described the role of the transcription factor ATF7 in mediating 
epigenetic changes involved in innate immune memory, most notably after LPS stimulation. 
Three days after the first LPS challenge, the expression of TNFa and Cxcl2 was decreased 
upon rechallenge with LPS, whereas the opposite was true three weeks after LPS challenge. 
Multiple pro-inflammatory genes were upregulated at the later time point, which was 
accompanied by reduced epigenetic marks associated with gene silencing and incomplete 
recruitment of ATF7, which is associated with formation of heterochromatin. This study also 
found that treatment with β-glucan induced phosphorylation of ATF7 analogous to treatment 
with LPS (24). Similarly, our study shows induction of tolerance, most notably with β-glucan 
and BCG, when cells are only briefly left to rest before rechallenge (24 hours), whereas a 
training effect is seen if cells are left to rest for 3 or 6 days. This could suggest the intriguing 
possibility that ATF7 or analogous mechanisms may be at play here. The importance of 
resting time in the induction of trained immunity is also shown by the remarkable increases 
in glycolysis of trained cells after 6 days of rest, compared to 1 day or 3 days of resting time.
Another insight from this study is that trained immunity does not translate only into 
increased pro-inflammatory response of monocytes, but is likely to involve a more general 
increase in the responsiveness of the cells, as witnessed by the amplification of both pro- 
and anti-inflammatory cytokines production, ROS production (in case of BCG and oxLDL) and 
metabolic activation. We should be of course cautious in the extrapolation of all the details 
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of the in-vitro model to the in-vivo situations: for example vaccination trials performed both 
in infants and in adults showed increased pro-inflammatory cytokine responses after BCG 
vaccination, whereas no effects were noted on anti-inflammatory cytokine reponses (8, 23, 
25).  Furthermore, in patients suffering from elevated lipoprotein(a), which induces trained 
innate immunity in vitro, the anti-inflammatory cytokine response was even decreased (Van 
der Valk et al., in press).
It is also important to note that different inducers of trained immunity lead to different 
phenotypical and functional changes, as witnessed by light microscopy, cytokine production 
and induction of ROS. Although a common denominator for the three priming stimuli 
studied here is the upregulation of both pro- and anti-inflammatory cytokine responses 
and the stimulation of glycolysis, other physiological processes such as induction of ROS or 
cell proliferation differ between different priming stimuli. When cytokine responses were 
corrected for cell counts, the cytokine responses were still strongly upregulated nevertheless. 
All in all however, these data suggest that each of these training stimuli induces different 
trained immunity functional programs, and this is not a surprise considering their diverse 
nature (5).
In conclusion, although the effects of these three stimuli on trained immunity have been 
described before, this is the first time that the kinetics of this in vitro model have been 
studied. This study describes the characteristics of an in vitro model to study the influence 
of different stimuli on the induction of trained innate immunity. This is a practical and useful 
methodological tool that will assist the research community in the investigation of this 
emerging field of immunology.
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SUPPLEMENTARY FIGURES
Supplementary Figure 1. Monocyte purity of different isolation steps. The proportion of 
T-cells was determined in whole blood, the PBMC fraction after Ficoll density gradient, the 
purified monocyte fraction after Percoll density gradient and after 1 hour adherence and 
washing of the purified Percoll isolated monocytes. T-cell contamination is approximately 
5% after adherence and washing.
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Supplementary Figure 2. Increased pro-inflammatory cytokine production is dependent 
on both training and resting time. (A) IL-6 production after re-stimulation in pg/ml; cells 
were trained for 2h, 4h or 24h with βglucan (upper panel), BCG (middle panel) or oxLDL 
(lower panel), and rested for 24h, 3d or 6d. (B) TNFα production after re-stimulation in pg/
ml; cells were trained for 2h, 4h or 24h with βglucan (upper panel), BCG (middle panel) or 
oxLDL (lower panel), and rested for 24h, 3d or 6d (n=6, * p<0.05, ** p<0.01, *** P<0.001)
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.Supplementary Figure 3. Training induces changes in cell morphology. (A) Cell 
morphology of cells from 2hr-T; 24hr-R trained with RPMI (negative control) βglucan, BCG 
or oxLDL. Pictures were taken before re-stimulation (20x). (B) Cell morphology of cells from 
2hr-T; 3d-R (C) Cell morphology of cells from 2hr-T; 6d-R (D) Cell morphology of cells from 
4hr-T; 24hr-R (E) Cell morphology of cells from 4hr-T; 3d-R (F) Cell morphology of cells from 
4hr-T; 6d-R (G) Cell morphology of cells from 24hr-T; 24hr-R (H) Cell morphology of cells 
from 24hr-T; 3d-R
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Supplementary figure 4. Anti-inflammatory cytokine production is increased in trained 
monocytes. (A) Production of the anti-inflammatory cytokine IL-10. (B). Production of the 
anti-inflammatory cytokine IL-1Ra increases upon training, not only after restimulation, 
but also on baseline. Cells were trained for 2h, 4h or 24h with βglucan (upper panel), BCG 
(middle panel) or oxLDL (lower panel), and rested for 24h, 3d or 6d (n=6,^=p0,06 * p<0.05, 
** p<0.01, *** P<0.001). 
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Supplementary Figure 5. Morphological changes after 24hr training and 6 days resting 
persist after 24h of restimulation. Cell morphology of cells trained with either RPMI, 
β-glucan, BCG or oxLDL and restimulated with RPMI, LPS or Pam3Cys.
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OX-LDL INDUCES LONG-TERM PRO-INFLAMMATORY 
CYTOKINE PRODUCTION AND FOAM CELL FORMATION VIA 
EPIGENETIC REPROGRAMMING OF MONOCYTES
Siroon Bekkering, Jessica Quintin, Leo AB Joosten, Jos WM van der Meer, Mihai G 
Netea, Niels P Riksen
Arterioscler. Thromb. Vasc. Biol (2014) 34(8):1731-8
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ABSTRACT
Objective 
Although the role of monocytes in the pathogenesis of atherosclerosis is well-established, the 
persistent vascular inflammation remains largely unexplained. Recently, our group reported 
that stimulation of monocytes with various microbial products can induce a long-lasting pro-
inflammatory phenotype via epigenetic reprogramming, a process termed ‘trained immunity’. 
We now hypothesize that oxidized LDL (oxLDL) also induces a long-lasting pro-inflammatory 
phenotype in monocytes, which accelerates atherosclerosis by pro-inflammatory cytokine 
production and foam cell formation.
Approach and Results 
Isolated human monocytes were exposed for 24 hours to medium or oxLDL. After washing and 
resting for 6 days, the cells were exposed to Toll-like Receptor 2 and 4 agonists. Pre-exposure 
to oxLDL increased mRNA expression and protein formation upon TLR2/4 stimulation of 
several pro-atherogenic proteins, including interleukin (IL)-6, IL-18, IL-8, tumor necrosis 
factor-α, monocyte chemoattractant protein-1 and matrix metalloproteinase 2, and 9. In 
addition, foam cell formation was enhanced after oxLDL exposure, which was associated with 
an upregulation of scavenger receptors CD36 and scavenger receptor-A and downregulation 
of ATP binding cassette transporters ABCA1 and ABCG1. Chromatin immunoprecipitation 
performed 6 days after oxLDL stimulation demonstrated increased trimethylation of lysine 
4 at histone 3 in promoter regions of tnfα, il-6, il-18, mcp-1, mmp2, mmp9, cd36 and sr-
a. Finally, pretreatment of the monocytes with the histone methyltransferase inhibitor 
methylthioadenosine completely prevented the oxLDL-induced long-lasting pro-inflammatory 
phenotype. 
Conclusions 
Brief exposure of monocytes to a low concentration of oxLDL induces a long-lasting pro-
atherogenic macrophage phenotype via epigenetic histone modifications, characterized by 
increased pro-inflammatory cytokine production and foam cell formation. 
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INTRODUCTION
Atherosclerosis is a chronic inflammatory disorder of the arterial vessel wall, which is initiated 
by an accumulation of lipoproteins in the intimal layer of the vascular wall. Subsequent 
activation of the overlying endothelium leads to the recruitment of circulating monocytes1. 
Monocyte entry into the vessel wall is crucial for the onset of the disease, since mice lacking 
monocyte chemokines or their receptors have less atherosclerosis2-4. Within the intimal layer, 
monocytes differentiate into macrophages that subsequently engulf oxidized low density 
lipoprotein (oxLDL) particles via scavenger receptors, mainly CD36 and Scavenger Receptor-A 
(SR-A)5, leading to the formation of foam cells6. In addition, lesional macrophages can be 
activated by various stimuli, leading to the release of pro-inflammatory cytokines and matrix 
degrading proteins, thereby promoting disease progression and plaque destabilization7,8. 
This activation of macrophages occurs via membrane-bound and intracellular pattern 
recognition receptors (PRRs), including Toll-like receptor (TLR) 2 and -4. Interestingly, the 
rate of progression of atherosclerosis is critically dependent on the characteristics of the 
circulating monocyte pool. It has been established in mouse models of atherosclerosis that 
hypercholesterolemia and a myocardial infarction can accelerate atherogenesis be changing 
the number and characteristics of circulating monocytes9,10. Although the role of monocytes 
in atherosclerosis has now been well-established, it still remains elusive why the strong 
inflammatory response in the arterial wall persists in time.   
Recently, our group reported that monocytes can build up an immunological memory after 
microbial stimulation via epigenetic reprogramming of histone modifications, and this 
mechanism has been termed ‘trained immunity’11,12. In humans, monocytes isolated from 
healthy volunteers after Bacillus Calmette–Guérin (BCG) vaccination present an increased 
production of pro-inflammatory cytokines ex-vivo after re-exposure to various unrelated 
pathogens13. This enhanced pro-inflammatory state of the monocytes could be detected up 
to one year after first exposure14. In addition to BCG, ‘trained immunity’ can also be induced 
by Candida albicans and its cell wall component β-glucan15. It has been shown that trained 
immunity is at least partly mediated by an increased trimethylation of histone 3 at lysine 
4 (H3K4me3), which is associated with an increased expression of target genes upon re-
stimulation of the cells, including various pro-inflammatory cytokines. The kinetics of the 
epigenetic process leading to this sustained functional reprogramming of monocytes and 
macrophages has recently been described, and the epigenetic units responsible for this 
process have been termed “latent enhancers”16.   
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A genome wide analysis of the epigenetic changes induced by the exposure of monocytes 
to β-glucan revealed that the top-500 genes with a clear increase of H3K4Me3 include many 
genes that are involved in the process of atherosclerosis. Therefore, we recently hypothesized 
that trained innate immunity contributes to atherosclerosis12. We now investigate whether 
sustained epigenetic remodeling of monocytes can also be induced by non-microbial stimuli 
that are relevant in atherosclerosis, such as oxLDL. In addition, we characterize in detail 
the phenotype of the long-term activated monocyte-derived macrophage with regard to 
production of cytokines and chemokines that orchestrate the process of atherosclerosis and 
with regard to foam cell formation.  
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MATERIALS AND METHODS
Cells and reagents
Human peripheral blood mononuclear cells (PBMCs) were isolated from blood of healthy 
volunteers (Sanquin Bloodbank Nijmegen, the Netherlands) by density-gradient centrifugation 
using Ficoll-Paque (GE Healthcare, Zeist, The Netherlands). β-glucan (b-1,3-(D)-glucan) was 
kindly provided by Professor David Williams (College of Medicine, Johnson City, USA). Stimuli 
and inhibitors used are lipopolysaccharide (LPS; Sigma-Aldrich, St. Louis, MO; from E. coli 
serotype 055:B5, further purified as described1) and LPS from Bartonella, further purified 
as described1 as anti-TLR4, Pam3Cys (EMC microcollections, Tübingen, Germany; L2000), 
histone methyltransferase inhibitor methylthioadenosine (MTA, Sigma-Aldrich, D5011), 
histone demethylase inhibitor Pargyline (Sigma-Aldrich, P8013), Anti-TLR2 (Invivogen, maba-
htlr2), IgG Isotype control (Invivogen, maba2-ctrl), SYK inhibitor (EMC microcollections, 
574711), JNK inhibitor SP600125 (AG Scientific, S-2022), PI3K inhibitor 3MA (Sigma, 
M9281), ERK inhibitor U0126 (Promega, V112A), Cytochalasin B (Sigma, C6762), acetylated 
LDL (Bioconnect, BT906). Rabbit-anti-actin antibody (A5441) was purchased from Sigma; 
polyclonal rabbit anti-CD36 antibody (PA1-16813) was purchased from Thermo scientific, 
Pierce Antibodies; monoclonal mouse-anti-human MRS1/SR-A (MAB27081) was purchased 
from R&D systems (Minneapolis, MN).
Training of adherent monocytes
Adherent monocytes were trained as described previously (depicted in figure 1)2. Briefly, 
monocytes were isolated from PBMCs by adhering 5·106 PBMCs/ml to polysterene for 1h 
at 37°C, 5% CO2 in 96-, 24- or 6-well culture plates (Corning, New York, USA). Non-adherent 
cells were removed by washing with warm PBS. Monocytes were cultured in RPMI 1640 
Dutch-modified culture medium (Life Technologies/Invitrogen, Breda, The Netherlands) 
supplemented with 10 mM glutamine (Invitrogen), 10 µg/mL gentamicin (Centraform), 10 
mM pyruvate (Invitrogen) and 10% pooled human serum. 
The monocytes were incubated with β-glucan (1 or 5 μg/ml), LDL (1-100 μg/ml), oxLDL 
(1-100 μg/ml) or acLDL (1-100 μg/ml) for 24h, after which the cells were washed and re-
incubated in culture medium. In inhibition experiments, cells were pre-incubated with the 
inhibitors 1h prior to adding the stimuli. Inhibitors used are either RPMI or RPMI+DMSO 
as a negative control, MTA (1 mM), Pargyline (3 μM), aTLR2 (10 μg/ml), IgG control (10 μg/
ml),  aTLR4 (100 ng/ml), SYKi (50 nM), SP600125 (20 μM), 3MA (20 mM), U0126 (10 μM) 
and cytochalasin B (1 μg/ml). After 7 days of incubation in supplemented RPMI medium, 
cells were exposed to either medium alone, 10 ng/mL LPS or 10 µg/mL Pam3Cys for 24h at 
37°C, 5% CO2. After 24h of incubation, supernatants were collected and stored at -20°C. Cell 
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death was assessed by measuring lactate dehydrogenase (LDH) in the supernatants using 
a Cytotox96® nonradioactive cytotoxicity assay (Promega Corporation, Madison, WI, USA). 
Production of pro-inflammatory cytokines was measured in supernatants by ELISA according 
to the manufacturers’ instructions (IL-6, IL-8 (Sanquin, Amsterdam, The Netherlands); TNFα, 
IL-1β (R&D Systems, Minneapolis, USA)). The MCP-1 ELISA was performed according to the 
manufacturers’ instructions using antibodies anti-Human CCL2 Purified (14-7099), anti-
CCL2 Biotin (13-7096) and Human CCL2 Recombinant Protein (14-8398), all obtained from 
eBioscience (Halle-Zoersel, Belgium). Gene expression of these cytokines was measured as 
indicated below by qPCR. 
Quantitative Real-Time PCR
For qRT-PCR, monocytes were trained as described above and subjected to re-stimulation on 
day 7 with LPS (10 ng/ml) for 4 hours. At day 0 after adherence, at day 1 after 24h training 
and after re-stimulation at day 6, cells were stored in TRIzol reagent (Invitrogen). Total RNA 
purification was performed according to the manufacturer’s instructions. RNA concentrations 
were measured using NanoDrop software, and isolated RNA was reverse-transcribed using 
the iScript cDNA Synthesis Kit (Bio-rad, Hercules, CA). qPCR was performed using the SYBR 
Green method (Applied Biosciences, Carlsbad, CA). Used primers are listed in table 1 (Biolegio, 
Malden, The Netherlands). Samples were analyzed following a quantitation method with 
efficiency correction, and HPRT was used as a housekeeping gene. Relative mRNA expression 
levels of non-primed and non-stimulated samples were used as reference.
Gene Forward primer Reverse primer
HPRT CCTGGCGTCGTGATTAGTGAT AGACGTTCAGTCCTGTCCATAA
IL-6 AACCTGAACCTTCCAAAGATGG TCTGGCTTGTTCCTCACTACT
TNFa CCTCTCTCTAATCAGCCCTCTG GAGGACCTGGGAGTAGATGAG
MCP-1 CCAGTCACCTGCTGTTATAAC TGGAATCCTGAACCCACTTCT
IL-18 TGTCGCAGGAATAAAGATGGCT CCTTGGTCAATGAAGAGAACTTGGT
IL-8 ACTGAGAGTGATTGAGAGTGGAC AACCCTCTGCACCCAGTTTTC
MMP2 TACAGGATCATTGGCTACACACC GGTCACATCGCTCCAGACT
MMP8 ACCAAAGAGATCACGGTGACA TCCATGTTTCTTCGGCATCAAAA
MMP9 TGTACCGCTATGGTTACACTCG GGCAGGGACAGTTGCTTCT
CD36 CTTTGGCTTAATGAGACTGGGAC GCAACAAACATCACCACACCA
SR-A/
MSR1
CCAGGTCCAATAGGTCCTCC CTGGCCTTCCGGCATATCC
ABCA1 GGTGATGTTTCTGACCAATGTGA TGTCCTCATACCAGTTGAGAGAC
ABCG1 CGGAGCCCAAGTCGGTGTG TTTCAGATGTCCATTCAGCAGGTC
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TLR4 GGCATGCCTGTGCTGAGTT CTGCTACAACAGATACTACAAGCACACT
TLR2 GAATCCTCCAATCAGGCTTCTCT GCCCTGAGGGAATGGAGTTTA
HO1 AAGACTGCGTTCCTGCTCAAC AAAGCCCTACAGCAACTGTCG
ARG1 GATTCCCGATGTGCCAGGATT GCCAATTCCTAGTCTGTCCACTT
CD163 TGAAGACTCTGGATCTGCTGA GAACTGGTGACAAAACAGGCA
iNOS TTCAGTATCACAACCTCAGCAAG TGGACCTGCAAGTTAAAATCCC
HLA-DRB1 CGGGGTTGGTGAGAGCTTC AACCACCTGACTTCAATGCTG
DC-SIGN TCAAGCAGTATTGGAACAGAGGA CAGGAGGCTGCGGACTTTTT
CD83 AAGGGGCAAAATGGTTCTTTCG GCACCTGTATGTCCCCGAG
Table 1. Primer sequences used for qRT-PCR analysis (5’-3’)
Preparation of oxidized LDL
Oxidized LDL was prepared by incubation with 20 μmol CuSO4/L for 15h at 37°C in a shaking 
water bath as described previously3, 4. To induce foam cell formation at day 6, trained monocytes 
were first incubated in serum-free RPMI medium for 4h and subsequently incubated with 
RPMI medium alone or RPMI containing oxidized LDL at 50 µg/mL for 24h. Incubation of 
primed monocytes with this concentration of oxLDL alone caused no secretion of IL-6, TNFα 
or MCP-1, suggesting absence of endotoxin in the prepared LDL fractions. Accumulation of 
oxidized LDL was visualized by Oil-Red-O staining as described5 and the uptake was measured 
by ELISA, measuring intracellular apoB as described before 6. 
Western blotting experiments
Scavenger receptor expression on trained monocytes was measured in cell lysates using 
Western blots. Monocyte training was performed as described above. On day 6, cells 
were lysed using lysis buffer (50 mM Tris, pH 7.4, 150 mM NaCl, 2 mM EDTA, 2 mM EGTA, 
10% glycerol, 1% Triton X-100, 40 mM β-glycerophosphate, 50 mM sodium fluoride, 200 
µM sodium orthovanadate, complete mini EDTA-free protease inhibitor cocktail (Roche), 
and PhosphoSTOP Phosphatase Inhibitor Cocktail (Roche)). Total protein concentration of 
lysates was measured using a Pierce® BCA protein assay (Thermo Scientific, Rockford, IL) 
and 10% Tris-HCl gels were loaded with equal amounts of protein per lane (approx. 15 µg). 
Proteins were blotted onto a nitrocellulose membrane and the membrane was subsequently 
blocked with 5% milk (w/v) in Tris-buffered saline supplemented with Tween 20 (TBS-T). 
Primary antibodies (Rabbit-anti-CD36 1:1000, mouse-anti-SR-A 1:1000 and Rabbit-anti-Actin 
1:1000) were incubated in 5% milk in TBS-T overnight at 4°C. After three times washing with 
TBS-T, HRP-conjugated secondary antibodies were incubated for 1h at room temperature 
(RT, 1:5000 Swine-anti-rabbit-HRP or 1:5000 Rabbit-anti-mouse-HRP) in 5% ELK in TBS-T. 
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After three times washing, chemiluminescence was measured using ECL Plus Western Blot 
Detection Reagents (Amersham Biosciences, UK) and the Chemidoc XRS imager with Image 
Lab software (Bio-Rad, CA, USA). 
Chromatin Immunoprecipitation
For the assessment of H3K4me3, ChIP was performed as described previously7. In short, 
chromatin of cells on day 6 was fixated in methanol free 1% formaldehyde (28908, Thermo 
Scientific), followed by sonication and immunoprecipitation using antibodies against H3K4me3 
(Diagenode, Seraing, Belgium). ChIPed DNA was processed further for qPCR analysis. Primers 
used in the reaction are listed in table 2. Samples were analyzed following a comparative Ct 
method, myoglobin was used as a negative control and H2B as a positive control according to 
the manufacturer’s instructions.
Promotor of gene Forward primer Reverse primer
Myoglobulin AGCATGGTGCCACTGTGCT GGCTTAATCTCTGCCTCATGAT
H2B TGTACTTGGTGACGGCCTTA CATTACAACAAGCGCTCGAC
TNFa CAGGCAGGTTCTCTTCCTCT GCTTTCAGTGCTCATGGTGT
IL-6 TCGTGCATGACTTCAGCTTT GCGCTAAGAAGCAGAACCAC
IL-18 ATGCACTGGGAGACAATTCC CTCCCTCCACCTTCTTCCTC
MCP-1/CCL2 CCGAGAGGCTGAGACTAACC CTATGAGCAGCAGGCACAGA
CD36 TCACGCATTTATGTACTGAGGA TGCTCCAACATTTGGACAAT
SR-A/MSR1 GCATCTGGTACATGAAGAAAGG TGTGCATTGATGAGAGTGCT
MMP2 CTGCATCCAGACTTCCTCAG GTCCTGGCAATCCCTTTGTA
MMP8 GAGCAGAAATGGAAGCGTCT AAAGAAAGCCAGGAGGGGTA
MMP9 CAGTCCACCCTTGTGCTCTT CTCTGCCAGCTGCCTGTC
Table 2. Primers used for ChIP qPCR analysis (5’-3’)
Statistical analysis
Each experiment was performed at least 6 times. Data are presented as means ± SD. For Oil-
Red staining and Western blotting, representative pictures are shown. Group comparisons 
were performed using the Wilcoxon signed-rank test. P-values<0.05 (*) are considered 
significant; (**) p<0.01; (***) p<0.001.
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RESULTS
β-glucan training induces enrichment of H3K4me3 on genes relevant for 
atherosclerosis
From our previous work on monocyte training with β-glucan, we analyzed the top 500 
H3K4Me3 enriched genes for their involvement in the process of atherosclerosis15. These 
genes not only involved various cytokines and chemokines that are relevant in atherogenesis, 
but also scavenger receptors and other proteins involved in foam cell formation and proteins 
involved in atherosclerotic plaque destabilization (Supplementary Table I). 
OxLDL but not LDL induces training of monocytes in vitro
Using the established in vitro model of human primary monocyte training, we explored the 
effect of LDL and oxLDL on training (Figure 1A). Incubation of monocytes with LDL and oxLDL 
did not induce cytokine production (IL-6, TNFα or IL-1β) in the first 24h stimulation-period 
(Suppl. Figure I B-D). Moreover, incubation with oxLDL in a concentration up to 10 µg/ml 
and incubation with LDL (up to 100 µg/ml) was not cytotoxic, as demonstrated by a Lactate 
Dehydrogenase (LDH) cytotoxicity assay (Supplementary figure I A). However, incubation of 
cells with oxLDL on day 1 induced a significant dose-dependent increase in IL-6 and TNFα 
production by monocytes that were re-stimulated with TLR ligands on day 6. A significantly 
increased cytokine production was observed for stimulation of both TLR4 (Lipopolysaccharide 
(LPS), figure 1B and C) and TLR2 (Pam3Cys, Supplementary figure II A-B). Interestingly, pre-
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Figure 1: Priming with low concentrations of oxLDL but not native LDL augments IL-6 and TNFα 
production upon re-stimulation with LPS. (A) Schematic representation of the in vitro experimental 
setup. (B) IL-6 and (C) TNFα production was measured in the supernatants of adherent monocytes 
from healthy volunteers, exposed for 24h to either medium alone, β-glucan as a positive control, or 
different concentrations of oxidized LDL or native LDL. After washing and six days of resting period, 
monocytes were re-stimulated with LPS (n=8, * P<0.05, ** p<0.01 compared to the RPMI control). 
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incubation with native LDL in a concentration up to 100 µg/ml did not have any effect on the 
capacity of monocytes to produce IL-6 and TNFα upon re-stimulation, suggesting that the 
modification of LDL is required to induce training. In an additional set of experiments, oxLDL 
was kept in the medium for the entire 6-day resting period. Similar potentiating effects on the 
inflammatory profile of monocytes were obtained (Supplementary figure III).  
To assess whether training could also be induced by alternative modification of LDL, we 
repeated the experiments with acetylated LDL (acLDL), which also binds SR-A but not CD36. 
Indeed, re-stimulation of the cells on day 6 with either TLR4 or TLR2 agonists induced an 
increase in IL-6 and TNFα production, similar to oxLDL, albeit higher concentrations of acLDL 
were required (Supplementary figure II C). 
Characteristics of oxLDL-induced trained monocyte-derived macrophages
In our experimental design, after 24h exposure to oxLDL, the monocytes were kept in RPMI 
culture medium supplemented with 10% serum for 6 additional days until re-stimulation on 
day 6. During this period, the monocytes differentiate into monocyte-derived macrophages. 
We have previously reported that training with β-glucan did not induce skewing of the 
macrophages into type M1 or M2 macrophages15. In addition, monocytes can also differentiate 
into dendritic cells (DCs), such as TNF and nitric oxyde synthase (iNOS) producing DCs (Tip-
DC)17. It should be realized that this categorization into distinct macrophage phenotypes 
likely represents a simplified model since it recently a spectrum of macrophage activation 
states was revealed upon stimulation with various stimuli, extending the current M1 versus 
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Figure 2: Primed monocytes have 
a more atherogenic cytokine 
and chemokine profile upon re-
stimulation than non-primed 
monocytes.β-glucan and oxLDL 
primed monocytes produce more 
IL-6, TNFα, IL-8 and MCP-1 upon 
re-stimulation than untrained 
monocytes. Cytokine levels are 
measured in supernatants of 
cultured adherent monocytes 
from healthy volunteers, 
trained by either β-glucan, 
oxLDL or medium alone for 
24h, and re-stimulated after 
6 days with TLR2 or TLR4 
agonists. (n≥10 per group, * 
p<0.05, ** p<0.01, *** p<0.005 
compared to the RPMI control)
71
oxLDL induced trained immunity in vitro
4
M2-polarization model18. To better characterize the phenotype of the monocytes-derived 
macrophages on day 7 after stimulation with oxLDL, we measured the expression of several 
markers of classically activated and alternatively activated macrophages, and of inflammatory 
Tip-DC’s on day 7 (Suppl. Fig. IV). We observed no significant differences in expression of 
TLR4, TLR2 and iNOS (M1 markers), Arginase1 and CD163 (M2 markers), and HLA-DR, DC-
SIGN and CD83 expression (DC markers). 
Training of monocytes induces an atherogenic cytokine and chemokine response 
upon secondary stimulation
A broad spectrum of cytokines and chemokines have been implicated to play a role in 
atherogenesis, including IL-6, IL-18, TNFα, Monocyte Chemoattractant Protein 1 (MCP-1) and 
IL-819. To study the effect of brief exposure to oxLDL on the production of these cytokines 
and chemokines, monocytes were trained for 24h by either medium alone as a negative 
control, β-glucan as a positive control, or oxLDL. After washing on day 1 and the additional 
six days resting period, cells were re-stimulated by LPS and Pam3Cys for 4h or 24h to study 
the induction of mRNA production and cytokine or chemokine production, respectively. Both 
β-glucan and oxLDL training of monocytes augmented the production of IL-6, TNFα, IL-8 and 
MCP-1 (Figure 2). We subsequently assessed whether the potentiation of cytokine production 
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Figure 3:  mRNA expression of pro-atherogenic cytokines is enhanced in trained monocytes. 
Adherent monocytes of healthy volunteers were exposed to either β-glucan, oxLDL or 
medium alone for 24h, and re-stimulated after 6 days with LPS for 4h. Relative mRNA 
expression values are shown, compared to the untrained control. Expression of il-6, tnfα, 
mcp-1, il-8, il-18, mmp2 and mmp9 but not mmp8 in trained monocytes is significantly 
higher on upon re-stimulation then in untrained monocytes (n=6 per group, * p<0.05)
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is exerted at the gene transcription level. Upon re-stimulation of trained monocytes, il-6, tnfα, 
il-8, mcp-1 and also il-18 mRNA expression showed a significant up-regulation compared to 
the untrained control (Figure 3A-E). Interestingly, whereas the basal levels of il-6, tnfα and 
il-8 showed no difference upon training, the baseline expression of il-18 was significantly 
upregulated (Suppl. Fig V) and the baseline expression of mcp-1 shows a similar effect, albeit 
not significantly, suggesting enhanced constitutive expression of these genes. 
In addition to enhanced cytokine production, we also observed an enhanced baseline mRNA 
expression of Matrix Metalloproteinase 9 (MMP9), and increased expression of MMP2 and -9 
upon LPS re-stimulation, two of the most important matrix degrading proteins, responsible 
for plaque destabilization (Fig 3E, G). In contrast, MMP8 was not upregulated at baseline or 
upon re-stimulation (Fig 3F and Suppl. Fig. V). The upregulation of mmp2 and mmp9, and 
not mmp8 mRNA is in accordance with our previous findings on H3K4Me3 enrichment in the 
promoter regions of MMP2 and 9, but not MMP8 after training with β-glucan (Suppl. Table I).
Foam cell formation is enhanced in trained monocytes-derived macrophages
In the vessel wall, the uptake of oxLDL by macrophages leads to the generation of foam cells, 
thereby contributing to the formation of atherosclerotic plaques6. Therefore, we explored 
foam cell formation of trained monocyte-derived macrophages in our in-vitro model. For 
this purpose, we trained adherent monocytes and subsequently induced foam cell formation 
on day 6 by incubation with a high dose of oxLDL. Oil Red O staining revealed an increased 
intracellular accumulation of lipid droplets in cells stimulated with oxLDL and β-glucan 
compared to control cells (Figure 4A-C). The first 24h priming of monocytes with a low dose of 
oxLDL did not induce foam cell formation (data not shown). To quantify the uptake of oxLDL by 
foam cells, intracellular apolipoprotein B (ApoB) levels were measured and compared to the 
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Figure 4: Foam cell formation is significantly 
enhanced in trained monocytes in vitro.
Adherent monocytes of healthy volunteers 
were exposed to β-glucan, oxLDL or medium 
alone for 24h and rested for 6 days in 
supplemented medium. 4h before foam cell 
induction, the cells were starved from serum 
and were subsequently incubated with a 
high amount of oxLDL (50 µg/mL) for 24h. 
Intracellular apoB levels were measured by 
ELISA (D) and foam cell morphology of trained 
monocytes was compared to untrained 
monocytes by staining with Oil Red O (A-C, 
single cell, 40x; A. RPMI, B. β-glucan, C. oxLDL) 
(representative pictures, n=6, * p<0.05)
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medium control. Both β-glucan and oxLDL exposure significantly increased the intracellular 
ApoB concentration on day 6 (Figure 4D).
Trained monocytes have an increased expression of scavenger receptors and 
reduced expression of cholesterol efflux transporters
OxLDL is taken up by macrophages via scavenger receptors, of which CD36 and Scavenger 
Receptor A (SR-A/MSR-1) are considered the most important5. Interestingly, the genes of 
these receptors showed enriched H3K4me3 in our previous study of training with β-glucan 
(Suppl. Table 1). To study the expression of these scavenger receptors, we trained adherent 
monocytes with oxLDL and on day 6 the cells were processed for analysis by Western 
blot. We found that both CD36 and SR-A were strongly up-regulated in trained monocytes 
in comparison to untrained controls (Fig. 5A). RNA expression analysis also showed up-
regulation of gene expression CD36 and SR-A (Fig 5B-C). Because foam cell formation 
represents the net effect of cholesterol influx and efflux, we also studied the expression of 
the cholesterol efflux transporters ATP Binding Cassette Transporters ABCA1 and ABCG1. For 
both transporters, there was a significant down-regulation of mRNA expression (Fig 5D-E). 
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Figure 5: Expression of scavenger 
receptors CD36 and SR-A is increased 
on trained monocytesAdherent 
monocytes of healthy volunteers 
were exposed to either medium, 
β-glucan or oxLDL for 24h. After six 
days, cells were lysed and equal 
protein concentrations were put 
on SDS-PAGE. Arrows indicate the 
proteins CD36 (~86 kDa), SR-A (~220-
250 kDa, depending on dimerization/
trimerization) and actin as control. 
Two different healthy volunteers are 
shown, pictures are representative of 
at least 6 donors. Protein expression 
for both receptors was enhanced 
for β-glucan training and oxLDL 
training, compared to the untrained 
control (A). Subsequently, mRNA 
expression of CD36 (B) and SR-A (C) 
was measured in cells on day 0 and 
day 6, and show increased mRNA 
expression of the scavenger receptors. 
Cholesterol efflux transporters 
ABCA1 (D) and ABCG1 (E) show 
downregulated mRNA expression 
upon training. (n=6, * p<0.05
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Enriched H3K4me3 on the promoters of pro-atherogenic genes by oxLDL 
exposure
Our previous reports showed that training of monocytes by β-glucan increased H3K4me3 
at the level of the promoters of pro-inflammatory cytokine genes. Here, we investigated 
whether oxLDL training also induced H3K4 trimethylation on genes encoding for pro-
inflammatory cytokines, chemokines, MMPs or scavenger receptors. Therefore, we trained 
adherent monocytes as described above and performed chromatin immunoprecipitation 
(ChIP) on H3K4me3 on day 6, to assess sustained epigenetic changes. The %input H3K4me3 
on the promoters of TNFα, IL-6, MCP-1, IL-18, MMP2, MMP8, MMP9, CD36 and SR-A were 
measured and compared to the untrained control. We confirmed enrichment of H3K4me3 
on the promoters of TNFα, IL-6, MCP-1, IL-18, CD36, SR-A, MMP2 and MMP9 but not MMP8, 
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Figure 6:  Training induces enriched H3K4me3 on the promotors of pro-atherogenic genes. Chromatin 
Immunoprecipitation of histone 3 lysine 4 trimethylation (H3K4me3) was performed on chromatin 
from adherent monocytes from healthy volunteers, which were trained as described previously. 
Quantification of H3K4me3 was performed by qPCR analysis of the promotors of TNFα, IL-6, IL-
18, MCP-1, MMP2, MMP8, MMP9, CD36 and SR-A. Results are shown as %input and myoglobulin 
was used as a negative control. Significant upregulation of H3K4me3 on the promotors of TNFα, 
IL-6, IL-18, MCP-1, MMP2, MMP9, CD36 and SR-A but not MMP8 was shown for β-glucan training 
as well as oxLDL training (n=6, * p<0.05, ** P<0.01, compared to the untrained RPMI control)
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which correlates with the mRNA expression data (Fig. 6). 
OxLDL training of monocytes is dependent on methyltransferases
Finally, to show that training by oxLDL is indeed dependent on histone methylation, we used 
the nonselective pharmacological blocker of histone methyltransferases methylthioadenosine 
(MTA). We pre-incubated adherent monocytes with either culture medium or 1 mM of MTA, 
1h before adding either culture medium, β-glucan or oxLDL. After a 24h incubation period, 
washing and 6 day resting, the cells were re-stimulated on day 6 with LPS and Pam3Cys. As a 
control, cells were also pre-incubated with the nonselective demethylase inhibitor Pargyline 
(3 µM). IL-6 and TNFα concentrations were measured in the supernatant and compared to 
the untrained control (Figure 7A-B and Suppl. Fig VI A-B). Indeed, pretreatment with MTA 
completely abolished the training induced by oxLDL, whereas pargyline did not affect the 
training. Similarly, the augmented foam cell formation on day 6 after training with oxLDL was 
completely abolished by pretreatment with MTA (Fig. 7C). 
Training of oxLDL is induced via a Toll-Like Receptor pathway
oxLDL can activate innate immune cells via TLR4, -2, -6 and CD36 heterodimerization 20. To 
assess the mechanisms of oxLDL training, we pre-incubated the cells with TLR4 and TLR2 
blockers before exposure to oxLDL on day 1. Pretreatment of the cells with both TLR4 and TLR2 
blockers showed a partial reduction of the training effect (Figure 8A-B). Next, we examined 
which intracellular pathways are responsible for the training effect. Therefore, we pretreated 
the cells with pharmacological inhibitors of several intracellular pathway proteins, which are 
known to be involved in the TLR pathways, including ERK, PI3K, SYK and JNK. Pretreatment of 
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Figure 7:  Methyltransferase inhibition prevents training by oxLDL. TNFα (A) and IL-6 (B) 
levels were measured in supernatants of adherent monocytes primed for 24h with either 
β-glucan as a positive control, oxLDL or medium alone in the absence or presence of the 
histone methyltransferase inhibitor MTA and the histone demethylase inhibitor Pargyline. 
At day 6, cells were re-stimulated with LPS. Next, foam cell formation was measured after pre-
treatment of the cells with histone methyltransferase inhibitor MTA (C). Results are shown as 
fold induction, compared to the untrained control group. (n=8 per group, * p<0.05, ** p<0.01) 
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the cells with inhibitors of ERK and PI3K significant reduced the cytokine production on day 
6, whereas inhibition of SYK and JNK showed no effect. (Figure 8D-G). Finally, we excluded 
that CD36-mediated endocytosis of oxLDL is involved, by demonstrating that pretreatment of 
the cells with cytochalasin B, an inhibitor of actin polymerization, did not inhibit the training 
(Figure 8C). 
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Figure 8:  Pathway analysis of oxLDL 
training. TNFα levels were measured 
in supernatants of adherent 
monocytes primed for 24h with either 
β-glucan as a positive control, oxLDL 
or medium alone in the absence or 
presence of TLR4 or TLR2 inhibitors 
(A-B), cytochalasin B (C) or several 
intracellular pathway inhibitors (D-G). 
At day 6, cells were re-stimulated with 
LPS. Results are shown as %change 
in training or fold of change and 
compared to the untrained control 
group. (n=5 per group, * p<0.05)
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DISCUSSION
In this study, we demonstrate that macrophages derived from monocytes that have been 
exposed to modified forms of LDL, including oxLDL, show a long-term pro-inflammatory 
phenotype, due to epigenetic reprogramming of histones. These findings provide a novel 
mechanism that can contribute to the persistent vessel wall inflammation that is characteristic 
of atherosclerosis and can provide novel pharmacological targets to treat patients with 
atherosclerosis. 
It is generally accepted that mononuclear phagocytes play a central role in the various 
stages of atherosclerosis8. The prevailing paradigm has long dictated that monocytes and 
macrophages do not have any immunological memory, in contrast to cells of the adaptive 
immune system. This assumption was recently challenged by the observation that 24 hours 
exposure of human monocytes to C. albicans, β-glucan or BCG induced long-term activated 
macrophages by epigenetic reprogramming of their transcriptional programs13-15. Analysis of 
markers for M1 and M2 macrophages suggested global pan-activation of these cells rather 
then simple skewing into M1 or M2 subtypes15. Since an analysis of the top 500 regions of 
enriched H3K4me3 after stimulation with these microbial products revealed many genes that 
are of importance in the initiation and progression of atherosclerosis (Suppl. Table I), we 
recently argued that this mechanism of trained innate immunity could explain the persistent 
vessel wall activation in atherosclerosis12. 
OxLDL is crucial for the development of atherosclerosis by inducing cytokine and chemokine 
production in macrophages by stimulation of membrane-bound CD36 and TLR’s 2, 4, and 620,21. 
In addition, in isolated endothelial cells, oxLDL promotes IL-8 and MCP-1 secretion by increased 
acetylation of histone H3 and H422. Based on these findings, we have now demonstrated 
that 24h exposure of isolated human monocytes to a low concentration of oxLDL induces 
the formation of macrophages with a long-lasting pro-inflammatory phenotype. These cells 
have several characteristics that can contribute to the formation of atherosclerotic plaques. 
By increased production of IL-6, TNFα, IL-8, IL-18 and MCP-1, these cells can promote and 
maintain inflammation in the vessel wall. Moreover, by up-regulation of scavenger receptors 
CD36 and SR-A and reduced expression of cholesterol export transporters ABCA1 and ABCG1, 
foam cell formation is augmented in these cells. Finally, increased production of MMP2 and 
MMP9 can contribute to destabilization of the atherosclerotic plaque. This long-lasting pro-
atherogenic phenotype induced by oxLDL resulted from enrichment of H3K4Me3 in the 
promoter regions of the various cytokines, chemokines and transporters and was prevented 
by pharmacological inhibition of histone methyltransferases. 
78
Chapter 4
mRNA analysis of oxLDL-stimulated monocyte-derived macrophages revealed no significant 
changes in expression of M1, M2 or DC markers. These findings argue against simple skewing 
of these cells into pro-inflammatory classically activated macrophages or pro-inflammatory 
dendritic cells, as previously also described for stimulation of monocytes with β-glucan15. 
Pathway analyses with pharmacological inhibitors revealed that the effects of oxLDL are 
dependent on stimulation of TLR2 and 4. Experiments with the inhibitor of actin polymerization 
cytochalasin B demonstrated that CD36-mediated endocytosis of oxLDL is not required for 
the training of monocytes to occur. In addition, the observation that acLDL, which also binds 
SR-A but not CD36 suggests that CD36 is not needed to induce this biological effect23. Further 
characterization of the signaling pathways revealed that ox-LDL-induced training is critically 
dependent on activation of the MAP kinases ERK1/2 and PI3-K, but not SYK and JNK.  
Our findings have three important implications. Firstly, our results increase our understanding 
of atherogenesis by revealing a novel mechanism that can contribute to the persistent 
inflammation of the vessel wall that is characteristic for atherosclerosis. Secondly, this 
mechanism might offer a novel explanation for the association between infections and 
atherosclerosis24. Interestingly, administration of BCG, which has been shown to induce 
training of monocytes13, to rabbits fed a cholesterol-enriched diet augments the formation of 
atherosclerosis25. Based on these findings it is tempting to speculate that exposure to micro-
organism such as C. pneumoniae induces histone modifications in circulating monocytes, 
which subsequently home to the arterial endothelial lining and promote atherogenesis. 
In endothelial cells, exposure to C. pneumoniae induces inflammatory gene expression 
via acetylation of histone H4 and phosphorylation and acetylation of histone H326. Finally, 
our results provide novel pharmacological targets to prevent or slow down the process of 
atherosclerosis: histone modifications are not static but amenable to (pharmacological) 
modulation by interfering with histone methyltransferases and histone demethylases. 
Particularly in the field of hematology and oncology, nonspecific methyltransferase inhibitors 
and histone deacetylase inhibitors are already used in clinical trials27T. As a proof-of-concept 
Choi et al showed that pharmacological modulation of histone acetylation can indeed 
modulate the development of atherosclerosis28. Treatment of LDL-R-/- mice with the histone 
deacetylase inhibitor Trichostatin A increased atherosclerotic lesion size, and increased 
macrophage accumulation in aortic sinus. 
A few limitations of our study need to be discussed. Firstly, to prevent H3K4Me3 in our 
experiments, we used MTA, which is a nonselective histone methyltransferase inhibitor. More 
specific inhibitors of H3K4Me3 are currently not available. To exploit our findings to develop 
novel pharmacological strategies in the treatment of atherosclerosis, the development of 
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these more specific inhibitors is critical. Secondly, we only studied H3K4Me3, which is only 
one of the epigenetic marks associated with an open transcriptionally active chromatin. 
Additional experiments are required to fully understand the epigenetic pathways involved in 
oxLDL-induced training of monocytes. Finally, our study only involves in-vitro stimulation of 
isolated human monocytes. It needs to be emphasized that we used LDL that was oxidized in 
vitro using copper sulphate, which probably does not represent fully the in vivo modified LDL 
in the vessel wall. In addition, acLDL does not occur in vivo and we cannot exclude additional 
oxidation of acLDL during the 24 hour incubation period. Therefore, to translate our findings 
to clinical practice, it is critical to perform future studies to investigate whether the epigenetic 
marks can be identified in patients with risk factors for atherosclerosis or patients with 
established atherosclerosis.
In conclusion, we provide the first in vitro evidence that oxLDL exposure of human monocytes 
induces epigenetic histone modifications that result in a long-lasting pro-inflammatory 
phenotype with increased production of pro-inflammatory cytokines and chemokines, 
augmented foam cell formation, and increased production of MMPs. Future studies both 
in animal models and in humans are necessary to provide definitive evidence that this 
mechanism affects the development of atherosclerosis and is amenable to pharmacological 
modulation.  
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SUPPLEMENTARY FIGURES
Type Gene Function
Cytokines and chemotac-
tic proteins
IL-6
MCP-1/CCL2
TNFα
TGFβ
IL-18
Osteopontin/SPP1
AIF1
Inflammation, induction of 
SMC proliferation
Scavenger receptors and 
foam cell formation
CD36
MSR-1
SOAT1, 
ACAT2
Uptake of oxLDL
Matrix degradation, 
plaque instability
Cathepsin B
Cathepsin H
Cathepsin S
Cathepsin L
A2M
MMP9
MMP2 
ADAM9
Matrix degradation, plaque 
instability, reduction of 
cholesterol efflux in macro-
phages
Other inflammatory CD63
LTA4H
CD74
LGALS3
CD18
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Other LP-PLA2
Lipase A
LPL
FABP4, 
AQP9, 
PFN1, 
ACSL1
HSP90
GRN, 
LAMP2
PPIB
CRABP2
S100A4
IFI30
ACP5
CFL1
ALDOa
Lipases induce the oxidation 
and enzymatic modification 
of LDL
Supplementary Table I. β-glucan training induces H3K4me3 enrichment of various genes 
that are relevant for the process of atherosclerosis
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Supplementary Figure I. Cytotoxicity and stimulatory effects of LDL and oxLDL. The 
supernatant of the first 24h incubation period was studied for the release of LDH as a result 
of cytotoxic cell death (A). No significant increase of LDH release was observed for either 
β-glucan, LDL or oxLDL up to 10 μg/ml. 50 and 100 μg/ml oxLDL induced cytotoxic cell death 
(n=5). Incubation with these stimuli did not induce any cytokine production itself (IL-6, TNFα 
and IL-1β) at t=24h.  
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Supplementary Figure II. Priming with low concentrations of oxLDL and acetylated LDL 
but not native LDL can induce upregulated IL-6 and TNFα production upon re-stimulation 
with Pam3Cys. IL-6 and TNFα production was measured in the supernatants of adherent 
monocytes from healthy volunteers, exposed for 24h to either medium alone, β-glucan as 
a positive control, or different concentrations of oxidized LDL (A-B), acetylated LDL (C-D) or 
native LDL (A-B). After washing and six days of resting period, monocytes were re-stimulated 
with Pam3Cys (n=6, * p<0.05, ** p<0.01 compared to the untrained control).
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Supplementary Figure III. Effect of continuous exposure of monocytes to oxLDL during 
7 days on cytokine production. Adherent monocytes were first exposed for 24h to RPMI, 
β-glucan or 10 μg/ml oxLDL, where after the stimulus was washed away and the cells were 
rested in RPMI medium supplemented with pooled human serum with or without 5 μg/
ml oxLDL for 6 days. After 6 days, the cells were re-stimulated with LPS and Pam3Cys, and 
IL-6 and TNFα levels were measured in the supernatant. (n=6, * p<0.05 compared to the 
untrained control) 
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Supplementary figure IV. Characteristics of trained cells on day 6. The monocyte-derived 
trained cells on day 6 were studied for differentiation markers for M1 and M2, as well as 
DC markers, and compared to the untrained control. No differences were observed in M2 
markers ARG1 and CD163, or M1 markers iNOS, TLR4 and TLR2 or DC markers HLA-DRB1, 
CD83 and DC-SIGN (n≥3 per group).  
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Supplementary Figure V. baseline mRNA expression levels. RNA expression levels of 
unstimulated cells were measured at day 6 and compared to the untrained control. No 
significant differences were observed for il-6, tnfα, il-8 and mmp8 expression levels. Baseline 
expression of il-18 and mmp9 were significantly increased, and a non-significant trend was 
observed for mcp-1. Mmp2 expression was significantly downregulated upon training (n=6, 
* P<0.05).
il-6
baseline
0.0
0.1
0.2
0.3
0.4
0.5
ns
ns
Re
la
tiv
e
m
RN
A
ex
pr
es
sio
n
mcp-1
baseline
0
10
20
30
40
ns
ns
Re
la
tiv
e
m
RN
A
ex
pr
es
sio
n
tnfα
baseline
0.0
0.5
1.0
1.5
ns
ns
Re
la
tiv
e
m
RN
A
ex
pr
es
sio
n
mmp2
baseline
0
2
4
6
*
*
Re
la
tiv
e
m
RN
A
ex
pr
es
sio
n
il-18
baseline
0
5
10
15
*
*
Re
la
tiv
e
m
RN
A
ex
pr
es
sio
n
mmp8
baseline
0.0
0.5
1.0
1.5
ns
ns
Re
la
tiv
e
m
RN
A
ex
pr
es
sio
n
il-8
baseline
0
2
4
6
8
ns
ns
Re
la
tiv
e
m
RN
A
ex
pr
es
sio
n
mmp9
baseline
0
20
40
60 0.1094
*
Re
la
tiv
e
m
RN
A
ex
pr
es
sio
n
RPMI β-gluca n oxLDL
89
oxLDL induced trained immunity in vitro
4
Supplementary Figure VI. Methyltransferase inhibition prevents training of monocytes by 
oxLDL. TNFα (A) and IL-6 (B) levels were measured in supernatants of adherent monocytes 
primed for 24h with either β-glucan as a positive control, oxLDL or medium alone in the 
absence or presence of the histone methyltransferase inhibitor MTA and the histone 
demethylase inhibitor Pargyline. At day 6, cells were re-stimulated with Pam3Cys. Results are 
shown as fold induction, compared to the untrained control group. (n=8 per group, * P<0.05, 
** p<0.01)
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ABSTRACT
Background
Elevated lipoprotein(a) [Lp(a)] is a prevalent, independent cardiovascular risk factor but the 
underlying mechanisms responsible for its pathogenicity are poorly defined. Since Lp(a) 
is the prominent carrier of pro-inflammatory oxidized phospholipids (OxPL), part of its 
atherothrombosis might be mediated through this pathway. 
Methods
In vivo imaging techniques MR imaging, 18F-FDG-PET/CT and SPECT/CT were used to measure 
subsequently atherosclerotic burden, arterial wall inflammation and monocyte trafficking 
to the arterial wall. Ex vivo analysis of monocytes was performed using FACS analysis, 
inflammatory stimulation assays and transendothelial migration assays.  In vitro studies to 
the pathophysiology of Lp(a) on monocytes were performed using an in vitro model for 
trained immunity.
Results
We show that subjects with elevated Lp(a) (108 [50-195] mg/dL; n=30) have increased arterial 
inflammation and enhanced PBMCs trafficking to the arterial wall, compared with subjects 
with normal Lp(a) (7 [2-28] mg/dL; n=30). In addition, monocytes isolated from subjects 
with elevated Lp(a) remain in a long-lasting primed state, as evidenced by an increased 
capacity to transmigrate and produce pro-inflammatory cytokines upon stimulation (n=15). 
In vitro studies show that Lp(a) contains OxPL and augments the pro-inflammatory response 
in monocytes derived from healthy controls (n=6). This effect was markedly attenuated by 
inactivating OxPL on Lp(a) or removing OxPL on apo(a). 
Conclusions 
These findings demonstrate that Lp(a) induces monocyte trafficking to the arterial wall and 
mediates pro-inflammatory responses through its OxPL content. These findings provide a 
novel mechanism by which Lp(a) mediates cardiovascular disease. 
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INTRODUCTION
Lipoprotein(a) [Lp(a)] is a plasma lipoprotein composed of apolipoprotein(a) [apo(a)] 
covalently bound to apolipoprotein B-100 (apoB) of a low density lipoproteins (LDL)-like 
particle (Figure S1). A role for Lp(a) in atherogenesis has now been established by both meta-
analyses of epidemiological studies, as well as by genome-wide association and Mendelian 
randomization studies showing a strong, independent and likely causal relationship between 
Lp(a) and myocardial infarction, stroke, peripheral artery disease and calcific aortic valve 
stenosis.1,2 
Despite evidence of causality and the fact that one-fifth of the general community has 
elevated Lp(a) levels of >50 mg/dl3, Lp(a) is not routinely measured in clinical risk assessment. 
This reluctance appears to be due to a lack of understanding of the pathophysiological 
mechanisms by which Lp(a) mediates cardiovascular disease (CVD),  as well as the lack of 
specific therapeutic interventions to potently lower Lp(a) levels4. Consistent with known 
mechanisms of atherogenicity of LDL, Lp(a)’s atherogenic capacity could in part reflect the 
response-to-retention phenomenon of an apoB-containing particle5. The disproportionately 
large impact of Lp(a) on CVD  risk compared with LDL, however, implies that additional 
pathogenic pathways need to be considered6. 
Over the last decade, a large body of experimental and clinical evidence has documented that 
Lp(a) is the main lipoprotein carrier of phosphocholine (PC) containing oxidized phospholipids 
(OxPL) in plasma7–9, which has led to the hypothesis that a major component of the risk mediated 
by Lp(a) is through its content of OxPL10. OxPL is recognized as a danger associated molecular 
pattern (DAMP) by pattern recognition receptors (PRRs) on innate immune cells, leading to 
a wide range of pro-inflammatory and plaque destabilizing processes11–13. In epidemiological 
studies, the level of OxPL on apoB-containing lipoproteins (OxPL-apoB), which predominantly 
reflects Lp(a) associated OxPL, was found to be highly predictive of future CVD risk14,15. Most 
recently, a further link between Lp(a), OxPL and inflammation was discovered, showing that 
the risk of Lp(a) and OxPL-apoB in mediating coronary atherogenesis and cardiovascular 
events was conditional on an inflammatory IL-1 haplotype16. Here, we report that subjects 
with elevated plasma Lp(a) levels are characterized by increased inflammatory activity of 
the arterial wall as well as an enhanced inflammatory response of circulating monocytes, 
for which OxPL carried by Lp(a) were identified as obligatory intermediates. These findings 
indicate a novel link between Lp(a), its associated OxPL and accelerated atherogenesis in 
humans. 
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METHODS
Study subjects
This was a single-center study in subjects with elevated Lp(a) and subjects with normal Lp(a), 
matched for age, gender and BMI. Exclusion criteria consisted of active smoking, history of 
clinically-manifest cardiovascular disease or diabetes, and lipid lowering therapies including 
statins. Each subject provided written informed consent. The study and radiation exposure 
(<10mSv in total) was approved by the local institutional review board and conducted 
according to the principles of the International Conference on Harmonization–Good Clinical 
Practice guidelines.
Biochemical Measurements 
EDTA plasma obtained through venous blood samples were taken after overnight fasting 
and stored using standardized protocols. Plasma Lp(a), total cholesterol (TChol), high density 
lipoprotein cholesterol (HDL-C) and triglyceride (TG) levels were analyzed using commercially 
available enzymatic methods. Low density lipoprotein cholesterol (LDL-C) levels were 
calculated using the Friedewald equation and subsequently corrected for Lp(a)-cholesterol 
(LDLc – [Lp(a) in mmol/L*0.3])17. Oxidized phospholipids on apolipoprotein B-100 (OxPL-
apoB) and on apolipoprotein(a) (OxPL-apo(a)), were measured as follows: apoB-100 and 
apo(a) were captured on microtiter wells using appropriate antibodies and the content of 
OxPL quantified by monoclonal antibody E06 and  reported as nM, as previously described10. 
MR imaging 
MR images were obtained with a 3.0 T whole-body scanner (Ingenia, Philips Medical Systems, 
Best, The Netherlands), using an 8 channel dedicated bilateral carotid artery coil (Shanghai 
Chenguang Medical Technologies, Shanghai, China). The normalized wall index (NWI= 
mean wall area/outer wall area) was calculated18 by one blinded experienced reader at the 
core laboratory using semi-automated measurement software (VesselMass, Leiden, the 
Netherlands). 
PET/CT imaging 
PET/CT scans were performed on a dedicated scanner (Philips, Best, the Netherlands)19. All 
subjects fasted for at least 6 hours prior to infusion of 18F-FDG (200 MBq). After 90 min, 
subjects underwent PET imaging initiated with a low-dose non-contrast enhanced CT for 
attenuation correction and anatomic co-registration. PET/CT images were analyzed by blinded 
readers using OsiriX (Geneva, Switzerland; http://www.osirix-viewer.com/). The target-to-
background-ratio (TBR) was calculated from the ratio of arterial SUV and venous background 
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activity, as described previously19. 
SPECT/CT imaging 
SPECT/CT scans were performed at 3, 4.5 and 6 hours post infusion of 99m Tc-labeled 
autologous peripheral blood mononuclear cells (PBMCs) (200 MBq) on a dedicated scanner 
(Symbia T16, Siemens, Erlangen, Germany)20. In each subject, around 20.106 PBMCs were 
isolated and labeled with 99mTc-(1100 megabecquerel/2mililiter). SPECT/CT images were 
analyzed by blinded readers using OsiriX20. Accumulation of labeled PBMCs in the arterial 
wall was quantified by the ratio of the averaged maximum counts in the artery divided by 
the averaged mean counts in the blood, reported as the arterial-wall-to-blood-ratio (ABR)20. 
Flow cytometry 
Blood samples were collected into K3EDTA BD Vacutainer1 (BD Biosciences, San Jose, CA) 
tubes, after which 50 μL of whole blood was added to each flow cytometry tube plus the 
appropriate amounts of each antigen specific mAb were added, defined after titration of the 
dose recommended by the manufactures. See supplementary for detailed information.
Cells 
Human PBMCs were isolated from blood using Ficoll-Paque Premium (d=1.077g/ml) density 
gradient centrifugation (GE Healthcare, UK). For in vitro experiments, human PBMCs were 
isolated from blood of healthy volunteers (Sanquin Bloodbank, Nijmegen, The Netherlands). 
CD14pos monocytes were isolated using a Ficoll-Paque plus (Pharmacia Biotech, Uppsala, 
Sweden) density gradient, followed by magnetic activated cell sorting (MACS) using CD14-
coated MicroBeads according to manufacturer’s instructions (MACS, Miltenyi Biotec, Leiden, 
The Netherlands). Primary Human Arterial Endothelial Cells (HAECs) were purchased from 
Lonza (Baltimore, MD) and routinely cultured on fibronectin (FN; 10 μg/ml) coated culture 
flasks (TPP, Switzerland) or glass-slides for imaging in EGM2 medium containing SingleQuots 
(Lonza). Endothelial cells were cultured up to 6 passages. 
Antibodies and reagents 
Actin (clone AC-40) mAb was purchased from Sigma-Aldrich (Zwijndrecht, Netherlands). 
Filamentous actin (F-actin) was stained with Phalloidin Texas-red (Invitrogen), and the 
nucleus with Hoechst 33258. β-glucan (b-1,3-(D)-glucan) was kindly provided by Professor 
David Williams (College of Medicine, Johnson City, USA), r-apo(a) (8K-IV), r-apo(a) 17K and 
17KΔLBS10 were derived as previously described9. Stimuli and inhibitors used are oxPAPC 
(Invivogen), LPS (Sigma-Aldrich, St. Louis, MO; from E. coli serotype 055:B5, further purified 
as described)21, Pam3Cys (EMC microcollections, Tübingen, Germany; L2000), anti-OxPL 
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antibody Mouse monoclonal EO6 (Avanti Polar Lipids, Inc, Alabaster, Alabama, USA, 330001), 
purified mouse IgM Isotype control antibody (Biolegend, San Diego, California, USA, 401602). 
In the monocyte assays, Lp(a), LDL and HDL were isolated from 3.5 mL plasma from subjects 
with either high or normal Lp(a) levels by KBr-density gradient ultracentrifugation; plasma 
density was adjusted to d=1.25 g/mL with solid KBr (0.385 g/mL plasma), a discontinuous 
gradient was formed by carefully layering 2 mL of d=1.225 g/mL KBr solution, followed by 4 
mL of d=1.100 g/mL KBr solution, and a top layer of 3 mL of d=1.006 g/mL KBr solution was 
added. The samples were centrifuged for 20 hours at 10°C at 29,000 rpm in a SW 41 Ti rotor 
(Beckman Coulter Inc., CA). The LDL, Lp(a) and HDL fractions were sliced out and dialyzed 
against PBS. LAL assay showed negligible endotoxin levels (<0.05 EU/mL) in the isolated 
fractions. For the western immunoblots, Lp(a) was purified from the lipid apheresis eluate of 
a single donor undergoing LDL apheresis with high Lp(a) levels (140 mg/dL) and 16 KIV and 18 
KIV repeats. The apheresis eluate was subjected to ultracentrifugation in NaBr and the 1.08 
> d > 1.06 g/mL fraction was collected. This fraction was applied to a SW-400 gel filtration 
column, which was eluted in 0.5mL fractions. Each fraction was assayed for the presence 
of apo(a) and apoA-I by ELISA. The fractions containing apo(a) but not apoAI were pooled, 
buffer exchanged into PBS and concentrated using Amicon centrifugal filter units (Millipore). 
Apo(a) was dissociated from Lp(a) based on the methods described previously22,23. Briefly, 
the solution containing Lp(a) was adjusted to a final concentration of 100 mM ACA and 2 mM 
dithiothrietol and incubated at room temperature for 1 h. The reaction mixture was adjusted 
to a density of 1.3 g/ml with NaBr and the solution was centrifuged at 50,000 rpm to separate 
apo(a) from the LDL released by reduction and intact Lp(a). 
Western immunoblot
Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) of apo(a), Lp(a), and 
LDL (100 ng protein), in reducing (with beta-mercaptoethanol (BME)) and non-reducing 
conditions, was carried out using 3-8% gradient polyacrylamide gels in Tris-acetate SDS 
running buffer. Proteins were transferred to a PVDF membrane, which was blocked with 3% 
BSA in PBS-Tween. Membranes were then incubated with either biotinylated LPA4 (0.004 mg/
ml), biotinylated E06 (0.004 mg/ml), or MB47 (0.006 mg/ml) probing for apo(a), OxPL, and 
human apoB-100 respectively. Protein detection was performed with streptavidin conjugated 
to horseradish peroxidase (HRP) from (R and D Systems) and visualized with ECL (Amersham).
Detection of OxPL by LC-MS/MS
To document the presence of PC-containing OxPL in Lp(a) purified by ultracentifugation, 
Lp(a) was isolated from 3 donors. Details of the LC-MS/MS procedures is described in the 
Supplement. 
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Transendothelial migration assay 
Human aortic endothelial cells (HAECs) were cultured on a fibronectin (FN)-coated glass cover 
to confluency and stimulated overnight, i.e. 12 hours with TNFα (10 ng/ml)24. Monocytes 
(1*106 cells/ml) were added to the HAECs monolayer for 30 min in a humidified atmosphere 
of 5% CO2 at 37 °C and fixed with 3.7% formaldehyde (Sigma-Aldrich, Zwijndrecht, the 
Netherlands). After fixation, multiple images were recorded with a Zeiss Axiovert 200 
microscope (Plan-apochromat 10x/0.45 M27 Zeiss-objective; Carl Zeiss Inc., Jena, Germany), 
and analyzed using Image-J software (http://rsb.info.nih.gov/nih-image/). After treatment and 
fixation in 3.7% formaldehylde in PBS (+1 mM CaCl2, 0.5 mM MgCl2), cells were permeabilized 
in PBS-T (PBS + 0.1% Triton-X100) for 10 min, stained for nuclei and filamentous actin for 45 
min, washed and stored in PBS (+1 mM CaCl2, 0.5 mM MgCl2) until imaged using a confocal 
laser-scanning microscope (LSM510 META, Carl Zeiss MicroImaging, Jena, Germany) with a 
Zeiss Plan-Apochromat, 63x /1.40 oil objective. Monocyte motility was determined by plating 
freshly isolated monocytes into fibronectin (Sanquin Reagents, Netherlands) coated Lab-Tek 
Chambers (Thermo-Scientific, Rochester, NY) containing N-2-Hydroxyethylpiperazine-N’-2-
Ethanesulfonic Acid (HEPES)-buffer + 1mM CaCl2 + 0.5% v/v human albumin and 0.1% w/v 
glucose. Videos were acquired using a wide-field microscope (Axio Observer Z1, Carl Zeiss 
MicroImaging, Jena, Germany) equipped with a humidified atmosphere climate chamber 
with 5 % CO2 and 37 °C, and analysed using the Tracking Tool (Gradientech, Uppsala Science 
Park, Uppsala, Sweden).  
In vitro monocyte priming and challenge assay 
Monocytes were isolated from PBMCs by adhering 5·106 PBMCs/ml to polystyrene for 1h at 
37°C, 5% CO2 in 96-, or 6-well culture plates (Corning, New York, USA). Non-adherent cells 
were removed by washing three times with warm PBS. Monocytes were cultured in RPMI 
1640 Dutch-modified culture medium (Life Technologies/Invitrogen, Breda, The Netherlands) 
supplemented with 10 mM glutamine (Invitrogen), 10 µg/mL gentamicin (Centraform), 10 
mM pyruvate (Invitrogen) and 10% pooled human plasma. The monocytes were primed for 
24 hours with either RPMI, β-glucan (5 μg/ml), isolated Lp(a) (0.5-250 µg/ml), LDL (10 μg/
ml), HDL (10 μg/ml ), r-apo(a) constructs (8K-IV 0.001-0.5 µg/ml; 17K and 17KΔLBS10 0.1 
µg/ml), OxPAPC (0.05-10 µg/ml) or 10% plasma from subjects with high or normal Lp(a) 
levels (before and after apoB precipitation of the apoB-containing lipoprotein fraction with 
polyethylene glycol 8000, Sigma P-213925), after which the cells were washed and incubated 
in supplemented culture medium for 6 days. In inhibition experiments using E06 (1 nM) or 
IgM control (1 nM), stimuli were pre-incubated with the inhibitors 1h prior to adding the 
stimuli to the cells. After 6 days of rest in supplemented RPMI medium, cells were exposed 
to either medium alone, 10 µg/mL Pam3Cys or 10 ng/ml lipopolysaccharide. After 24h of 
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incubation, supernatants were collected and stored at -20°C. Production of cytokines was 
measured in supernatants by ELISA according to the manufacturer’s instructions (TNFα (R&D 
Systems, Minneapolis, USA) and IL-6 (Sanquin, Amsterdam, The Netherlands), or the human 
inflammatory cytokine Cytometric Bead Array according to the manufacturer’s instructions 
(BD Biosciences, 551811).
Statistical Analysis 
Data are presented as the mean (standard deviation) or the median (min-max) for continuous 
variables, and as a number (percentage) for categorical variables. To examine the difference 
in clinical characteristics, imaging parameters and ex vivo monocyte phenotype and function 
between subjects with elevated or normal Lp(a) we performed student T-test or Mann-
Whitney U test for normal and non-normal distributed variables, respectively. Normality was 
examined by means of inspection of histograms and the Shapiro-Wilk test. Variances in both 
groups were examined and tested for similarity using Levene’s Test for Variance. To assess the 
differences in PBMCs accumulation as imaged with SPECT, a linear mixed model for repeated 
measurements was applied (fig 1D-F). In vitro monocyte experiments were performed at 
least 6 times, and analyzed using the Wilcoxon signed-rank test. A two-sided P-value below 
0.05 was considered statistically significant. All data were analyzed using Prism version 5.0 
(GraphPad software, La Jolla, California) or SPSS version 21.0 (SPSS Inc., Chicago, Illinois). 
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RESULTS 
Increased arterial wall inflammation in subjects with elevated Lp(a)
To determine if Lp(a) influences arterial wall inflammation, we included subjects with elevated 
Lp(a) levels (mean of 108 mg/dL [range 50-195]; n=30) or normal Lp(a) levels (mean of 7 mg/
dL [range 2-28]; n=30) matched for age, gender and body mass index (Table 1). None of the 
subjects were currently smoking, had a history of clinically-manifest cardiovascular disease or 
diabetes, or used lipid-lowering therapies such as statins. Aside from Lp(a) levels, subjects did 
not differ in blood pressure, non-Lp(a) lipoprotein profile or circulating leukocytes (Table 1). 
As expected, subjects with elevated Lp(a) exhibited significantly higher levels of OxPL-apoB 
and specifically, OxPL on apo(a) lipoproteins (OxPL-apo(a)) (Table 1). The normalized wall 
index (NWI) of the carotids, as assessed with magnetic resonance imaging (MRI)18, was not 
significantly different between groups (Table 1, Figure S2A). 
Positron emission tomography with computed tomography (PET/CT) imaging was performed 
to image arterial wall 18F-fluorodeoxyglucose uptake (18F-FDG), as a marker of arterial wall 
inflammation26. In subjects with elevated Lp(a), arterial wall 18F-FDG uptake, quantified as 
Figure 1: Increased arterial wall inflammation in subjects with elevated Lp(a). (A) Cross-sectional 18F-FDG 
PET/CT images demonstrating an increased 18F-FDG uptake (yellow) in the left carotid (top, indicated 
by white arrow) and aorta (bottom) in a subject with normal Lp(a) (left) and a subject with elevated 
Lp(a) (right), quantified as the maximum target to background ratio (TBR) in the (B) carotid arteries, and 
(C) ascending aorta in subjects with elevated Lp(a) (n=30) and normal Lp(a) (n=30), (D) cross-sectional 
SPECT/CT images demonstrating increased autologous 99mTc-labeled PBMCs accumulation (blue; at T=6 
hours post-infusion), depicted as the arterial wall to blood pool ratio (ABR) at the level of (E) the carotids 
and (F) ascending aorta in subjects with elevated Lp(a) (n=15) and normal Lp(a) (n=15). **=p<0.01.
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the target to background ratio (TBR), was significantly higher compared with subjects with 
normal Lp(a) (Figure 1A); both in the carotids (Figure 1B) as well as in the aorta (Figure 1C). 
Of note, the inflammatory activity in subjects with elevated Lp(a) did not correlate to arterial 
wall dimensions (NWI, normalized wall index) as assessed with MRI (Figure S2B). 
In view of the intricate relation between resident arterial wall macrophages and circulating 
monocytes27, we subsequently investigated the impact of elevated Lp(a) on circulating 
immune cells in vivo. We used an imaging approach to monitor the trafficking of technetium-
99m (99mTc)-labeled autologous PBMCs to the arterial wall, using single photon emission 
computed tomography with computed tomography (SPECT/CT)20. PBMCs were found 
to accumulate at a substantially higher rate in the arterial wall within 3-6 hours after re-
infusion in subjects with elevated Lp(a) compared with those with normal Lp(a) (Figure 1D). 
The arterial wall-to-blood-pool ratio (ABR)20 values were significantly higher in subjects with 
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Figure 2. Monocytes have an activated and inflammatory phenotype in Lp(a) subjects. (A) Bar 
graphs display the expression (quantified as delta MFI) of chemokine, adhesion and transmigration 
markers on monocytes as assessed with flow cytometry in subjects with elevated Lp(a) (n=15, black 
bars) compared with normal Lp(a) (n=15, grey bars), (B) bar graph and (C) microscope images 
demonstrating increased endothelial transmigration of monocytes (calculated per at least 4 fields of 
view) isolated from subjects with elevated Lp(a) (n=15, black bar) compared with normal Lp(a) (n=15, 
grey bar), coinciding with augmented spreading and adhesion as illustrated nucleus (Hoechst, blue) 
and F-actin (green) stain, (D) bar graphs showing expression (quantified as delta MFI) of scavenger 
and other receptors on monocytes in subjects with elevated Lp(a) (n=15, black bars) compared with 
subjects with normal Lp(a) (n=15, grey bars), (E-H) in response to an overnight challenge to Pam3Cys 
(10 μg/ml), monocytes isolated from subjects with elevated Lp(a) (n=15, black bars) produced higher 
levels of IL-1β (E), IL-6  (F) and TNFα (G) and lower levels of IL-10 (H), compared with monocytes 
of subjects with normal Lp(a) (n=15, grey bars). ^=p<0.06, *=p<0.05, **=p<0.01, ***=p<0.001.
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elevated Lp(a) in both the carotids (Figure 1E) and aorta (Figure 1F). Collectively, these in 
vivo imaging studies indicate that subjects with elevated Lp(a) levels have increased arterial 
inflammatory activity, which coincides with more autologous immune cell accumulation in 
their arterial wall. Further, there is a strong correlation between the TBR indices from PET/CT 
imaging and the ABR values from PMBCs imaging and respective Lp(a) plasma levels (Table 2). 
Monocytes increasingly migrate in subjects with elevated Lp(a) 
We next questioned whether the increased arterial wall immune cell accumulation was 
preceded by an intrinsic cellular activation leading to enhanced migration. To this end, we 
analyzed adhesion and migration markers of blood monocytes in subjects with elevated 
versus normal Lp(a) using flow cytometry (gating strategy in Figure S3A)28. Monocytes from 
subjects with elevated Lp(a) expressed more C-C chemokine receptor type 7 (CCR7), L-selectin 
(also described as the cluster of differentiation 62 ligand; CD62L) and integrin alpha and beta 
chains; CD11b, CD11c and CD2929 (Figure 2A), for which the latter two showed a (borderline) 
significant correlation with the Lp(a) plasma levels (Table 2).
To evaluate the functional relevance of increased expression of adhesion and migration 
markers, we performed transendothelial migration (TEM) experiments24 with monocytes 
isolated from subjects with and without elevated Lp(a). Twelve hours prior to performing 
the migration assay, human arterial endothelial cells (HAECs) were stimulated with TNFα 
to mimic dysfunctional endothelium. Freshly isolated monocytes of subjects with elevated 
Lp(a) showed a 3-fold higher TEM rate compared with monocytes isolated from subjects 
with normal Lp(a) (Figure 2B). Staining of the nucleus and F-actin illustrated that monocytes 
derived from subjects with elevated Lp(a) have augmented spreading and adhesion compared 
with monocytes of subjects with normal Lp(a) (Figure 2C). In addition, monocytes of subjects 
with elevated Lp(a) also showed higher motility when plated on fibronectin-coated surfaces 
(movie S1), lending further support to an increased transmigratory tendency. 
Thus, in subjects with elevated Lp(a), circulating monocytes exhibit an enhanced capacity to 
adhere and transmigrate the endothelium. Whereas generalized markers of inflammation, 
such as plasma levels of CRP, do not relate with Lp(a) levels, a number of inflammatory 
markers measured on the monocytes of the subjects are proportional to their Lp(a) levels 
(Table 2).
Atherogenic monocyte response in subjects with elevated Lp(a)
In addition to migration markers, monocytes of subjects with elevated Lp(a) expressed 
increased levels of the scavenger receptors CD36 and SRA (Figure 2D), also correlating to Lp(a) 
plasma levels (Table 2), whereas the expression of other receptors such as CD163, CD200R 
and CD206 was not different (Figure 2D). To assess whether this activated phenotype also 
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translated to an enhanced inflammatory response, we performed a challenge assay using 
Toll-like receptor (TLR) ligands. After an overnight stimulation with a TLR2 ligand (Pam3Cys), 
monocytes isolated from subjects with elevated Lp(a) produced higher levels of tumor 
necrosis factor alpha (TNFα), interleukin 1 beta (IL-1β) and IL-6 (Figure 2E-G). Conversely, the 
production of IL-10 was lower (Figure 2H). Similar results were observed upon stimulation 
with the TLR4 ligand lipopolysaccharide (LPS) (Figure S4A-D). In aggregate, we observed 
an activated state of monocytes, potentially resulting from their priming by Lp(a), or some 
associated component found in the plasma of subject with elevated Lp(a).
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Figure 3. Isolated Lp(a) primes monocytes towards a responsive state. (A,B) priming of healthy 
monocytes with plasma of a subject with high Lp(a) (1st grey bar) for 24h resulted in an increased 
production of TNFα and IL-6 upon re-stimulation with Pam3Cys (10 µg/mL) on day 6, compared with 
plasma of normal Lp(a) (1st white bar). In addition, after lipid-depletion (2nd white and grey bar) 
this effect of high Lp(a) plasma was profoundly reduced compared to the undepleted control (n=6), 
(C,D) priming of healthy monocytes with β-glucan (5 µg/mL, positive control, black bar) or Lp(a) 
(grey bar, 250 μg/mL) for 24h, induced an increased production of TNFα and IL-6 upon re-stimulation 
with Pam3Cys (10 µg/mL) on day 6, compared with priming with RPMI (negative control, white bar). 
LDL (grey bar, 10 μg/mL)  or HDL (grey bar, 10 μg/mL) did not induce this increase (n=6) (E,F) in 
addition, various concentrations of Lp(a) (grey bars) for 24h, resulted in a dose-dependent increased 
production of TNFα and IL-6 upon re-stimulation with Pam3Cys (10 µg/mL) on day 6 (n=6) compared 
to priming with RPMI (negative control, white bar) (G,H) priming of healthy monocytes with LDL (10 
μg/mL) (grey bar) did not result in higher cytokine levels after Pam3Cys (10 µg/mL) compared to 
the negative control RPMI (white bar), in contrast to β-glucan (5 µg/mL, positive control, black bar) 
(n=6), whereas (I,J) priming of healthy monocytes with β-glucan (5 µg/mL, positive control, black bar) 
or the r-apo(a) construct 8K-IV (grey bars) induced increased cytokine levels after Pam3Cys (10 µg/
mL) (n=6), compared with RPMI (negative control, white bar). *=p<0.05, **=p<0.01, ***=p<0.001.
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Lp(a) and its associated OxPL induce prolonged responsiveness in monocytes
Lp(a) was isolated by ultracentrifugation, the lipid soluble material was extracted, and LC-MS/
MS was performed on the extracted material an shown to have the following OxPLs: POVPC, 
PGPC, PONPC, PAzPC and KDdiA-PC, with PONPC being the most abundant (Figure S5A-B). 
To address priming by Lp(a), or some associated component found in the plasma of subject 
with elevated Lp(a), we performed a series of in vitro studies, in which we analyzed the 
ability of various plasma components to activate monocytes. As a positive control for 
monocyte activation we used β-glucan, a cell wall component of C. Albicans, since we have 
extensively demonstrated that β-glucan induces a long-lasting pro-inflammatory phenotype 
in monocytes30.
First, priming of healthy monocytes with plasma from subjects with high Lp(a) for 24 hours, 
with a subsequent washout and resting period, increased the production of TNFα and IL-6 
after an overnight challenge with the TLR2 and TLR4 ligands Pam3Cys or LPS, respectively 
(Figure 3A,B and Figure S6A,B), whereas normal Lp(a) plasma did not activate monocytes. 
Lipid depletion of the above plasma profoundly decreased the cytokine production of the 
in-origin high Lp(a) plasma, indicating that a lipophilic particle might be responsible for the 
observed effect (Figure 3A,B and Figure S6A,B).
In line with the difference in Lp(a) levels between both plasma, priming of healthy monocytes 
with purified Lp(a) for 24 hours, induced an increased production of TNFα and IL-6 at day 7, 
after an overnight TLR challenge (Figure 3C-F and Figure S6C-F). Please note that priming with 
the isolated lipoprotein fractions LDL and HDL did not induce monocyte activation (Figure 
3C,D and Figure S6C,D).
Next, we assessed the effects of Lp(a)’s main components separately; using isolated LDL, 
apo(a) separated from Lp(a), and recombinant apo(a) [r-apo(a)] constructs containing various 
numbers of kringles9. Whereas priming with LDL had no prolonged effects on monocytes 
(Figure 3G,H and Figure S6G,H), priming with an 8 kringle IV (8K-IV) r-apo(a) construct 
elicited an enhanced cytokine response in healthy donor monocytes at day 7 after overnight 
stimulation with TLR ligands (Figure 3I,J and Figure S6I,J). 
In view of the role of Lp(a) as carrier of OxPL7–9, we hypothesized an important role for 
OxPL in monocyte activation. In support of this concept, we show via immunoblotting that 
both Lp(a) and apo(a) contain OxPL, whereas LDL isolated from the same plasma as Lp(a) 
does not (Figure 4A).  To further demonstrate the role of OxPL in mediating the activation 
of monocytes, we utilized monoclonal antibody E06, which binds to the PC moiety of OxPL 
and potently inhibits their pro-inflammatory properties, but does not bind to native, non-
oxidized phospholipids31–33. Whereas the 8K-IV apo(a) construct, containing covalently bound 
OxPL9,  potently activated monocytes (Figure 3I,J and Figure S6I,J), pre-incubation of the 8K-
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IV construct with E06 inhibited its priming effects  (Figure 4B,C and Figure S6K,L). 
The role of OxPL was further validated using 2 additional constructs consisting of 17 kringles 
(17K) but varying in the functionality of the lysine binding site (LBS) on kringle IV type 10 
(KIV10), which in turn is related to the ability of the apo(a) constructs to have covalently 
bound OxPL 9,34. Thus, 17K is a r-apo(a) construct with an intact LBS that has covalently 
bound OxPL, whereas 17KΔLBS10 has a mutated LBS and lacks immunologically detected 
OxPL9,34.  Consistent with our previous findings with Lp(a), priming with 17K induced a state of 
Figure 4. OxPL induce the enhanced monocyte response . (A) Immunoblotting of purified apo(a), 
Lp(a) and LDL; OxPL, apo(a), and apoB-100 resolved on SDS-PAGE in reducing and non-reducing 
conditions, were detected using the monoclonal antibodies E06, LPA4 and MB47 respectively. 
E06 immunostained apo(a) and Lp(a) but not LDL isolated from the same subject, (B,C) pre-
treatment with the E06 antibody (1 nM) against OxPL inhibited the increased monocyte response 
after priming with 8K-IV (0.1 µg/mL, grey bars) and subsequent challenge with Pam3cys, shown 
as % of the initial priming with 8K-IV, corrected for IgM control antibody (n=6), (D,E) priming 
with β-glucan (5 µg/mL, positive control, black bar) and the r-apo(a) construct 17K (0.1 µg/mL, 
grey bar) induced increased cytokine production after Pam3Cys (10 µg/mL), whereas 17KΔLBS 
lacking OxPL (0.1 µg/mL, grey bar) did not (n=6), (F,G) priming with β-glucan (5 µg/mL positive 
control, black bar) and oxPAPC (grey bars) increased the monocyte responsiveness compared 
with RPMI (negative control, white bar) (n=6). ^=p<0.06, *=p<0.05, **=p<0.01, ***=p<0.001.
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increased responsiveness in monocytes, whereas such effects were absent with the mutant 
17KΔLBS10 (Figure 4D,E and Figure S6M,N). Finally, we show that short-term priming with 
purified oxidized-1-palmitoyl-2-arachidonoyl-sn-3-glycero-phosphocholine (OxPAPC), a 
mixture of OxPL, also results in a dose-dependent enhanced cytokine production at day 7 in 
response to an overnight challenge with TLR ligands (Figure 4F,G and Figure S6O,P). 
Collectively, these data show that subjects with elevated Lp(a) exhibit increased arterial wall 
inflammation coinciding with an increased responsiveness of monocytes, in which OxPL 
carried by Lp(a) are obligatory mediators. 
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DISCUSSION
In this translational work, we provide evidence in support of the concept that pro-
inflammatory OxPL are major contributors to the atherogenicity of Lp(a) by showing that 
(i) subjects with elevated Lp(a) have increased arterial inflammation in vivo, (ii) monocytes 
isolated from subjects with elevated Lp(a) remain in a long-lasting activated state ex vivo, 
and (iii) Lp(a) elicits the pro-inflammatory response in healthy monocytes in vitro, an effect 
markedly attenuated by removing or inactivating OxPL present on Lp(a) and specifically on 
apo(a). 
We demonstrate an increased inflammatory activity in the arterial wall in subjects with 
elevated Lp(a), who present with enhanced 18F-FDG uptake in the arterial wall proportional to 
their Lp(a) levels. In analogy to the enhanced glucose consumption in inflamed tissue, arterial 
wall 18F-FDG uptake has been proposed as a marker of atherogenic inflammation, supported 
by previous studies documenting 18F-FDG uptake primarily in macrophage-rich areas in 
atherosclerotic plaques26. In addition, we report that this increased local inflammatory 
activity coincides with a higher accumulation rate of autologous PBMCs in the arterial wall as 
visualized by SPECT/CT imaging. Whereas we previously demonstrated augmented influx of 
PBMCs in advanced atherosclerotic plaques20, the present finding emphasizes that in subjects 
at increased risk for atherosclerotic disease due to Lp(a) elevation, PBMC accumulation in 
the arterial wall is significantly enhanced also at sites without plaques. The increased arterial 
inflammatory signal in our subjects with elevated Lp(a) cannot be attributed to differences in 
atherosclerotic burden for two reasons: first, the normalized wall index of the carotids on MRI 
did not differ from controls, and second, inflammatory measures of the arterial wall did not 
correlate with structural arterial wall metrics. The absence of a consistent relation between 
Lp(a) elevation and established surrogate markers of atherosclerotic burden observed in 
this as well as in previous studies35,36 implies that Lp(a) may increase CVD risk by enhancing 
plaque vulnerability rather than accelerating plaque burden.  
To address whether intrinsic cellular activation precedes enhanced PBMC migration in 
Lp(a) subjects, we subsequently analyzed isolated circulating monocytes, which are key 
contributors to the technetium uptake by PBMCs20. Using ex vivo assays, we were able to 
recapitulate our in vivo findings. First, we found that monocytes isolated from subjects with 
elevated Lp(a) displayed an increased capacity to transmigrate the endothelium. Second, we 
observed that monocytes isolated from subjects with elevated Lp(a) have enhanced capacity 
to produce pro-inflammatory cytokines upon TLR stimulation. Previous experimental studies 
already showed that the apo(a) component of Lp(a) was able to also activate endothelial 
cells37, whereas apo(a) also co-localized with the adhesion molecule Mac-1 in the arterial 
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wall38. When integrating these data, subjects with elevated Lp(a) might be burdened by a 
double hit comprising activated monocytes as well as endothelial cells, both predisposing for 
increased arterial wall inflammation. 
In support of a causal role for Lp(a) in driving monocyte activation, a series of in vitro 
experiments substantiate that (i) high Lp(a) plasma induce monocyte activation in vitro, which 
is abolished after lipid-depletion, (ii) among the isolated lipoprotein fractions, only Lp(a) 
and apo(a) (particles both carrying OxPL) have the capacity to induce long-term monocyte 
activation. 
In humans, more than 85% of plasma lipoprotein-associated OxPL are present on Lp(a). 
On Lp(a), OxPL is present in the lipid phase (i.e. removable from Lp(a) by delipidation with 
organic solvents) as well as covalently attached to apo(a)8,9. Here we found five oxPL species 
on Lp(a), comprising POVPC, PGPC, PONPC, PAzPC and KDdiA-PC, with PONPC being the most 
abundant. Previously, PONPC was shown to be the most abundant OxPL in the debris of distal 
protection devices from coronary bypass graft, carotid and renal interventions.39 
Recombinant 17K apo(a) containing covalently bound OxPL but not 17KΔLBS r-apo(a), which 
lacks E06 detectable OxPL9, reproduced Lp(a) priming of monocyte activation. The key 
epitope that E06 recognizes is the phosphocholine (PC) headgroup when presented in the 
proper conformation on OxPL. Sequencing the VH and VL chains of E06 revealed that these 
were identical to those regions of the T15 IgA natural antibody, which has been crystallized 
with its antigen, the PC moeity40. Further detailed lipidomic study of a large variety of lipids, 
oxidized lipids and oxidized-lipid adducts revealed that like T15, the IgM E06 only bound to 
oxidized phosphocholine containing phospholipids (e.g. PC - and only when the sn2 side chain 
was oxidized and or adducted to a protein), but not to native PAPC suggesting that oxidation 
products of the sn2 PUFA generated from oxidized PAPC appeared to generate the correct 
conformational epitope of the PC to allow recognition by E0632,40. 
Here, we demonstrate that the proinflammatory effects of apo(a) can be blocked by E06. 
Further we show that a recombinant apo(a) that contains bound OxPL is capable of activating 
monocytes, whereas the nearly identical, but mutated recombinant apo(a) that has lost the 
ability to bind OxPL does not have monocyte activation properties, indicating the necessity 
for OxPL to mediate monocyte activation. In aggregate, these data indicate that the OxPL 
carried by Lp(a) are obligatory danger signals in eliciting the prolonged potentiation of the 
monocyte response in vitro. 
These findings are also complementary to prior reports demonstrating that OxPL are danger 
associated molecular patterns (DAMPs). The PC headgroup on OxPL is recognized by multiple 
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innate PRRs12; for example, both CD36 and SR-B1 bind the PC on OxPL31,41 and consequently, 
E06 blocked the uptake of OxLDL by these macrophage scavengers42. In addition, both acute 
and chronic lung injury in mice have been shown to lead to the generation of OxPL in the 
brochiolavage fluid, which in turn caused cytokine production by macrophages that was 
dependent on TLR4, and E06 was capable of blocking the pro-inflammatory properties of 
the OxPL43. Similarly, the OxPL content of apoptotic cells was shown to induce endothelial 
expression of IL-8, and more recently, the OxPL on apo(a) was shown to be necessary for 
apo(a) mediated upregulation of IL-8 by macrophages33,34. Hence, the mechanisms by which 
OxPL accelerates atherosclerosis have been attributed both to mediating uptake of OxLDL 
into macrophages to generate foam cells, as well as to a variety of pro-inflammatory and 
plaque destabilizing processes11–13. In addition, recent studies suggest that such DAMP/
PAMPs induce long-term potentiation of their inflammatory response in vitro via epigenetic 
alterations30,44,45. Future studies will need to focus on elucidating how and for how long OxPL-
Lp(a) induce adaptive responses of monocytes. 
Whereas the present study cannot substantiate that OxPL also is a prerequisite for monocyte 
activation in humans in vivo, it is interesting to note that our subjects with elevated Lp(a) 
exhibited 4-fold higher OxPL-apoB levels (OxPL associated with all apoB lipoproteins) and 
even 20-fold higher OxPL-apo(a) levels (OxPL associated with Lp(a) lipoproteins) compared 
with subjects with normal Lp(a). This increased circulating OxPL content in subjects with 
elevated Lp(a) suggests that a comparable impact of OxPL may hold true in vivo. In support, 
we have previously shown that OxPL-apoB levels were potent predictors of progressive 
atherosclerosis as well as the risk of cardiovascular disease and death in patients14–16,46.
It remains to be established whether lowering of Lp(a) and OxPL will also lead to a reduction 
in arterial wall inflammation and eventually CVD risk. Recently, an antisense-based approach 
was reported that specifically lowered Lp(a) levels by ~80%, and to a similar degree their 
associated OxPL-apoB and OxPL-apo(a) levels47,48. With the development of such therapies 
to effectively lower Lp(a)49, we should be able to design appropriate clinical trials to 
aid in dissecting the (causal) relation between Lp(a) and cellular as well as arterial wall 
inflammation. In addition to Lp(a)-lowering therapies, the present findings may also provide 
novel targets to modulate the atherogenic impact of Lp(a). Because the OxPL content of Lp(a) 
appears to mediate the pro-inflammatory effect on monocytes, oxidation-specific epitope 
targeted therapy using specific antibodies may also bear clinical potential50. At present these 
approaches are being evaluated in experimental settings only51,52. 
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In summary, our findings strengthen the case for the inflammatory hypothesis of Lp(a) by 
addressing the increased inflammatory activity in the arterial wall, corresponding to an 
enhanced accumulation of activated immune cells, in which Lp(a)’s associated OxPL are 
obligatory intermediates.
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TABLES
Table 1. Clinical characteristics of included subjects
Characteristic Subjects with 
normal Lp(a)
(n=30)
Subjects with 
elevated Lp(a) 
(n=30)
P value
Age, y 53 ± 12 52 ± 11 0.858
Gender, %male (n) 45 (9) 43 (15) 0.820
BMI, kg/m2 24 ± 4 24 ± 3 0.914
DBP, mmHg 79 ± 7 81 ± 8 0.399
SBP, mmHg 131 ± 8 134 ± 12 0.144
Smoking, %active 0 (0) 0 (0) -
NWI 0.42 ± 0.06 0.39 ± 0.04 0.161
Lp(a), mg/dL 7 [2-28] 108 [50-195] <0.001
OxPL-apo(a), nM 3.0 [0.5-26.0] 69.1 [40.9-92.5] <0.001
OxPL-apoB, nM 4.1 [2.3-6.3] 15.8 [5.9-31.1] <0.001
TChol, mmol/L 5.21 ± 0.83 5.79 ± 1.44 0.127
LDLc*, mmol/L 2.91 ± 0.80 2.80 ± 1.16 0.621
HDLc, mmol/L 1.68 ± 0.42 1.60 ± 0.40 0.481
TG, mmol/L 0.80 [0.24-2.18] 0.82 [0.39-2.16] 0.684
CRP, mg/L 2.30 [0.40-4.40] 1.13 [0.30-1.90] 0.180
HbA1c, mmol/mol 36 [34-39] 35 [33-38] 0.100
Creatinine, umol/L 76 [66-80] 70 [55-87] 0.304
ALT, U/L 27 ± 10 27 ± 6 0.766
AST, U/L 25 ± 11 27 ± 8 0.427
WBC, 109/L 5.4 ± 1.3 5.7 ± 1.3 0.522
Monocytes, 109/L 0.43 ± 0.15 0.43 ± 0.12 0.996
Neutrophils, 109/L 3.1 ± 1.4 3.3 ± 1.09 0.710
Lymphocytes, 109/L 2.4 ± 2.6 2.2 ± 1.7 0.666
Eosinophils, 109/L 0.16 ± 0.13 0.15 ± 0.16 0.891
Basophils, 109/L 0.03 ± 0.01 0.03 ± 0.01 0.809
Data are presented as mean ± SD, n (%) or median [min-max]. ALT indicates alanine 
transaminase; apo(a), apolipoprotein(a); apoB, apolipoprotein B-100; AST, aspartate 
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transaminase; BMI, body mass index; CRP, C-reactive protein, CVD, cardiovascular disease 
(including myocardial infarction, stroke or peripheral artery disease); HbA1c, hemoglobin 
A1c; HDLc, high density lipoprotein cholesterol; DBP, diastolic blood pressure; LDLc, 
low density lipoprotein cholesterol; Lp(a), lipoprotein(a); NWI, normalized wall index; 
OxPL, oxidized phospholipids; SBP, systolic blood pressure; Tchol, total cholesterol; TG, 
triglycerides; WBC, white blood cell count, *LDLc corrected for Lp(a)-cholesterol. 
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Table 2. Correlations between inflammatory metrics and Lp(a) levels 
Method Parameter
Spearman correlation
with Lp(a) level
PET imaging TBR, carotid 0.31^
TBR, aorta 0.45**
SPECT imaging ABR, carotid 0.72*
ABR, aorta 0.65*
Whole plasma level CRP, mg/L 0.24
Flow cytometric assay CD11b, ΔMFI 0.27
CD11c, ΔMFI 0.42^
CD29, ΔMFI 0.50*
SRA, ΔMFI 0.42^
CD36, ΔMFI 0.48*
Ex vivo monocyte
cytokine production
TNFα, pg/mL 0.27
IL-6, pg/mL 0.18
Correlation coefficients of the Spearman’s rho test are shown, correlations are flagged with 
^p<0.06, *p<0.05, **p<0.01, ***p<0.001. 
TBR and ABR are imaging metrics, CRP was measured in whole plasma, TNFα and IL-6 were 
measured as products of monocytes after TLR ligand challenge, and CD11b, CD11c, CD29 
and CD36 expression on monocytes were measured by flow cytometry as described in 
Methods.
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SUPPLEMENTAL MATERIAL
Additional Methods
Flow cytometry 
The following fluorochrome labeled mAb were used: phycoerythrin-CyChrome7 (PE-
CyTM7)-anti CD14, allophycocyanin (APC)-Cy7-anti CD16, peridinin-chlorophyll-protein 
(PerCP)-Cy5.5-anti HLA-DR, PE-anti CD11b, APC-anti CD11c, APC-anti CD18, APC-anti CD29, 
fluorescein isothiocyanate (FITC)-anti CD32, APC-anti CD36, PE-anti CD62L, APC-anti CD192 
(CCR2), FITC-anti CD195 (CCR5) [all from BD Biosciences, San Jos, CA, USA]; PE-anti CD204 
(SR-A) [R&D systems, Abingdon, UK] and PE-anti CD197 (CCR7) [Biolegend, SanDiego, CA, 
USA]. Samples were incubated for 20 min at RT in the dark. To lyse red blood cells, 700 
μL of PharmLyse1 (BD Biosciences, San Jose, CA) was added for 12 min, after which the 
samples were centrifuged at 400g for 5 min, the supernatant discarded and the samples 
resuspended in 400 μL of staining buffer. All data were collected on a FACS Calibur (Becton 
Dickinson, NJ), compensation was performed using single color fluorochromes and BD 
FacsComp beads, and samples were analyzed using FlowJo software (version 5.4+); for 
gating strategy and representative histograms see Figure S3. Delta mean fluorescence 
intensity (MFI) was obtained by subtracting median MFI from the isotype from the median 
MFI of the marker in corresponding color. Please note that the delta MFI values of CD62L 
were scaled down by a factor 10.000 to fit the bar graph.
Lipid Extraction 
The lipids were extracted by the method previously described by Folch et al. with modifications.1, 
2 The lipid extracts were stored in CM (2:1), flushed with nitrogen, capped and stored at -800C 
till analysis. The internal standard mixture spiked into each sample prior to extraction consisted 
of  1,2-dinonanoyl-sn-glycero-3-phosphocholine (DNPC),  1-heptadecanoyl-2-hydroxy-sn-
glycero-3-phosphocholine (17:0 LPC)3.  Synthetic 1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-
3-phosphocholine  (POVPC), 1-palmitoyl-2-glutaroyl-  sn  -glycero-3-phosphocholine (PGPC), 
1-palmitoyl-2-azelaoyl-sn-glycero-3-phosphocholine (PAzPC), and 1-palmitoyl-2-(9’-oxo-
nonanoyl)-sn-glycero-3-phosphocholine were purchased from Avanti Polar Lipids (Alabaster, 
AL). 1-palmitoyl-2-(4-keto-dodec-3-ene-dioyl) phosphatidylcholine (KDdiA-PC) were from 
Cayman  Chemicals  (Ann  Arbor,  MI)
HPLC 
The detection of oxidized PCs were carried out in reverse-phase (RP) chromatography as 
reported previously2, 4-7. Briefly lipid extracts were reconstituted in an RP solvent system 
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consisting of Acetonitrile-Isopropanol-Water (65:30:5 vol/vol/vol). Thirty microliters of 
the sample was injected on to Ascentis Express C18 HPLC column (15cmx2.1mm, 2.7µm; 
Supelco Analytical, Bellefonte, Pennsylvania, USA) and using a Prominence UFLC  system 
from Shimadzu Corporation (Canby, Oregon, USA).  Elution was performed by linear 
gradient of solvent A (Acetonitrile/Water, 60:40 vol/vol) and solvent B (Isopropanol/
Acetonitrile, 90:10, vol/vol) both the solvents containing 10 mM ammonium formate and 
0.1% formic acid. The time program used was as follows: initial solvent B at 32% until 4.00 
min; switched to 45% B; 5.00 min 52% B; 8.00 min 58% B; 11.00 min 66% B; 14.00 min 70% 
B; 18.00 min 75% B; 21.00 min 97% B; 25.00 min 97% B; 25.10 min 32% B until the elution 
was stopped at 30.10 min. A flow rate of 260 µl/min was used for analysis, and the column 
and sample tray were held at 45 and 4˚C, respectively. 
Mass Spectrometry 
The HPLC system was coupled to 4000 QTRAP® triple quadrupole mass spectrometer system 
with a Turbo V electrospray ion source from AB Sciex (Framingham, Massachusetts, USA). 
For phosphatidylcholine, the detection was carried out in positive ion mode by MRM of 6 
transitions using PC-specific product ion (184.3 m/z, Da), which corresponds to the cleaved 
phosphatidylcholine. The MRM settings were as follows: declustering potential=125, entrance 
potential=10, collision energy=53, collision cell exit potential=9 and dwell time= 50 msec. 8, 9
  For each synthetic OxPL, POVPC, PGPC, PONPC, PAzPC and KDdiA-PC external 
calibration  (i.e.,  using plasma-free  standard  solutions)  was  carried  out to estimate linear 
range and sensitivity for these analytes and relative ionization compared to DNPC at equimolar 
levels. Concentrations of analytes were determined from calibration curves (1/x weighted 
linear regression) plotted as ratio of analyte peak area/DNPC peak area versus the amount of 
analyte on a column. The instrument was tuned by direct infusion of poly(propylene glycol) 
(PPG) in both positive and negative modes and external mass calibration was performed at 
regular intervals. Retention time window in MRM was set to detect peaks of significance 
within 60 seconds of confirmed retention time and data was collected utilizing Analyst® 
Software 1.6 (AB Sciex). Multi-quant® Software 2.1 (AB Sciex) was used to compare peak 
areas of internal standards and unknown analytes to quantitate the results.  
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SUPPLEMENTAL FIGURES
Fig. S1. Schematic of lipoprotein(a)
Lipoprotein (a) [Lp(a)] is composed of apolipoprotein(a) [apo(a)] covalently linked to 
apolipoprotein B-100 (apoB) of LDL. This LDL contains a central core of neutral lipids, 
surface phospholipids (PL) and free cholesterol (FC). Apo(a) comprises an inactive protease 
domain (P) and a series of loop structures termed kringle (K), including KIV type 2, (KIV2) 
which is present in 3 to >40 copies. Genes encoding an apo(a) allele with smaller numbers 
of  KIV2 repeats lead to higher levels of Lp(a) in plasma, presumably due to higher rates of 
hepatic synthesis. Phosphocholine containing oxidized phospholipids (OxPL) are present in 
the lipid phase and covalently bound to apo(a) in the areas near KIV-10 and KV.
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Fig. S2. Arterial wall dimensions assessed with MR imaging
(A) Cross-sectional MR images used to quantify the arterial wall dimension, expressed as 
the normalized wall index (NWI), of the carotid arteries of normal Lp(a) and elevated Lp(a) 
subjects, (B) scatterplot illustrating no correlation between the arterial wall dimension 
(NWI, normalized wall index) and inflammation (TBR, target to background ratio, as 
assessed with 18F-FDG PET/CT) in subjects with elevated Lp(a). 
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Fig. S3. Gating strategy to define monocyte population and representative histograms
(A) The monocyte population was gated as follows; the leukocyte population was gated 
on a forward side scatter and subsequently viewed on a CD14/CD16 plot in which the 
CD14posCD16pos cell cloud was gated, after which these cells were then shown on the 
CD16/HLA-DR plot to exclude the HLA-DRnegCD16pos cells. For gating graphs log scale was 
used, percentages of cells in gates are shown. Cells were analyzed using FlowJo software 
(version 5.4+). (B) Representative FACS histograms (of Figure 2A) show the expression of 
chemokine, adhesion and transmigration markers and (C) the expression of scavenger and 
other receptors (Figure 2D) on monocytes as assessed by flow cytometry of subjects with 
elevated Lp(a) (red line) compared with subjects with normal Lp(a) (blue line). The isotype 
control (orange line) was similar between the two groups and therefore only one isotype 
control is showed. 
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Fig. S4. Monocytes of Lp(a) subjects have an increased response to LPS
In response to an overnight challenge to LPS (10 ng/ml) monocytes isolated from subjects 
with elevated Lp(a) (black bars, n=15) produced higher levels of TNFα, IL-1β and IL-6 and 
lower levels of IL-10, compared to monocytes of subjects with normal Lp(a) (grey bars, 
n=15). *=p<0.05, **=p<0.01. 
A DCB
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Fig. S5. Levels of OxPC molecules identified in human Lp(a) 
Quantitation was based on internal standard DNPC, details are given in methods. (A) 
Identification of oxPC molecules on human Lp(a). Single ion plots of MRM analysis of 
human  Lp(a) lipid extract. Reversephase separation of the most abundant fragmented 
OxPC products (i)POVPC, (ii) PGPC, (iii) PONPC, (iv) PAzPC, (v) KDdiA-PC (n=3), and (B) 
quantification of oxPC molecules on human Lp(a) (n=3).
A B
Re
la
tiv
e 
in
te
ns
ity
ng
/1
00
ug
 p
ro
te
in
PO
VP
C
PG
PC
PO
NP
C
PA
zP
C
KD
diA
-PC
OxPL on Lp(a)
i
ii
iii
iv
v
KDdiA-PC
PAzPC
PONPC
PGPC
POVPC
Fig. S6. Lp(a) and its OxPL load induce an enhanced monocyte response to LPS
(A,B) priming healthy monocytes with plasma with high Lp(a) (grey bars) for 24h resulted 
in an increased production of TNFα and IL-6 upon re-stimulation with LPS (10 ng/mL) on 
day 6, compared with plasma of normal Lp(a) (white bars). In addition, after lipid-depletion 
this effect was profoundly reduced (n=3), (C,D) priming of healthy monocytes with β-glucan 
(5 µg/mL, positive control, black bar) or Lp(a) (grey bar, 250 μg/mL) for 24h, induced an 
increased production of TNFα and IL-6 upon re-stimulation with LPS (10 ng/mL)  on day 6, 
compared with priming with RPMI (negative control, white bar), LDL (grey bar, 10 μg/mL)  
or HDL (grey bar, 10 μg/mL) (n=6), (E,F) 
127
Lipoprotein(a) induced arterial wall inflammation and monocyte activation
5
in addition we show a dose-dependent increased production of TNFα and IL-6 after LP(a) 
priming, upon re-stimulation with LPS (10 ng/mL) on day 6, compared with priming with 
RPMI (negative control, white bar) (n=6), (G,H) priming with LDL (10 µg/mL, grey bar) 
did not increase cytokine production after LPS (10 ng/mL) (n=6), (I,J) priming of healthy 
monocytes with β-glucan (5 µg/mL, positive control, black bar) or the r-apo(a) construct, 
8K-IV, (grey bars) increased TNFα and IL-6 production after LPS (10 ng/mL) (n=6), compared 
to RPMI (negative control, white bar), (K,L) pre-treatment with the E06 antibody (1 nM) 
against OxPL inhibited the priming effects of 8K-IV (0.1 µg/mL, grey bars), whereas IgM (1 
nM) did not (n=6), (M,N) β-glucan (5 µg/mL, positive control, black bar) and the r-apo(a) 
construct 17K priming (0.1 µg/mL grey bar) increased cytokine production upon LPS (10 
ng/mL), whereas 17KΔLBS lacking OxPL (0.1 µg/mL, grey bar) did not (n=6), (O,P) priming 
with β-glucan (5 µg/mL, positive control, black bar) and oxPAPC (grey bars) increased the 
monocyte response upon LPS (10 ng/mL) compared to RPMI (negative control, white bar) 
(n=6). ^=p<0.06, *=p<0.05, **=p<0.01, ***=p<0.001
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ABSTRACT
Background and aims 
We have recently reported that monocytes can undergo functional and transcriptional 
reprogramming towards a long-term pro-inflammatory phenotype after brief in vitro exposure 
to atherogenic stimuli such as oxidized LDL. This process is termed ‘trained immunity’, and 
is mediated by epigenetic remodeling and a metabolic switch towards increased aerobic 
glycolysis. We hypothesize that trained immunity contributes to atherogenesis. Therefore, 
we investigated the inflammatory phenotype and epigenetic remodeling of monocytes from 
patients with and without established atherosclerosis. 
Methods
Monocytes were isolated from 20 patients with severe symptomatic coronary atherosclerosis 
(total plaque score >4 on coronary computed tomography angiography) and 17 patients 
with asymptomatic carotid atherosclerosis and matched controls for both groups. Ex vivo 
stimulation, RNA analysis and Chromatin Immunoprecipitation was performed.
Results
Monocytes from patients with symptomatic atherosclerosis have a higher production of pro-
inflammatory cytokines upon LPS stimulation than healthy controls (TNFα 499±102 versus 
267±45 pg/ml, p=0.01). This was associated with lower histone 3 lysine 4 trimethylation 
(H3K4me3) (19% vs 33%, p=0.002), and lower H3K27me3 (0.005% vs 0.8%, p<0.0001) on the 
TNFα promoter. Furthermore, relative mRNA expression of the glycolytic rate limiting enzymes 
hexokinase 2 and phospho-fructokinase was higher in patients (0.7±0.2 vs 0.3±0.1 resp. 
1.7±0.2 vs 1.0±0.1, P=0.007 resp. 0.003) compared to control individuals. Interestingly, this 
pro-inflammatory phenotype was only present in patients with symptomatic atherosclerosis, 
and not in patients with asymptomatic carotid atherosclerosis. 
Conclusion
Circulating monocytes of patients with symptomatic, but not asymptomatic, atherosclerosis 
have a pro-inflammatory phenotype and increased expression of glycolytic enzymes, 
associated with epigenetic remodeling at the level of histone methylation.  
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INTRODUCTION
Cardiovascular diseases (CVD) are the leading cause of death worldwide, projected to cause 
30 million deaths per year in 20301. The main underlying pathological process of CVD is 
atherosclerosis, a chronic low-grade inflammatory disorder of the arterial wall. Macrophages 
are the most abundant cells found in plaques and play central roles in the various stages of 
atherosclerosis2. Plaque macrophages are both derived from circulating monocytes that bind 
to activated endothelial cells and enter the intimal layer as well as from local proliferating 
plaque macrophages3. The mechanism that explains the persistent non-resolving inflammation 
within atherosclerotic plaques remains to be elucidated. 
We recently proposed that trained immunity contributes to the persistent vascular 
inflammation that characterizes atherosclerotic plaques4. Trained immunity denotes 
the process through which innate immune cells can adopt a long-term pro-inflammatory 
phenotype after brief exposure to certain pathogen- and danger-associated molecular 
patterns, such as oxidized low density lipoprotein (oxLDL) particles5. Brief in vitro exposure of 
human monocytes to oxLDL induces a long-lasting pro-inflammatory macrophage phenotype 
that is characterized by increased pro-atherogenic cytokine and chemokine production and 
increased foam cell formation. The key mechanisms underlying this phenotype are epigenetic 
reprogramming at the level of histone methylation and a shift in the intracellular metabolism 
from oxidative phosphorylation towards an increased aerobic glycolysis (ie. the Warburg 
effect)6. 
To test the hypothesis that trained immunity contributes to the development of atherosclerosis, 
we now performed a first proof-of-concept study in patients with established atherosclerosis. 
We aimed to investigate whether circulating monocytes of patients with atherosclerosis have 
a pro-inflammatory phenotype, and whether this is associated with epigenetic marks and 
change in metabolism that are characteristic of trained immune cells. To explore whether the 
role of trained immunity differs in the various stages of atherosclerosis, we studied monocytes 
from patients with symptomatic coronary atherosclerosis and subjects with asymptomatic 
carotid atherosclerosis.
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MATERIALS AND METHODS
Study participants
Patients with symptomatic coronary atherosclerosis were selected from patients who 
had been referred to the cardiac emergency ward of the Canisius Wilhelmina Hospital in 
Nijmegen from October 2013 to March 2014 because of chest pain, and who were evaluated 
with coronary computed tomography angiography (CCTA). We selected twenty patients 
with a total plaque score (TPS)>4 (patients) and twenty control patients with a TPS=0 
(controls). Patients and controls were matched for age, gender and body mass index (BMI). 
Exclusion criteria were an acute coronary syndrome (at present or in the past), presence of 
a coronary stent, bypass surgery in the past, heart failure liver or renal failure, as well as use 
of anti-inflammatory medication other than statins, and thrombocyte aggregation inhibitors. 
Additional exclusion criteria were diabetes, rheumatoid arthritis, or other autoimmune 
diseases and signs/symptoms of acute infection. 
Patients with asymptomatic carotid atherosclerosis were selected using carotid ultrasound 
from the participants of the population-based IN CONTROL study, from October 2013 to 
July 2015. A total of 39 asymptomatic subjects were included. Exclusion criteria for this 
study were a recent cardiovascular event, history of bariatric surgery or bowel resection, 
inflammatory bowel disease, renal dysfunction, increased bleeding tendency, use of oral 
subcutaneous anti-coagulant therapy, and use of thrombocyte aggregation inhibitors other 
than acetylsalicylic acid. 
All laboratory analyses were performed blinded for group allocation. The study protocol 
was approved by the Institutional Review Board Arnhem/Nijmegen, The Netherlands, and 
prospectively registered at Clinicaltrials.gov (number NCT02393768) 
Evaluation of atherosclerotic burden
Evaluation of total plaque score (TPS)
CCTA total plaque score was calculated of each patient as described previously1. Briefly, a 
64-slice MDCT scanner (Philips) was used to obtain CAC and MDCT Image acquisition using 
an ECG-synchronized axial scan protocol and post-processing CT and CAC studies using 
IntelliSpace Philips software. Prior to image acquisition, beta-blockers were administered 
targeting a heart rate of <60 bpm., and patients received nitroglycerin 0.8 mg sublingually. 
Prospective electrocardiographically gated step-and-shoot contrast-enhanced MDCT imaging 
was performed, initiated from 10 mm above the level of the left main artery to 10 mm below 
the inferior myocardial apex with scan parameters being 64 x 0.625 mm sections (2.5 mm), 
collimation tube currents of 350 to 780 mAs and tube voltage of 100 or 120 kV. In the rare 
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event that prospective scanning was not possible, retrospective or helix scanning was used. 
Reconstruction of the MDCT scans was performed with reconstructed images obtained, using 
an ecg-triggered protocol, at 75% from the previous RR-interval, or at 75% and 40% from the 
previous RR-interval if a helix scan-protocol was used. The TPS was determined by summing 
the number of evaluable coronary segments with calcific or non-calcific plaque, or mixed 
plaque, where non calcified and mixed plaque was assigned with 1 point and calcified plaque 
with 0 (maximum score = 16). Two independent experienced operators scored all CT images 
and both operators were blinded for all clinical information.
Carotid plaque detection
Carotid ultrasound was performed using an MyLabClass C Ultrasound machine (Esaote BV, 
Maastricht, The Netherlands) with a 3-11 MHz linear-array transducer. Longitudinal images 
of both common carotid arteries were obtained in the optimal projection (anterolateral, 
lateral or posterolateral). Measurement of the intima-medial thickness (IMT) was performed 
offline by the sonographer at the time of examination, using semi-automatic edge-detection 
software (Artlab, Esaote BV, Maastricht, The Netherlands) in the far wall. A plaque in 
the carotid arteries was defined as local thickening of the IMT of >50% compared to the 
surrounding vessel wall or an IMT > 1.5 mm. 
Blood sampling, isolation and stimulation of monocytes
EDTA plasma was obtained by venous blood sampling and was stored using standardized 
protocols. Plasma total cholesterol, HDL-c and LDL-c levels were analyzed using commercially 
available enzymatic methods. PAXgene tubes (Preanalytix, GmbH, Switzerland) were 
incubated for at least 2h at room temperature before storage at -20C until RNA isolation. 
Human peripheral blood mononuclear cells (PBMCs) were isolated from EDTA blood using 
Ficoll-Paque density gradient centrifugation (GE Healtcare, UK). Monocytes were isolated 
by magnetic activated cell sorting (MACS) using CD14-coated MicroBeads according to 
manufacturer’s instructions (MACS, Miltenyi Biotec, Leiden, The Netherlands). Monocytes 
were diluted to 1x106/ml in RPMI 1640 Dutch-modified culture medium (Life Technologies/
Invitrogen, Breda, The Netherlands) supplemented with 10 mM glutamine (Invitrogen), 10 
µg/mL gentamicin (Centraform), 10 mM pyruvate (Invitrogen). A total of 5x105 monocytes 
were seeded per well on flat-bottom 96-well plates (Corning, New York, USA) and stimulated 
for 24h with RPMI only as a negative control, 10 ng/ml LPS (Sigma-Aldrich, St. Louis, MO; 
from E. coli serotype 055:B5, further purified as described7) or 10 μg/ml Pam3Cys (EMC 
microcollections, Tübingen, Germany; L2000). After 24h, plates were centrifuged and 
supernatants were stored at -20C until cytokine assessment. 
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Cytokine measurements
Cytokine production was determined in supernatants using commercial ELISA kits for IL-
1β, TNFα (R&D systems, MN, USA), IL-6 and IL-10 (Sanquin, Amsterdam, The Netherlands) 
following the instructions of the manufacturer. MCP-1 ELISA was performed following the 
manufacturers’ instructions using antibodies anti-Human CCL2 Purified (14-7099), anti-
CCL2 Biotin (13-7096) and Human CCL2 Recombinant Protein (14-8398), all obtained from 
eBioscience (CA, USA). Cytokines in plasma of patients with coronary atherosclerosis and 
controls were determined using commercial high sensitive ELISA kits for TNF-α (eBioscience, 
CA, USA) and IL-6 (R&D systems, MN, USA) and MCP-1 as described above. hsCRP in plasma 
was determined using the high sensitive ELISA kit for CRP (R&D systems, MN, USA). Cytokines 
in plasma of subjects with carotid atherosclerosis and controls were measured using the 
Simple Plex platform (Protein Simple, San Jose, CA). 
RNA isolation from PAXgenes
Total RNA purification was performed according to the manufacturer’s instructions (PreAnalytiX 
GmbH, Switzerland). RNA concentrations were measured using NanoDrop software, and 
isolated RNA was reverse-transcribed using the iScript cDNA Synthesis Kit (Bio-rad, Hercules, 
CA). qPCR was performed using the SYBR Green method (Applied Biosciences, Carlsbad, 
CA). Used primers are listed in Supplementary Table 1 (Biolegio, Malden, The Netherlands). 
Samples were analyzed using the ΔCt method, and HPRT was used as a housekeeping gene. 
Gene Forward primer Reverse primer
HPRT CCTGGCGTCGTGATTAGTGAT AGACGTTCAGTCCTGTCCATAA
IL-6 AACCTGAACCTTCCAAAGATGG TCTGGCTTGTTCCTCACTACT
TNFα CCTCTCTCTAATCAGCCCTCTG GAGGACCTGGGAGTAGATGAG
MCP-1 CCAGTCACCTGCTGTTATAAC TGGAATCCTGAACCCACTTCT
IL-8 ACTGAGAGTGATTGAGAGTGGAC AACCCTCTGCACCCAGTTTTC
IL1β CAGCTACGAATCTCCGACCAC GGCAGGGAACCAGCATCTTC
IL1Ra GCCTCCGCAGTCACCTAAT TCCCAGATTCTGAAGGCTTG
STAT3 ACCAGCAGTATAGCCGCTTC GCCACAATCCGGGCAATCT
HIF1α GAACGTCGAAAAGAAAAGTCTCG CCTTATCAAGATGCGAACTCACA
c-MYC GGCTCCTGGCAAAAGGTCA CTGCGTAGTTGTGCTGATGT
HK2 TTGACCAGGAGATTGACATGGG CAACCGCATCAGGACCTCA
PFKFB3 ATTGCGGTTTTCGATGCCAC GCCACAACTGTAGGGTCGT
PDK1 AGTGCCTCTGGCTGGTTTTG GCATCTGTCCCGTAACCCTC
PKM1 CGAGCCTCAAGTCACTCCAC GTGAGCAGACCTGCCAGACT
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PKM2 ATTATTTGAGGAACTCCGCCGCCT ATTCCGGGTCACAGCAATGATGG
ASL CAGTGGACCCCATCATGGAGA GGCTTTGCTGCCTTGAACATC
MDH1 GGTGCAGCCTTAGATAAAT AGTCAAGCAACTGAAGTTC
ACAT1 AAGGCAGGCAGTATTGGGTG ACATCAGTTAGCCCGTCTTTTAC
PDHA1 TGGTAGCATCCCGTAATTTTGC ATTCGGCGTACAGTCTGCATC
TALDO1 CTCACCCGTGAAGCGTCAG GTTGGTGGTAGCATCCTGGG
Table 1. Primers for qPCR
Chromatin immunoprecipitation
For the assessment of histone methylation, ChIP was performed as described previously8. 
In short, monocytes were cross-linked in methanol free 1% formaldehyde (28908, Thermo 
Scientific), followed by sonication to shear-DNA and immunoprecipitation using antibodies 
against H3K4me3, H3K27me3 and H3K9me3 (Diagenode, Seraing, Belgium). ChIPed DNA was 
processed further for qPCR analysis. Primers used in the reaction are listed in Supplementary 
Table 2. Samples were analyzed following a comparative Ct method, myoglobin was used as 
a negative control for H3K4me3, GAPDH for H3K9me3 and EIF4A2 for H3K27me3, H2B was 
used as a positive control for H3K4me3, ZNF UTR for H3K9me3 and MYT1 for H3K27me3 
according to the manufacturer’s instructions.
Promoter of gene Forward primer Reverse primer
Myoglobulin AGCATGGTGCCACTGTGCT GGCTTAATCTCTGCCTCATGAT
H2B TGTACTTGGTGACGGCCTTA CATTACAACAAGCGCTCGAC
GAPDH CACCGTCAAGGCTGAGAACG ATACCCAAGGGAGCCACACC
ZNF UTR AAGCACTTTGACAACCGTGA GGAGGAATTTTGTGGAGCAA
EIF4A2 GGGGAAAGCGAGGTTTAACT TTACAGGGTCGCTGGAAATC
MYT1 TTGGGGTTTGGAATTCTCTG CAGTCTTTGTTCTCCGCACA
IL6 TCGTGCATGACTTCAGCTTT GCGCTAAGAAGCAGAACCAC
IL1b CTGGCGAGCTCAGGTACTTC ACACATGAACGTAGCCGTCA
TNFa1 AGAGGACCAGCTAAGAGGGA AGCTTGTCAGGGGATGTGG
TNFa2 CAGGCAGGTTCTCTTCCTCT GCTTTCAGTGCTCATGGTGT
TNFa3 GTGCTTGTTCCTCAGCCTCT ATCACTCCAAAGTGCAGCAG
TNFa4 TGTCTGGCACACAGAAGACA CCCTGAGGTGTCTGGTTTTC
TNFa5 AGCCAGCTGTTCCTCCTTTA TTAGAGAGAGGTCCCTGGGG
TNFa6 TGATGGTAGGCAGAACTTGG ACTAAGGCCTGTGCTGTTCC
Table 2. Primers used for ChIP qPCR analysis (5’-3’)
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Statistics
Data are presented as mean (standard deviation) for continuous variables and as a number 
(percentage) for categorical variables. To examine the difference in clinical characteristics 
between the different patient groups, we performed unpaired student T-tests or Mann-
Whitney U tests for normal and non-normal distributed variables, respectively. Ex vivo 
monocyte experiments were analyzed using the Mann-Whitney U test. In vitro experiments 
were analyzed using the Wilcoxon signed rank test. A two-sided P-value below 0.05 was 
considered statistically significant. All data were analyzed using Prism version 5.0 (GraphPad 
software, La Jolla, California) or SPSS version 21.0 (SPSS Inc., Chicago, Illinois). 
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RESULTS
Baseline characteristics
Baseline characteristics of the patients with symptomatic and subjects with asymptomatic 
atherosclerosis and controls for both groups without atherosclerosis are listed in Table 1. 
The average total plaque score (TPS) derived from the Coronary Computed Tomography 
Angiography (CCTA) was 6.3 in patients (A), indicating severe coronary atherosclerosis, and 
0 in controls (B), indicating no coronary atherosclerosis (table 1). Patients with symptomatic 
coronary atherosclerosis (group A) and controls (group B) were matched for age, gender and 
body mass index (BMI). There were no significant differences between group A and B in blood 
pressure, total cholesterol, lipoprotein(a), LDL cholesterol, glucose or plasma creatinine. 
High density lipoprotein (HDL) cholesterol was slightly lower in patients with coronary artery 
disease (CAD) (1.45 mmol/L vs. 1.26 mmol/L, p=0,04). Statin use was higher in patients than 
controls (75% vs. 15%, p<0,001). 
Similarly, there were no significant differences between subjects with (C) and without (D) 
asymptomatic carotid plaques, besides the presence of plaques measured by carotid 
ultrasound. 
Increased systemic inflammation in patients with symptomatic atherosclerosis 
We measured baseline circulating high-sensitive C-reactive protein (hsCRP), cytokines and 
chemokines in patients with symptomatic CAD and controls. Plasma samples of patients with 
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Figure 1. Inflammatory markers in plasma.  (A). IL-6, TNFα, MCP-1 and hsCRP were measured in EDTA 
plasma from patients with symptomatic CAD vs. matched controls. Baseline inflammation in patients 
with symptomatic CAD was increased compared to controls. (B). IL-6 and hsCRP were measured in 
plasma from patients with asymptomatic carotid atherosclerosis vs. matched controls. Asymptomatic 
carotid atherosclerosis subjects showed no increased baseline inflammation compared to controls. 
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symptomatic CAD did not show significantly higher concentrations of IL-6 and TNFα (Fig 1A), 
although this may be due to the lack of power. There was no difference in MCP-1 concentration. 
hsCRP was significantly higher in patients compared to controls (P<0.01). Subjects with 
asymptomatic carotid atherosclerosis showed no differences in pro-inflammatory cytokines 
and hsCRP plasma concentrations (Fig 1B) compared to controls.
Increased cytokine and chemokine production by monocytes from subjects with 
symptomatic, but not asymptomatic, atherosclerosis
After overnight stimulation with the Toll-like receptor (TLR) 4 ligand lipopolysaccharide (LPS), 
monocytes isolated from patients with symptomatic CAD showed an increased production of 
interleukin-6 (IL-6), tumor necrosis factor-α (TNFα), IL-1β, IL-8 and monocyte chemoattracting 
protein-1 (MCP-1; Fig 2A) compared to controls. Similar results were observed upon 
stimulation with the TLR2 ligand Pam3Cys (Supplementary Figure 1). No differences were 
observed in production of the anti-inflammatory cytokine IL-10, since levels were below 
Figure 2. Ex vivo stimulation of monocytes (A) Monocytes from patients with symptomatic CAD 
have a pro-inflammatory phenotype upon ex vivo stimulation of TLR4 compared to matched 
controls. Monocytes from patients and controls were stimulated with TLR4 ligand LPS for 
24h and IL-6, TNFα, IL-1β, IL-8 and MCP-1 were measured in the supernatant after 24h of 
incubation at 37°C, 5% CO2 (n=20 vs 20, * p<0.05, ** p<0.01). (B) Monocytes from patients 
with asymptomatic carotid atherosclerosis do not show an increased pro-inflammatory 
phenotype upon ex vivo stimulation of TLR4. Monocytes from subjects with carotid 
atherosclerosis and controls were stimulated with TLR4 ligand LPS for 24h and IL-6, TNFα, IL-
1β, IL-8 and MCP-1 were measured in the supernatant after 24h of incubation at 37°C, 5% CO2. 
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detection level (data not shown). 
In contrast, monocytes from subjects with asymptomatic carotid atherosclerosis did not show 
increased production of IL-6, TNFα, IL-1β, IL-8 and MCP-1 upon TLR4 stimulation compared 
to control subjects without carotid atherosclerosis (Fig 2B). Similar results were obtained 
after stimulation of the leukocytes by the TLR2 ligand Pam3Cys (Supplementary Figure 2).
Circulating cells of patients with symptomatic CAD have a pro-inflammatory 
phenotype associated with metabolic reprogramming
Increased pro-inflammatory cytokine expression
To further characterize the pro-inflammatory phenotype in the patients with symptomatic 
CAD, we measured baseline RNA expression of pro-inflammatory cytokines and other 
inflammatory genes. Baseline expression of TNFα, IL-1β and IL-1RA was significantly higher 
in patients with symptomatic CAD compared to controls (Fig 3A and supplementary Fig 3B), 
expression of MCP-1, IL-8, IL-6 as well as the expression of HIF-1α, c-MYC and STAT3 showed 
no difference. 
Increased intracellular metabolism
We have recently reported that the persistent pro-inflammatory phenotype of monocytes after 
induction of trained immunity by β-glucan is critically dependent on epigenetic reprogramming 
and a metabolic shift towards increased aerobic glycolysis6. Trained monocytes switch from 
oxidative phosphorylation to aerobic glycolysis to produce sufficient ATP in an efficient and 
fast way to maintain the increased inflammatory state. We measured mRNA expression of 
hexokinase 2 (HK2) and phosphofructokinase 3 (PFKFB3), the two rate-limiting enzymes in 
the glycolysis pathway, as well as the expression of other important metabolic enzymes in 
patients with symptomatic CAD and control patients. Patients with symptomatic CAD showed 
a higher baseline expression of HK2, PFKFB3, pyruvate kinase 1 (PKM1), argininesuccinate 
lyase (ASL), malate dehydrogenase 1 (MDH1), pyruvate dehydrogenase alpha 1 (PDHA1) and 
transaldolase 1 (TALDO1) (Fig 3A and Suppl Fig 3B). This is consistent with an upregulation 
of genes of the glycolytic pathway, but also enzymes in the pentose-phosphate pathway and 
Krebs cycle (Fig 3B). Expression of HK2 and IL-1b (R=0.41, p=0.01), PFKFB3 and TNFα (R=0.45, 
P=0.006) and PFKFB3 and IL-1β (R=0.78, p<0.001) are significantly correlated, corroborating 
an association between upregulated glycolysis and an increased baseline inflammatory state 
(Suppl Fig 3A). 
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Increased cytokine production is associated with lower repressive epigenetic 
marks in patients with symptomatic CAD 
Trained immunity is mediated by epigenetic reprogramming at the level of histone 
methylation9. Previously we showed that increased cytokine production after brief exposure 
to oxLDL or β-glucan was associated with an enrichment of the activating histone mark 
H3K4me3, and training was prevented by nonselective inhibitors of methyltransferases5,10. 
Since patients with symptomatic CAD have elevated pro-inflammatory cytokine production 
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Figure 3. Increased baseline inflammation and glycolysis in patients with symptomatic 
CAD . (A). Baseline RNA expression of cytokines and metabolic rate-limiting enzymes are 
significantly increased in patients with symptomatic CAD compared to controls (high 
expression = red, low expression = blue) (n=17 vs 18) (B). Schematic overview of metabolic 
pathways and significantly upregulated genes in patients with CAD, highlighted in green. 
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on baseline, as well as increased pro-inflammatory cytokine production upon ex vivo 
stimulation, we hypothesized that this is due to epigenetic reprogramming of the monocyte 
population. We assessed H3K4me3 levels on the promoters of IL-6, IL-1β and TNFα, since 
these were significantly upregulated upon ex vivo stimulation. Surprisingly and in contrast 
to what we observed in our in vitro experiments with β-glucan and oxLDL-induced training5, 
the promoters of these pro-inflammatory genes had lower H3K4me3 in patients with 
symptomatic CAD than controls (Fig 4A). Since TNFα showed the most significant increase 
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Figure 4. Patients with symptomatic CAD have a different epigenetic landscape than healthy 
controls. (A). Chromatin immunoprecipitation of H3K4me3 in monocytes from patients with 
symptomatic CAD and controls was performed. Levels of H3K4me3 were measured on the 
promoters of tnfα, il-6 and il-1b and were lower in patients compared to controls. (B). The tnfα 
promoter was studied in more detail and showed an overall lower H3K4me3 throughout the 
promoter region (C). ChIP of repressive mark H3K9me3 showed no significant difference in H3K9me3 
on the promoter of tnfa in patients compared to controls. (D). ChIP of repressive mark H3K27me3 
showed a significantly lower H3K27me3 throughout the tnfα promoter in patients compared to 
controls. The expression of the methyltransferase EZH2 for H3K27me3 showed no difference. (E). 
The level of H3K27me3 was negatively correlated with the baseline RNA expression of tnfα. Levels 
of H3K4me3 and H3K27me3 are correlated as well (n=20 vs 20, * p<0.05, ** p<0.01, *** p<0.001)
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in both plasma levels, baseline RNA expression as well as ex vivo production in patients 
vs. controls, we investigated this cytokine in more detail. Using six primers covering most 
part of the promoter (suppl. fig 4A), we confirmed consistent downregulation of H3K4me3 
throughout the promoter (Fig. 4B). 
The overall activation state of the chromatin, however, is dictated not only by the activating 
mark H3K4me3, but also by alternative activating marks and repressive marks. Two important 
repressive histone marks are trimethylation of H3K9 and trimethylation of H3K2711. 
H3K27me3 in particular has been associated with control of gene expression upon ex vivo 
LPS stimulation12,13. Using our in vitro model of oxLDL training, we observed long-term lower 
repressive marks on the promoter regions of pro-inflammatory genes. Both H3K9me3 as 
well as H3K27me3 in vitro are lower in trained than untrained monocytes for IL-6 and TNFα 
(suppl. Fig. 4B). Following these observations, we were interested in the repressive marks in 
our patients. For H3K9me3, no significant differences were observed on the TNFα promoter 
region (Fig 4C). With regard to H3K27me3, the TNFα promoter showed a lower occupancy 
throughout the whole promoter (p<0.0001, Fig 4D). Interestingly, levels of H3K27me3 were 
correlated to the levels of H3K4me3 on the promoter of TNFα (R=0.37, p=0.03, Fig. 4E) and 
negatively correlated to the expression of TNFα itself (R=-0.41, p=0.02, fig 4E). Expression of 
EZH2, the only methyltransferase known for inducing H3K27me3 was not different between 
patients and controls (Fig. 4D). H3K9me3 and H3K27me3 showed no differences for IL-6 and 
IL-1β (Suppl. Fig 4C). 
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DISCUSSION
The results of this study add additional evidence in favor of the hypothesis that trained innate 
immunity contributes to the process of atherosclerosis4. We demonstrated that circulating 
monocytes of patients with established atherosclerosis have a pro-inflammatory phenotype, 
associated with epigenetic remodeling at the level of histone methylation and increased 
expression of rate limiting enzymes of the glycolysis pathway and the pentose phosphate 
pathway. Interestingly, this pro-inflammatory phenotype was present only in patients with 
severe symptomatic coronary atherosclerosis, and not in patients with mild asymptomatic 
carotid atherosclerosis. 
The underlying molecular basis of trained immunity is only partially deciphered and comprises 
changes in chromatin organization and intracellular metabolism. In human monocytes trained 
with β-glucan, a shift from oxidative phosphorylation towards aerobic glycolysis through the 
AKT-mTOR-HIF-1a pathway was observed, accompanied by changes in histone marks such as 
H3K4me1, H3K4me3 and H3K27Ac. Both pathways are nonredundant, since pharmacological 
inhibitors of glycolysis, such as 2-deoxy-D-glucose and inhibitors of the mTOR pathway, such 
as metformin, as well as nonspecific inhibitors of histone methyltransferases, prevented 
β-glucan-induced trained immunity 6,10
Here we show that in patients with symptomatic CAD, monocytes display an increased 
pro-inflammatory cytokine response upon ex vivo TLR4/2 stimulation. Previously, ex vivo 
inflammatory responses in patients with and without atherosclerosis were studied mainly 
in whole blood or peripheral blood mononuclear cells (PBMCs)14–16. In addition, baseline 
expression of cytokines, baseline expression of the two rate-limiting glycolysis genes as well 
as the expression of several other enzymes in glycolysis, pentose phosphate pathway and 
Krebs cycle was increased in whole blood. In this study, the pro-inflammatory phenotype 
was also associated with changes in the epigenetic landscape in the monocytes. First we 
studied the level of H3K4me3, a long-term activating histone mark. In contrast to our in vitro 
observations, however, H3K4me3 occupancy on the TNFα promoter was lower in patients 
with CAD.  The accessibility of the chromatin is determined by activating epigenetic marks as 
well as repressive epigenetic marks. The repressive mark H3K27me3 importantly contributes 
to the LPS-induced pro-inflammatory cytokine production12. Previously, Wierda et al. used 
immunohistochemistry to show a reduction of global levels of H3K27me3 modification in 
vessels with advanced plaques, which was not accompanied by alterations in global levels 
of the corresponding histone methyltransferase EZH217, corresponding to our current 
findings. Greissel et al. showed in plaque macrophages a significant reduction of repressive 
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marks H3K9me2 and H3K27me2 with increasing plaque severity18. Although measured in 
plaque macrophages and not in circulating cells, these studies indicate that repressive marks 
are strongly associated with the severity of atherosclerotic disease. In our study, we also 
determined H3K9me3 and H3K27me3 on the TNFα promoter. Although H3K9me3 was not 
significantly different between patients with and without atherosclerosis, H3K27me3 was 
much lower and correlated to cytokine RNA expression levels. Recently, Schmidt et al. studied 
the transcriptional regulator network of human inflammatory macrophages by histone marks. 
They showed that when promoter regions only have H3K4me3 marks, they are in an open 
chromatin state. When promoter regions are additionally trimethylated on H3K27me3, the 
promoter region is ‘poised’ and transcription is prevented19. Furthermore, Kruidenier et al. 
showed that H3K27 demethylation is a critical determinant for LPS induced TNFα production, 
and higher baseline levels of H3K27me3 can result in lower TNFα production12.
Baseline RNA expression analysis showed increased expression of the rate-limiting enzymes of 
the glycolytic pathway as well as other important rate-limiting metabolic enzymes in patients 
with severe atherosclerosis. Previously, we have shown that trained immunity depends on 
a metabolic shift, resulting in increased glycolysis6,10. An increase in gene expression of the 
two rate-limiting glycolytic genes is compatible with this metabolic shift that characterizes 
trained immunity10. The upregulation of other rate-limiting metabolic enzymes involved 
in the pentose phosphate pathway and Krebs cycle indicates a more general activation of 
intracellular metabolism, as shown in figure 4B. Recently, Tawakol et al. showed that in plaque 
macrophages, there is a relationship between PFKFB3 expression and pro-inflammatory 
activation, via hypoxia-induced upregulation of macrophage glycolysis. The authors showed 
a linear relationship between macrophage energetics on the one hand and inflammatory 
activation on the other hand, regulated via PFKFB3 expression20. Furthermore, Shirai et al. 
showed that circulating monocytes and monocyte-derived macrophages from patients with 
established atherosclerosis have increased inflammation and glycolysis21. This study however 
differs markedly from our study, since these patients already suffered an acute myocardial 
infarction, which in itself is a well-known trigger of innate immune activation22. In our study, 
all subjects with coronary atherosclerosis were free from previous cardiovascular events. 
Here we show for the first time that baseline gene expression of glycolysis and intracellular 
metabolism genes in circulating cells is also increased in event-free patients with established 
atherosclerosis, which is also associated with changes in the epigenetic landscape. 
We propose that the pro-inflammatory phenotype of the circulating monocytes in the 
patients with severe coronary atherosclerosis reflects a trained immune phenotype, but we 
can only speculate about the stimulus that has instigated this immunological program. We 
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have previously shown that several PAMPs and DAMPs can induce trained immunity, including 
Bacillus Calmette-Guérin, Candida albicans, β-glucan, and pro-atherogenic stimuli such as 
modified LDL and Lp(a)5,8,9,23. Our patients and controls did not show any differences in total 
cholesterol levels, LDL cholesterol or Lp(a), but the majority of the patients were being treated 
with statins. It is probable that before the initiation of statin treatment, LDL was higher in the 
patients with CAD. Furthermore, the effects of statins on epigenetic modifications are still 
unknown. HDL cholesterol was lower in the patients, but we do not yet know the effects 
of HDL cholesterol on trained immunity. Interestingly, the trained immune phenotype of 
the circulation monocytes was only present in patients with severe symptomatic coronary 
atherosclerosis, and not in patients with asymptomatic carotid atherosclerosis, which was 
diagnosed by screening of healthy subjects. A potential explanation for this finding is that 
trained immunity contributes to the progression of complex atherosclerotic plaques and not 
to the initial formation of early lesions, which are observed in the majority of subjects. This 
finding is consistent with previous findings in patients with elevated levels of lipoprotein(a), 
which can also induce trained immunity in vitro23. Interestingly, most studies report that 
elevated lipoprotein (a) is not associated with early atherosclerotic lesions (e.g. carotid IMT) 
whereas elevated lipoprotein(a) is consistently associated with cardiovascular events, which 
mostly result from vulnerable atherosclerotic plaques24–26. Obviously, this finding requires 
confirmation in a larger cohort of patients. 
Limitations
Our study has several potential limitations. First of all, our results only indicate an association 
between atherosclerosis and trained immunity, and do not provide proof of causality. In theory, 
effects on the immune system could be caused by the atherosclerosis itself. Intervention 
studies in animal models of atherosclerosis will be required to provide final proof that trained 
immunity contributes to the development/progression of atherosclerosis. Secondly, the 
majority of patients with CAD used statins, in contrast to the control group. However, since 
statins are known to have potent anti-inflammatory effects27, it is very unlikely that they have 
contributed to the pro-inflammatory monocyte phenotype, although they may have partially 
masked its full effects. Thirdly, it is important to realize that RNA expression was studied 
in whole blood using PAXgene tubes, to prevent changes in the RNA expression levels by 
the isolation of monocytes. However, it is likely that differences in RNA expression that we 
observed between patients with and without atherosclerosis are relevant for the monocyte 
fraction: first, we measured expression of various cytokines that are predominantly derived 
from monocytes, including TNF, IL1b, and IL6. Secondly, there is a strong correlation between 
the expression of enzymes of the glycolytic pathway (HK2/PFKFB3) and these cytokines, 
suggesting that this increased glycolysis is relevant for monocytes. Finally, in a previous 
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study in patients with atherosclerosis, an increased expression of glycolytic enzymes was 
also observed in isolated monocytes after differentiation into M1 macrophages, compared to 
monocytes from patients without atherosclerosis21.  
Finally, with regard to the epigenetic reprogramming, we have only focused on a few epigenetic 
marks on the promoters of the various cytokines. We studied the ChIPed promoters of genes 
that were upregulated in protein and RNA expression and searched for association, whereas 
a more unbiased approach (e.g. genome wide ChIP seq) could reveal new pathways and 
models for explaining differences. 
Conclusion
Here we show that monocytes of patients with symptomatic CAD but not patients with 
asymptomatic carotid atherosclerosis have a pro-inflammatory phenotype, which is 
associated with metabolic reprogramming on the level of RNA expression towards increased 
glycolysis, and with epigenetic remodeling of pro-inflammatory genes. These findings 
suggest that trained immunity could play a role in the progression of mild and asymptomatic 
atherosclerotic plaques towards symptomatic disease. 
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Table 1. Baseline characteristics of included subjects. Data are presented as mean ± SD 
or n (%). BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; 
TChol, total cholesterol; LDLc, low density lipoprotein cholesterol; HDLc, high density 
lipoprotein cholesterol; Lp(a), lipoprotein(a)
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SUPPLEMENTARY MATERIAL
Supplementary Figure 1 
Monocytes from patients with symptomatic CAD have an inflammatory phenotype upon 
ex vivo stimulation of TLR2 compared to healthy controls. Monocytes from patients and 
controls were stimulated with TLR2 ligand Pam3Cys for 24h and IL-6, TNFα, IL-1β, IL-8 and 
MCP-1 were measured in the supernatant after 24h of incubation at 37°C, 5% CO2 (n=20 vs 
20, * p<0.05, ** p<0.01).
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Supplementary Figure 2
Monocytes from subjects with asymptomatic carotid atherosclerosis do not show an 
increased inflammatory phenotype upon ex vivo stimulation of TLR2 compared to matched 
controls. Monocytes from patients and controls were stimulated with TLR2 ligand Pam3Cys 
for 24h and IL-6, TNFα, IL-1β, IL-8 and MCP-1 were measured in the supernatant after 24h 
of incubation at 37°C, 5% CO2 (n=17 vs 22, * p<0.05, ** p<0.01).
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Supplementary Figure 3
The pearson correlation coefficient was calculated for baseline RNA expression of cytokines 
and metabolic rate-limiting enzymes. A. Cytokines TNFα and IL-1β and glycolytic genes hk2 
and pfkfb3 are significantly correlated (n=17 vs 18, p<0.05 was considered significant). B. 
Relative RNA expression of cytokines and metabolic rate-limiting enzymes in symptomatic 
CAD patients and matched controls (n=17 vs 18)
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Supplementary Figure 4
A. Schematic overview of the tnfα promoter and the designed primers. B. %input H3K9me3 
and H3K27me3 of IL-6 and TNFa of in vitro trained monocytes (n=4). C. %input H3K9me3 
and H3K27me3 of IL-6 and IL-1b in patients and controls (n=20 vs 20).
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ABSTRACT
Innate immune cells can display adaptive characteristics after infections or vaccinations, a 
process called trained immunity, which is mediated by interactions between immunological, 
metabolic and epigenetic pathways. Metabolome and transcriptome analysis of human 
trained monocytes identified cellular cholesterol synthesis pathway to play an important 
role in trained immunity. Pharmacological and genetic modulation of the cholesterol 
synthesis pathway indicated that the metabolite mevalonate is a crucial mediator of trained 
immunity. Mevalonate induces a trained immunity phenotype in human primary monocytes, 
accompanied by whole-genome histone modifications of inflammatory pathways. HMG-CoA-
reductase inhibitors (statins) that block mevalonate formation prevent trained immunity in 
terms of cytokine production, glycolysis, and enrichment of H3K4me3 histone marks. Finally, 
monocytes of patients with hyper IgD syndrome (HIDS) due to mevalonate kinase deficiency 
demonstrate a trained immunity phenotype at both immunological and epigenetic level, 
which likely explain their attacks of fever and inflammation. In conclusion, unraveling the 
role of the mevalonate pathway for the induction of trained immunity contributes to our 
understanding of the pathophysiology of HIDS, and identified potential novel therapeutic 
strategies in clinical conditions characterized by excessive induction of trained immunity.
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INTRODUCTION
The immune system is classically divided into the innate and the adaptive immune system. 
The innate immune system is rapid, relatively non-specific and cannot build immunological 
memory, whereas the adaptive immune system is slower, but specific and can build memory. 
However, the recent observation that innate immune cells can exert adaptive characteristics 
and can build a non-specific memory challenged this paradigm (1). This is supported by a 
wide variety of recent, but also older studies, in plants, invertebrates and mammals (2, 3). 
Cells of the innate immune system, such as monocytes and NK cells, are able to build up 
memory, a process that is dependent on epigenetic changes (4). Once these cells encounter 
a secondary stimulus, either similar or unrelated to the first insult, their response is altered, 
which could result both in a stronger or attenuated response. The induction of a non-specific 
memory resulting in an enhanced function of the innate immune system is termed ‘trained 
(innate) immunity’ (1, 2). 
Analysis of differentially regulated pathways in trained monocytes and macrophages already 
revealed an important role for changes in intracellular metabolism. A shift from oxidative 
phosphorylation to aerobic glycolysis (the Warburg effect), regulated via the mTOR-HIF1α 
pathway was identified as a central regulatory mechanism (5). Shifts in cellular metabolism 
are known to be important drivers of cell phenotype and activation (6). Interestingly, not 
only glucose metabolism, but also other metabolic pathways play an important role in 
reprogramming and polarization of cells. Recently, we described that also glutaminolysis 
and accumulation of fumarate contribute to the trained immunity phenotype, by inhibiting 
KDM5 demethylases and thus influencing the epigenetic remodeling (7). Here, we seek to 
unravel how the cholesterol synthesis pathway modulates trained immunity and epigenetic 
reprogramming; combining transcriptomic and epigenomic studies in both b-glucan and 
oxLDL trained monocytes. We validated the role of these processes in patients with hyper 
IgD syndrome (HIDS) that have a defective cholesterol synthesis pathway due to mevalonate 
kinase deficiency. 
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MATERIALS AND METHODS
Study subjects
Inclusion of healthy controls and HIDS patients was approved by the local institutional review 
board (CMO region Arnhem-Nijmegen) and conducted according to the principles of the 
International Conference on Harmonization–Good Clinical Practice guidelines. 
Cells and reagents
Buffy coats from healthy donors were obtained after written informed consent (Sanquin 
blood bank, Nijmegen, The Netherlands). β-glucan (b-1,3-(D)-glucan) was kindly provided 
by Professor David Williams (College of Medicine, Johnson City, USA). oxLDL was freshly 
prepared as previously described (8). Stimuli and pharmacological inhibitors used include 
lipopolysaccharide (LPS; Sigma-Aldrich, St. Louis, MO; from E. coli serotype 055:B5, further 
purified as described (9)), Pam3Cys (EMC microcollections, Tübingen, Germany), fluvastatin 
sodium hydrate (Sigma-Aldrich), (R)-Mevalonic acid lithium salt (Sigma-Aldrich), zaragozic 
acid (SantaCruz Biotechnology), 6-fluoromevalonate (Sigma-Aldrich), 2-deoxyglucose (Sigma-
Aldrich), rapamycin (Sigma-Aldrich), methyltioadenosine (Sigma-Aldrich), LXR-inhibitor 
GSK2033 (1μM, 10μM; Axon Medchem), or PPARδ-inhibitor GSK3787 (1μM, 10μM; Tocris).
PBMC and monocyte isolation 
PBMC isolation was performed by dilution of blood in pyrogen-free PBS and differential 
density centrifugation over Ficoll-Paque (GE healthcare, UK). Cells were washed thrice in 
PBS. Percoll isolation of monocytes was performed as previously described (10). Briefly, 150-
200·106 PBMCs were layered on top of a hyper-osmotic Percoll solution (48,5% Percoll (Sigma-
Aldrich, St Louis, MO, USA), 41,5% sterile H2O, 0.16M filter sterilized NaCl) and centrifuged 
for 15 minutes at 580 g. The interphase layer was isolated and cells were washed with cold 
PBS. Cells were resuspended in RPMI culture medium (Roswell Park Memorial Institute 
medium; Invitrogen, CA, USA) supplemented with 50μg/ml gentamicin, 2mM L-glutamine, 
and 1mM pyruvate and counted. An extra purification step was added by adhering Percoll 
isolated monocytes to polystyrene flat bottom plates (Corning, NY, USA) for 1 hour at 37°C; 
subsequently a washing step with warm PBS was performed to yield maximal purity. 
Monocyte training and inhibition experiments 
Monocytes were trained as described before (11). Briefly, 100,000 cells were added to flat-
bottom 96-well plates. After washing with warm PBS, monocytes were incubated with culture 
medium only as a negative control or 5μg/ml of β-glucan, 10 μg/ml oxLDL or 100-1000 μM 
(R)-mevalonic acid for 24h (in 10% pooled human serum). Cells were washed once with 200 
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μl of warm PBS and incubated for 5 days in culture medium with 10% pooled human serum 
and medium was changed once. Cells were restimulated with either 200μl RPMI, LPS 10 ng/
ml, or Pam3Cys 10 μg/ml. After 24h supernatants were collected and stored at -20oC. In some 
experiments, cells were pre-incubated (before β-glucan or oxLDL training) for 1 hour with 
20 μM fluvastatin sodium hydrate, 1-5 µM zaragozic acid, or 200 µM 6-fluoromevalonate. 
Concentrations were chosen as being highest non-toxic concentrations, based on pilot-
experiments (not shown).
Mouse experiments
Blood mononuclear cells from wild type mice were isolated using the density gradient cell 
separation medium histopaque 1083 (Sigma). Cells were incubated with β-glucan (5μg/ml) or 
mevalonate (500 μM) for 24h in the presence of 20ng/ml recombinant mouse granulocyte-
macrophage colony-stimulating factor (GM-CSF, PeproTech). Cells were then washed with PBS 
and were cultured until day 6 in 10% fetal bovine serum. Afterwards, they were stimulated 
with LPS (10ng/ml) for 24h in RPMI without fetal bovine serum. Levels of TNF and IL-6 were 
measured in cell culture supernatants.
The effect of fluvastatin (20μM) and potent inhibitors for LXR (1μM, 10μM; GSK2033, Axon 
Medchem) or PPARδ (1μM, 10μM; GSK3787, Tocris) on β-glucan-induced training was 
examined. Compounds were added during the first 24h. Treatment of cells with dimethyl 
sulfoxide (DMSO; Sigma) served as control in the case of LXR and PPARδ antagonism.
Cytokine and lactate measurements 
Cytokine production was determined in supernatants using commercial ELISA kits for human 
IL-1β, TNFα (R&D systems, MN, USA), human IL-6 (Sanquin, Amsterdam, The Netherlands), and 
mouse TNFα and IL-6 (Meso Scale Discovery) following the instructions of the manufacturer. 
Lactate concentration was measured using a Lactate Fluorometric Assay Kit (Biovision, CA, 
USA). 
Foam cell formation
To induce foam cell formation at day 6, trained macrophages were incubated with RPMI alone 
or RPMI containing oxidized LDL at 50 µg/mL for 24h. Incubation with this concentration of 
oxLDL alone caused no secretion of IL-6, TNFα or MCP-1, suggesting absence of endotoxin 
in the prepared LDL fractions. Accumulation of oxLDL was visualized by Oil-Red-O staining as 
described before (12).
RNA sequencing and chromatin immunoprecipitation 
10x106 monocytes were trained in vitro with β-glucan, oxLDL or R-mevalonate in 10cm 
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petridishes in 10ml medium volumes. After resting for 5 days in culture medium, the cells 
were harvested for RNA extraction or chromatin immunoprecipitation.
RNA extraction and cDNA synthesis
Monocytes isolated from HIDS patients and controls, and in vitro derived naive and mevalonate 
exposed macrophages, were lysed in Trizol reagent and stored at -80°C (Life Technologies). 
Total RNA was extracted from cells using the Qiagen RNeasy RNA extraction kit (Qiagen, 
Netherlands), using on-column DNAseI treatment. Ribosomal RNA was removed using the 
riboZero rRNA removal kit (Illumina). RNA was then fragmented into 200bp fragments by 
incubation for 4 minutes at 95°C in fragmentation buffer (200 mM Tris-acetate, 500 mM 
Potassium Acetate, 150 mM Magnesium Acetate, pH 8.2). First strand cDNA synthesis was 
performed using SuperScript III (Life Technologies), followed by synthesis of the second cDNA 
strand. Library preparation was performed using the KAPA hyperprep kit (KAPA Biosystems), 
using the USER enzyme to degrade the second cDNA strand. Quality of cDNA and the 
efficiency of ribosomal RNA removal was confirmed using quantitative RT-PCR using the IQ 
Sybr Supermix, with primers for GAPDH, 18S and 28S rRNA. 
Chromatin immunoprecipitation (ChIP)
Purified cells were fixed with 1% formaldehyde (Sigma-Aldrich) at a concentration of 
approximately 15 million cells/ml. Fixed cell preparations were sonicated using a Diagenode 
Bioruptor Pico sonicator using 5 cycles of 30 seconds on, 30 seconds off. One µg of chromatin 
(approx. 0.5-1 million cells) was incubated with dilution buffer, 12 µl protease inhibitor 
cocktail and 1µg of H3K27ac antibody or H3K4me3 (Diagenode) to a final volume of 300 µl, 
and incubated overnight at 4 ºC with rotation. Protein A/G magnetic beads were washed 
in dilution buffer with 0.15% SDS and 0.1% BSA, added to the chromatin/antibody mix and 
rotated for 60 minutes at 4°C. Beads were washed with 400µl buffer for 5 minutes at 4 °C with 
five rounds of washes. After washing chromatin was eluted using 200 µl elution buffer for 20 
minutes. Supernatant was collected, 8 µl 5M NaCl, 3µl proteinase K were added and samples 
were incubated for 4 hours at 65°C. Finally samples were purified using Qiagen Qiaquick 
MinElute PCR purification Kit and eluted in 20 µl elution buffer. 
For qPCR analysis, samples were analyzed using a comparative Ct method in which 
myoglobin was used as a negative control and H2B as a positive control according to the 
manufacturer’s instructions. The following primers were used for this analysis: myoglobulin 
forward AGCATGGTGCCACTGTGCT; myoglobulin reverse GGCTTAATCTCTGCCTCATGAT; 
H2B forward TGTACTTGGTGACGGCCTTA; H2B reverse CATTACAACAAGCGCTCGAC; TNFA 
forward GTGCTTGTTCCTCAGCCTCT; TNFA reverse ATCACTCCAAAGTGCAGCAG; IL-6 forward 
AGGGAGAGCCAGAACACAGA; IL-6 reverse GAGTTTCCTCTGACTCCATCG.
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Library preparation for sequencing 
Illumina library preparation was done using the Kapa Hyper Prep Kit (Kapa Biosystems). For 
end repair and A-tailing double stranded DNA was incubated with end repair and A-tailing 
buffer and enzyme and incubated first for 30 minutes at 20 °C and then for 30 minutes at 65°C.
Subsequently adapters were ligated by adding 30µl ligation buffer, 10 Kapa l DNA ligase, 5 µl 
diluted adaptor in a total volume of 110µl and incubated for 15 minutes at 15 °C. Post-ligation 
cleanup was performed using Agencourt AMPure XP reagent and products were eluted in 20 
µl elution buffer. Libraries were amplified by adding 25 µl 2x KAPA HiFi Hotstart ReadyMix 
and 5µl 10x Library Amplification Primer Mix and PCR, 10 cycles. Samples were purified using 
the QIAquick MinElute PCR purification kit and 300bp fragments selected using E-gel. Correct 
size selection was confirmed by BioAnalyzer analysis.   Sequencing was performed using the 
Illumina NextSeq500 machine and generated 43bp paired end reads. Samples for RNA-seq 
were treated to the above protocol exactly, except for a single additional step: After post-
ligation cleanup, and before library amplification, samples were incubated with 3 μL USER 
enzyme for 15 minutes at 37°C to digest the second cDNA strand. 
RNA-seq data analysis
To infer gene expression levels, RNA-seq reads were aligned to the Ensembl v68 human 
transcriptome using Bowtie 1 (13). Quantification of gene expression was performed using 
MMSEQ (https://github.com/eturro/mmseq) (14) Haplotype and isoform specific expression 
estimation using multi-mapping RNA-seq reads. Differential expression was determined using 
DEseq (http://bioconductor.org/packages/release/bioc/html/DESeq.html) (15) Differentially 
expressed genes were determined using pair-wise comparison between treatments, with a 
fold change >1.5, adjusted p value of <0.1, and RPKM >1. 
ChIP-seq data analysis
Sequencing reads were aligned to human genome assembly hg19 (NCBI version 37) using 
bwa (16). Duplicate and low quality reads were removed after alignment using Samtools 
and Bamtools (17, 18). For peak calling the BAM files were first filtered to remove the reads 
with mapping quality less than 15, followed by fragment size modeling (http://code.google.
com/p/phantompeakqual-tools/). MACS2 (http://github.com/taoliu/MACS/) was used to call 
the peaks (19).  H3K27ac peaks were called using the default (narrow) setting. Reads/peak 
tables were merged using Bedtools (20). Data were normalized using the R package DESeq1 
and then pair-wise comparisons were performed (fold change 1.5, adjusted p-adjvalue <0.1 
and reads/peal ≥10 in at least in any condition) to determine the differential peaks. 
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Statistics 
In-vitro monocyte experiments were performed at least 6 times and analyzed using a 
Wilcoxon signed-rank test or one-way ANOVA, where applicable. A P-value below 0.05 was 
considered statistically significant. All data were analyzed using Graphpad prism 5.0 (La Jolla, 
CA, USA). * p < 0.05, ** p < 0.01. Data are shown as means ± SEM. 
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RESULTS
Activation of the cholesterol synthesis pathway, but not the synthesis of 
cholesterol itself is essential for induction of trained immunity
B-glucan can induce a long-term reprogramming in monocytes and macrophages, resulting in 
enhanced function (21). Integrating the transcriptome and metabolome of b-glucan-trained 
macrophages showed an upregulation of several major metabolic pathways, such as glucose 
metabolism, glutaminolysis, and the cholesterol synthesis pathway (5, 7). The expression of 
several key enzymes in the cholesterol synthesis pathway was strongly increased by b-glucan 
training (Fig 1A), leading to the hypothesis that the cholesterol synthesis pathway contributes 
to trained immunity. 
Pharmacological inhibition of the rate-limiting enzyme HMG-CoA-reductase with fluvastatin 
prevented the induction of trained immunity by b-glucan, illustrated by decreased cytokine 
production upon re-stimulation. Moreover, lactate production was also decreased, indicating 
reduced glycolysis, which is an important component of the trained immunity phenotype 
(Fig 1B) (7). Additionally, when mouse mononuclear cells were trained with b-glucan, 
the induction of cytokine production upon LPS restimulation could also be inhibited with 
fluvastatin (Fig 1C). To further unravel which part of the cholesterol pathway is essential for 
this effect, several inhibitors of enzymes downstream of HMG-CoA-reductase were assessed 
for their capacity to modulate trained immunity (Fig 1A,B). To study whether cholesterol 
synthesis itself is necessary for training, cells were preincubated with zaragozic acid A, which 
inhibits squalene synthase. Preincubation of monocytes with zaragozic acid, however, did 
not inhibit the induction of pro-inflammatory cytokine production (Fig 1B), indicating that 
cholesterol itself is not essential for trained immunity. Secondly, 6-fluoromevalonate was 
used to inhibit mevalonate pyrophosphate (PP) decarboxylase. Mevalonate PP decarboxylase 
catalyzes the formation of isopentenyl-PP from mevalonate-5-PP. Pre-incubation of 
monocytes with 6-fluoromevalonate augmented the induction of pro-inflammatory cytokine 
production by β-glucan (Fig 1B), indicating that the accumulation of a molecule upstream of 
6-fluoromevalonate plays a role in the induction of cytokine production, and excluding a role 
for protein prenylation. 
We have previously reported that brief exposure to oxLDL also induced trained immunity 
(22). Pre-incubation of cells with fluvastatin also prevented oxLDL-induced trained immunity, 
both in terms of cytokine production upon restimulation and decreased lactate production 
and glycolysis. Incubation with fluvastatin prevented epigenetic reprogramming of both 
oxLDL and b-glucan training (Fig 1D, (7)), and also prevented increased foam cell formation, 
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which was induced by training with oxLDL (Fig 1E). OxLDL- and b-glucan-induced training was 
associated with enrichment of H3K4me3 on the promoter TNFA, which was prevented by 
fluvastatin (Fig 1D, (7)).
Mevalonate induces trained immunity by epigenetic reprogramming
As the induction of trained immunity is inhibited by fluvastatin and increased with 
6-fluoromevalonate, we came to the hypothesis that mevalonate is the metabolite from the 
cholesterol synthesis pathway that induces a trained immunity phenotype. Indeed, addition 
of exogenous mevalonate recaptured the b-glucan- and oxLDL-induced trained phenotype 
in the presence of fluvastatin (Fig 2A). We further investigated the induction of training by 
mevalonate and found that incubation of monocytes with mevalonate on day 0 increased 
cytokine production upon restimulation 6 days later (Fig 2B). Again, this could be reproduced 
in mouse monocytes (Fig 2C). Furthermore, pre-incubation with 6-fluoromevalonate 
potentiated the effect of mevalonate (Fig 2D). Interestingly, also lactate production was 
increased in mevalonate-trained macrophages (Fig 2E), which suggests activation of the 
glycolytic pathway similar to β-glucan-trained macrophages (5). Indeed, inhibition of 
glycolysis with 2-deoxyglucose and inhibition of mTOR with rapamycin prevented mevalonate-
induced trained immunity (Fig 2F). This shows a crucial role for glucose metabolism and 
mTOR signaling in mevalonate-induced trained immunity. In addition, to determine the 
role of histone methylation in the induction of trained immunity by mevalonate, we added 
methyltioadenosine (MTA, a non-selective methyltransferase inhibitor) to the in-vitro system 
during the first 24h. Addition of MTA prevented mevalonate-induced trained immunity in 
terms of increased cytokine production (Fig 2G). Indeed, mevalonate induced an enrichment 
of H3K4me3 on the promoters of IL6 and TNFA (Fig 2H), similar to the training by b-glucan 
and oxLDL (21, 22). 
Figure 1 - The cholesterol synthesis pathway in trained immunity. (A) Transcriptional expression of 
macrophages five days after β-glucan exposure. Red arrow = significant upregulation. Overview of 
the cholesterol synthesis pathway and the used inhibitors. (B) Monocytes were trained with β-glucan 
+/- inhibitors of the cholesterol synthesis pathway. Five days after β-glucan exposure, lactate 
concentrations were measured in the supernatants and macrophages were restimulated for 24h with 
LPS and TNFα concentrations were measured in the supernatant. (N=6, mean ± SEM). (C) Mouse blood 
mononuclear cells were trained with β-glucan +/- fluvastatin on day 1. At day 6 cells were stimulated 
for 24h and cytokines were determined in the supernatants. (N=6, mean ± SEM). (D) Monocytes were 
trained with oxLDL +/- fluvastatin for 24h. Five days later, epigenetic (H3K4me3) changes at the TNFA 
promoter and lactate concentrations in the supernatant were measured. Macrophages were also 
restimulated for 24h with LPS to determine TNFα concentrations in the supernatant. (N=6, mean ± 
SEM). (E) Monocytes were trained with oxLDL +/- fluvastatin for 24h. Five days later foam cell formation 
was induced by exposure to high concentration of oxLDL. After 24h cells were stained with Oil-Red-O. 
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Figure 2 - Mevalonate induces trained immunity. (A) Adding mevalonate during the first 24h 
can rescue the inhibition of oxLDL/β-glucan-induced training by fluvastatin. (N=6, mean ± SEM). 
(B) Human and (C) mouse monocytes were trained with mevalonate for 24h and restimulated 
with LPS at day 6. TNFα concentration were measured in the supernatants. (N=6, mean ± 
SEM). (D) When 6-fluoromevalonate was added during the first 24h, training with mevalonate 
could be enhanced. (N=6, mean ± SEM). (E) Lactate production of RPMI or LPS re-stimulated 
mevalonate-trained macrophages at day 6. (N=10, mean ± SEM). (F) When 2-deoxyglucose (2-
DG) or rapamycin were added during the first 24h, mevalonate and β-glucan induced training 
could be inhibited. (N=6, mean ± SEM). (G) Adding a methyltransferase inhibitor (MTA) inhibits 
the induction of trained immunity. (N=6, mean ± SEM). (H) H3K4me3 at promoters of TNFA 
and IL6 was assessed at day 5 of mevalonate-trained macrophages. (N=6, mean ± SEM).
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To further elucidate the mechanism through which mevalonate induces trained immunity, 
we performed RNA-sequencing and a whole-genome assessment of the histone mark 
H3K27ac by ChIP-sequencing in mevalonate-trained macrophages. Monocytes were trained 
as described above, and after 5 days of rest (before restimulation), monocyte-derived-
macrophages were harvested for ChIP- and RNA-sequencing (Fig 3A). Similar to fumarate-
trained macrophages no consistent differences were found in transcription profiles at this 
time point (7). This is consistent with previous observation for β-glucan trained macrophages 
that the major differences in gene expression are present during the first 24h after β-glucan 
stimulation, whereas at later time points transcriptional differences are less pronounced 
(23). Whole genome epigenetic analysis of mevalonate-trained macrophages, by chromatin 
immunoprecipitation of histone 3 lysine 27 acetylation (H3K27ac) did reveal noticeable 
differences between trained and non-trained macrophages. In total 223 defined peaks 
showed an upregulation of H3K27ac and 554 peaks showed a downregulation in mevalonate-
trained macrophages (Fig 3B-D, Table S1). When these peaks were compared with β-glucan-
trained macrophages, of the 223-upregulated peaks only few were also found in β-glucan-
trained macrophages. However, of the 554 downregulated peaks 397 were also found in 
the β-glucan-trained macrophages. Of these peaks 45% also showed a downregulation of at 
least 2-fold, showing a comparable signature in mevalonate and β-glucan-induced trained 
immunity (Table S1). Pathway analysis of these differentially regulated peaks in mevalonate-
trained monocytes, can be found in Fig 3E and shows the modulation of several important 
inflammatory pathways.
Monocytes of HIDS patients with mevalonate kinase deficiency have a 
trained immunity phenotype with higher cytokine production 
Mevalonate kinase deficiency in humans leads to Hyper-IgD syndrome (HIDS), an 
autoinflammatory disorder characterized by an accumulation of mevalonate (24, 25). HIDS 
patients experience periodic attacks of sterile inflammation with symptoms such as fever, skin 
lesions, lymphadenopathy, and arthralgia (26). Interestingly, white blood cells of HIDS patients 
were described to produce more cytokines, unstimulated as well as stimulated, indicating a 
pre-activated state (27). We hypothesized that this is due to a trained immunity phenotype 
of HIDS monocytes, likely induced by the accumulation of mevalonate. We investigated the 
cells of 3 adult HIDS patients (2 male, 1 female), all three with V377I mutations. In line with 
our hypothesis, purified monocytes from these patients produced significantly more TNFα, 
IL-6 and IL-1β upon stimulation with several ligands compared to healthy controls (Fig 4A). 
RNAseq analysis revealed that HIDS monocytes incubated in medium for 24h in the absence of 
exogenous stimulation display an overexpression of multiple genes (Fig 4B, Table S2), although 
with substantial interdonor variation (Fig S1). Pathway analysis of these expression data is 
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Figure 3 - Epigenetic changes induced by mevalonate. (A) Experimental set-up for mevalonate-
induced trained macrophages. (B) Summary of H3K27ac peaks that show higher or lower 
deposition in mevalonate-trained cells relative to control macrophages. (C) Boxplots of 
H3K27ac peaks. (D) Heatmap of H3K27ac intensity at peaks that show increased and decreased 
H3K27ac in mevalonate-trained macrophages. Data is plotted over an area of +/- 12kb 
from peak center. (E) Pathway analysis of H3K27ac differentially regulated genes. (N=2)
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displayed in Fig 4C and shows upregulated inflammatory pathways, such as NFkB signalling, 
supporting the hypothesis of a hyperinflammatory state. We performed whole-genome 
assessment of the histone mark H3K27ac by ChIP-sequencing in non-stimulated monocytes 
from the HIDS patients and controls. Due to variation between the three HIDS patients, only 
147 upregulated and 63 downregulated peaks were found to be different comparing HIDS 
patient to healthy controls (Table S3). The overlap betwenen the in-vitro mevalonate trained 
macrophages and HIDS circulating monocytes in terms of H3K27ac peaks was limited, due 
to differences in the cell types analysed (Fig S2). When specifically comparing peak-related 
genes between HIDS and mevalonate-activated samples one upregulated gene and 22 
downregulated genes were found (Table S3), but these could not be allocated to certain 
cellular pathways, because of the low number. When specifically assessing the expression 
data of HIDS patients for trained immunity-related genes an interesting comparison can 
be made. Expression profiles of pathways known to be important for induction of trained 
immunity such as glycolysis, mTOR pathway, and (innate) cytokines were assessed (4, 5, 21), 
comparing HIDS patients and healthy controls. This shows a clear increased induction of 
glycolysis and mTOR pathway in HIDS patients when their monocytes are stimulated with LPS 
(Fig 4D). Moreover, transcription of cytokines was evidently increased in monocytes of HIDS 
patients after 24h in RPMI medium, as was shown by increased production upon stimulation 
before (Fig 4A,D).
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Figure 4 - HIDS patients display a trained-immunity like phenotype. (A) Monocytes from HIDS patients 
and matched healthy volunteers were exposed ex vivo to several ligands for 24h. Cytokine were measured 
in the supernatants. (N=4, mean ± SEM). (B) Heatmap showing expression data of monocytes of HIDS 
patients versus healthy volunteers either unstimulated, or 24h stimulated with RPMI or LPS. (N=3 vs 
N=3). (C) Top pathways associated with genes that show higher expression in HIDS patients exposed 
to 24h RPMI compared to controls. (N=3 vs N=3). (D) Monocytes of 3 HIDS patients and 3 healthy 
volunteers were exposed to RPMI/LPS for 24h or left unstimulated (unstim). Fold increases of HIDS/
controls were calculated for genes in the glycolysis pathway, mTOR pathway or cytokines. (N=3 vs N=3).
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DISCUSSION
Trained immunity is associated with an upregulation of several cellular metabolic pathways, 
including glycolysis and glutamine metabolism. In this paper, we explored the role of the 
mevalonate-cholesterol pathway in the induction of trained immunity. We show that the 
cholesterol synthesis pathway is also essential for inducing trained immunity. Inhibition of the 
cholesterol synthesis pathway by statins down-regulated the increased cytokine production 
and epigenetic reprogramming induced by β-glucan as well as oxLDL. We also show that not 
the synthesis of cholesterol itself is essential, but the accumulation of mevalonate. 
Transcriptome and epigenome analysis showed that incubation of healthy monocytes with 
mevalonate alone results in trained macrophages that resemble the β-glucan-induced 
trained immunity phenotype. This indicates that next to fumarate, mevalonate is an essential 
metablite in the metabolo-epigenetics of trained immunity. RNA sequencing analysis showed 
that monocytes from patients with HIDS due to mevalonate kinase deficiency exhibit a 
trained immunity phenotype. 
The cholesterol synthesis pathway has been shown to affect epigenetic remodeling via 
induction of LXRα, which is induced by intermediates downstream in the cholesterol synthesis 
pathway (28, 29). Furthermore, downregulation of geranylgeranylation downregulates HDAC1 
activity and FPP and GGPP have been shown to inhibit the lysine specific demethylase 1 
(30, 31). However surprisingly, in the present study we show that intermediates downstream 
in the pathway are not essential for inducing trained immunity, while metabolites in the 
proximal part of the pathway, especially mevalonate, play an important role. We, thus, show 
that it is unlikely that isoprenylation plays a major role for the induction of trained immunity.
HIDS is one of the prominent hereditary autoinflammatory (‘periodic fever’) syndromes. 
HIDS patients carry mutations in mevalonate kinase that are responsible for the clinical 
picture of febrile attacks, skin lesions, arthritis and lymphadenopathy. The mutation in 
mevalonate kinase leads to accumulation of mevalonate and results in elevated excretion of 
mevalonic acid during attacks (25). In the treatment of HIDS inhibition of IL-1 with anakinra 
has become one of the cornerstones of the therapy (32), but HIDS is considered more and 
more a ‘multi-cytokine disease’, as also inhibition of IL-6 with tociluzimab and even anti-TNF 
treatment with etanercept have shown promising results in specific cases (33-36). We thus 
hypothesized that induction of a trained immunity phenotype, characterized by exaggerated 
cytokine production by monocytes due to mevalonate accumulation, could play a role in 
the pathophysiology of HIDS. This hypothesis was validated by both demonstration of 
exaggerated cytokine production in HIDS monocytes, accompanied by transcriptional and 
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epigenetic changes. Interestingly, statin treatment showed a reduced excretion of mevalonic 
acid in HIDS patients, and a decreased number of febrile days, supporting the concept that 
lowering mevalonate levels is beneficial for disease activity (37).  
Kastner et al. have shown that isoprenylation is an important mechanism that is deficient 
in HIDS patients and causative to the disease symptoms. The absence of protein 
geranylgeranylation results in compromised PI(3)K activity, which allows an unchecked TLR-
induced inflammatory response with constitutive activation of the pyrin inflammasome. 
Moreover, due to prenylation defects the GTPase RhoA is inactivated, which also results in 
pyrin inflammasome activation (38, 39). Interestingly, it was also shown that isoprenylation 
is not defective in HIDS patients due to increased flux through the isoprenoid/cholesterol 
biosynthesis pathway by elevating intracellular mevalonate levels (40). However, we now 
show that next to this mechanism based on defective prenylation, also the accumulation of 
mevalonate itself might play a role in developing the hyperinflammatory state observed in 
HIDS. 
A crucial aspect relates to the mechanisms through which mevalonate induces and modulates 
trained immunity. In T-cells, activation induces a shift from oxidative phosphorylation 
to aerobic glycolysis, similar to trained monocytes. In these cells it was shown that the 
increased glycolysis also fuels mevalonate metabolism (41). Glucose is increasingly taken up 
and converted into pyruvate. Subsequently, via a truncated TCA cycle, pyruvate is converted 
into acetyl-CoA and citrate, which is exported to the cytosol. There, the citrate is converted 
back into acetyl-CoA by ATP citrate lyase (42) and enters either the mevalonate pathway or 
fatty acid biosynthesis (41). Previously we have shown an increase in intracellular citrate in 
b-glucan trained cells, which might provide evidence of a similar mechanism in monocytes 
as well (7). An interesting observation of our study is the involvement of glycolysis and mTOR 
for the induction of trained immunity by mevalonate. Mevalonate-induced training can be 
counteracted by inhibiting glycolysis and mTOR signaling. The mechanism through which 
mevalonate induces this effect remains to be identified, but mevalonate could exert this effect 
either intra- or extracellularly. One possibility is activation of an LXR receptor by mevalonate, 
followed by transcriptional and epigenetic changes leading to shifts of glucose metabolism as 
well. Another scenario may involve release of mevalonate from the cells during induction of 
trained immunity, which can act in turn in an autocrine and paracrine manner and induce the 
observed effects on trained immunity. This mechanism is supported by the observation that 
mevalonate is able to signal via the IGF1 receptor (43). 
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Clinically, the discovery of a role for mevalonate for induction of trained immunity, and of a 
hyper-inflammatory phenotype in specific diseases, has important consequences. Inhibition 
of the cholesterol synthesis pathway in inflammatory conditions is thus potentially very 
relevant. Earlier studies have already shown that statins can improve survival from sepsis in 
mice (44) and also human studies demonstrate that statin use may be associated with better 
survival in sepsis (45). Also the development of rheumatoid arthritis is thought be reduced 
by statin treatment (46). Inhibition of the cholesterol synthesis pathway could therefore be 
an effective therapy in other hyper-inflammatory disorders in which trained immunity plays a 
role (1). However, to fully implement inhibition of the mevalonate pathway as a therapeutic 
option the exact role of trained immunity and mevalonate accumulation in these conditions 
should be first elucidated further. 
In conclusion, the cholesterol synthesis pathway, and in particular the intermediate 
mevalonate, is essential for inducing trained innate immunity. Incubation of monocytes with 
mevalonate induces a trained immunity phenotype, which covers a part of the β-glucan 
trained immunity phenotype, similar to fumarate. Patients with mevalonate accumulation 
acquire a trained immunity phenotype, by showing increased expression of cytokines and 
genes in the glycolysis pathway. Furthermore, inhibition of the cholesterol synthesis pathway 
by statins reduces the trained immunity phenotype. Statins could therefore be used as a 
treatment option for diseases, which are mediated via trained immunity, until more specific 
drugs for inhibiting trained immunity are available. 
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SUPPLEMENTARY FIGURES
Figure S1 - HIDS expression analysis. Heatmap of individual donors for genes that show LPS 
responses in controls and HIDS patients. Monocytes were either unstimulated (=baseline) 
or stimulated for 24h with RPMI/LPS.
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Figure S2 – Comparison of H3K27ac peaks in HIDS monocytes versus mevelonate-trained 
macrophages. The left hand side graphs display the median and mean read counts of the 
H3K27ac peaks that were significantly up or down in HIDS patient monocytes. At the right 
hand side graphs are display of median and mean read counts at the same H3K27ac peaks.
Table S1. Up- and down-regulated peaks of H3K27ac in mevalonate-trained macrophages 
and a comparison between mevalonate and beta-glucan trained macrophages.
!
182
Chapter 7
Table S2. RNAseq analysis of unstimulated or 24h RPMI- or LPS-stimulated monocytes from 
HIDS patients and controls (n=3). (data not shown)
Table S3. Whole-genome assessment of the histone mark H3K27ac by ChIP-sequencing 
from HIDS patients and controls (n=3). Comparison between histone acetylation of HIDS 
patients monocytes and mevalonate trained macrophages. (data not shown)
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ABSTRACT 
Efforts to reverse the pathologic consequences of vulnerable plaques are often stymied by the 
complex treatment resistant pro-inflammatory environment within the plaque. This suggests 
that pro-atherogenic stimuli, such as LDL cholesterol and high fat diets may impart longer 
lived signals on (innate) immune cells that persist even after reversing the pro-atherogenic 
stimuli. Recently, a series of studies challenged the traditional immunological paradigm that 
innate immune cells cannot display memory characteristics. Epigenetic reprogramming in 
these myeloid cell subsets, after exposure to certain stimuli, has been shown to alter the 
expression of genes upon re-exposure. This phenomenon has been termed trained innate 
immunity or innate immune memory. The changed responses of ‘trained’ innate immune 
cells can confer nonspecific protection from secondary infections, suggesting that innate 
immune memory has likely evolved as an ancient mechanism to protect against pathogens. 
However, dysregulated processes of immunological imprinting mediated by trained innate 
immunity may also be detrimental under certain conditions as the resulting exaggerated 
immune responses could contribute to autoimmune and inflammatory diseases, such as 
atherosclerosis. Pro-atherogenic stimuli most likely cause epigenetic modifications that 
persist for prolonged time periods even after the initial stimulus has been removed. In this 
review we discuss the concept of trained innate immunity in the context of a hyperlipidemic 
environment and atherosclerosis. According to this idea the epigenome of myeloid 
(progenitor) cells is presumably modified for prolonged periods of time, which, in turn, could 
evoke a condition of continuous immune cell over-activation.
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ATHEROSCLEROSIS, A PERSISTENT INFLAMMATORY DISEASE
Cardiovascular diseases (CVD), including stroke, and myocardial infarction, are the leading 
cause of mortality worldwide and together are responsible for approximately 17 million 
deaths per year [1]. The vast majority of cardiovascular events are caused by the rupture or 
erosion of atherosclerotic plaques in the arterial wall and the subsequent formation of an 
occluding thrombus. Traditionally, atherosclerosis is regarded as a disease of the developed 
Western Society, driven by the major classical risk factors dyslipoproteinemia, hypertension, 
diabetes, obesity, smoking, and a sedentary lifestyle. Interestingly, however, the development 
of atherosclerosis is not restricted to patients with a Western lifestyle. In a recent study, 
CT-scanning revealed signs of atherosclerosis in a third of mummies from several ancient 
populations, even in non-smoking populations that had an almost entirely marine diet [2]. 
These observations fit the paradigm shift in the early nineties that atherosclerosis is more 
than simply a vascular cholesterol storage disease, and that chronic low-grade vascular 
inflammation triggered by the deposited material could contribute to atherogenesis [3]. The 
inflammatory nature of atherosclerotic plaques was already recognized in the nineteenth 
century by Virchow [4], who wrote: “In some, particularly violent cases the softening 
manifests itself even in the arteries not as the consequence of a really fatty process, but as a 
direct product of inflammation”. 
In the last ten years, several novel non-traditional risk factors for atherosclerosis have been 
identified that are all associated with activation of the immune system. These include chronic 
inflammatory diseases such as rheumatoid arthritis, gout, psoriatic arthritis, and ankylosing 
spondylitis, as well as infections with bacteria or viruses, such as Chlamydia pneumonia, 
Porphyromonas gingivalis and human immunodeficiency virus (HIV) [5]. In addition, acute 
cardiovascular events occur more frequently in the weeks following an acute infection, such 
as pneumonia [6]. Recently, also cardiovascular events itself, such as myocardial infarction 
[7] or stroke were described to drive subsequent acceleration of atherosclerosis throughout 
the vascular system [8]. Finally, recent experimental evidence indicates that changes in diet 
and in dietary composition are able to directly influence lymphoid organs, thus profoundly 
and continuously influencing immune responses and the development of inflammatory and 
autoimmune diseases [9].
Although it is now well established that inflammation plays an essential role in the initiation, 
progression, and destabilization of atherosclerotic plaques, the mechanisms that drive the 
persistent non-resolving inflammation in the vessel wall remain incompletely understood. 
Macrophages are the most abundant inflammatory cells present in atherosclerotic plaques. 
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Cells of the adaptive immune system such as T and B lymphocytes are also present, but in lower 
numbers. Evidence is rapidly accumulating that innate immune cells can adopt a persistent 
pro-inflammatory phenotype after brief exposure to a variety of stimuli, a phenomenon that 
has been termed ‘trained innate immunity’ [10].
In this review, we discuss the concept that trained immunity contributes to the development 
of atherosclerosis, both in the setting of traditional cardiovascular risk factors, and in the 
setting of non-traditional risk factors, such as acute and chronic infections, and non-infectious 
chronic inflammatory disorders. In addition, it might well be that elevated dietary fats and 
consequently an alteration of the gut microbiota, impact immune homeostasis (dysbalance 
between inflammatory and tolerogenic processes), thus inducing a long-term epigenetic 
reprogramming of innate immune cells.
THE INNATE IMMUNE SYSTEM AND ATHEROSCLEROSIS
Within atherosclerotic plaques, macrophages are the most abundant subset of leukocytes. 
Arterial resident macrophages are derived from embryonic CX3CR1+ precursors and from 
bone marrow-derived monocytes that colonize the tissue immediately after birth [11, 12]. 
During atherogenesis, arterial plaque macrophages are sustained by local proliferation, but 
also by recruitment of Ly6Chigh monocytes [13]. Monocytes and macrophages are critically 
promoting the initiation, progression, and destabilization of atherosclerotic plaques by 
several mechanisms [14, 15]. In the early stages of atherosclerosis, macrophages contribute 
to the clearance of reactive lesional oxidized low-density lipoprotein (oxLDL) particles through 
scavenger receptor A (SR-A) and CD36 mediated uptake. In later stages, macrophages are 
impaired in their phagocytic functionality due to intracellular accumulation and defective 
efflux of oxLDL. Foam cell macrophages undergo apoptosis due to cellular stress and 
inflammatory responses, a process, which ultimately contributes to the formation of the 
pro-thrombotic necrotic core that characterizes mature atherosclerotic plaques. Damage 
Associated Molecular Patters (DAMPs), which accumulate in the atherosclerotic plaques, 
represent a source of endogenous danger ligands that can further activate macrophages 
by binding to specific Pattern Recognition Receptors (PRR), such as membrane-bound Toll 
Like Receptors (TLR), SR, and intracellular NOD-like receptors (NLRs) [16].  Multiple pro-
inflammatory triggers could hence cause an inflammatory milieu in the plaque. In addition, 
even the phase transition of cholesterol can cause inflammation as cholesterol crystals can 
activate the Nlrp3 (NOD-, LRR- and pyrin domain-containing 3) inflammasome, triggering the 
secretion of pro-inflammatory IL-1β and IL-18 [17]. Finally, lesional macrophages contribute 
to the remodeling of atherosclerotic plaques into a rupture-prone unstable phenotype by the 
production of proteases, such as matrix metalloproteinases [18]. Overall, plaque macrophages 
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display a marked phenotypic heterogeneity [19], which is dictated by the composition of the 
local DAMPs that are present in the specific environment during different stages of plaque 
development. 
Several studies have shown that hypercholesterolemia considerably increases the number of 
circulating Ly6Chigh pro-inflammatory monocytes in mice (or the CD14++CD16-/ CD14++CD16+ 
equivalent in humans), thereby accelerating atherosclerosis [20, 21]. Additionally, an 
acute myocardial infarction, stroke or sepsis can accelerate subsequent atherosclerosis 
by inducing monocytosis [7, 22]. Which factors are driving monocytosis in the context of 
a hypercholesterolemic environment remains to be fully resolved. Besides, although the 
adverse contribution of myeloid cells in atherosclerosis is generally accepted, it is still an 
open question why a strong pro-inflammatory response within the arterial wall fails to be 
resolved even after reducing potential inflammatory triggers. Recent studies have illuminated 
the mechanisms underlying the hypercholesterolemia-induced myelopoiesis and a shifting 
towards the pro-inflammatory Ly6Chigh monocytes  [23, 24]. Hitherto, the debate has primarily 
focused on the link between cholesterol accumulation within the plaque macrophage and 
local ongoing inflammatory processes. However, myeloid priming and reprogramming under 
hypercholesterolemic conditions can occur already within the bone marrow, due to an 
overload of cholesterol and defective efflux pathways in hematopoietic stem and myeloid 
precursor cells. Animal studies have shown that cholesterol efflux pathways in hematopoietic 
stem cells (HSC) are mediated by apolipoprotein E (ApoE), ATP-binding cassette transporter A1 
(ABCA1) and ABCG1 and these processes are controlling HSC expansion in the bone marrow. 
Transplantation of ABCA1-/- ABCG1-/- bone marrow into Ldlr-/- mice fed a Western type diet, 
as well as studies in ApoE-/- mice fed a Western type diet, induced dramatic leukocytosis 
(monocytosis and neutrophilia), which could be reversed by overexpression of the transgenic 
human Apo-AI [25-27]. The proliferative response in HSC was favored by increased cholesterol 
storage into the plasma membrane (due to impaired efflux), which resulted in increased 
expression of the proliferative cytokine receptors to IL-3, IL-5 and GM-CSF. Recent evidence 
suggests that Western type diet feeding also induces epigenetic modifications within HSC 
and myeloid progenitor subsets, potentially provoking increased myelopoiesis [28, 29]. Van 
Kampen et al. [29] revealed in competitive bone marrow transplantation experiments using 
Ldlr-/- recipients fed a chow diet that donor bone marrow from Western type diet fed animals 
markedly increased myeloid progenitor proliferation compared to donor bone marrow from 
chow fed animals. Bone marrow from Western type diet fed mice showed hypomethylation 
in CpG-regions in the genes encoding PU.1 and IRF8, key regulators of monocyte proliferation 
and macrophage differentiation. Consistently, blood leukocyte numbers were significantly 
increased as a result of increased circulating monocytes, along with the presence of a 
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more activated splenic macrophage phenotype and increased plaque sizes. In agreement 
with these data, Seijkens and colleagues [28] demonstrated in a competitive bone marrow 
transplantation study (transfer of normocholesterolemic bone marrow cells into either chow 
or high fat diet fed Ldlr-/- recipients) that a hypercholesterolemic BM microenvironment 
induced loss of HSC quiescence, characterized by increased expression of cyclin B1, C1 and 
D1, and skewed HSC development towards myeloid lineages, especially towards granulocytes 
and Ly6Chigh monocytes. HFD priming of bone marrow HSC remained even after transfer into 
normocholesterolemic mice and was associated with reduced H3K9/14 acetylation at the 
promoter of the retinoblastoma (RB) gene (involved in the control of excessive cell growth). 
In summary, these studies shed new light on the causality between hypercholesterolemia, 
altered epigenetic patterning in HSC and myeloid progenitors, and increased susceptibility to 
atherosclerosis.
Indeed, the concept of epigenetic regulation is being increasingly acknowledged as an 
important contributor in the pathogenesis of atherosclerosis and other metabolic diseases. 
Research within the last decade has provided an essential link between pro-atherogenic factors 
(amongst others diet, disturbed blood flow patterns, dyslipoproteinemia, hyperglycemia and 
microbiome) and reprogramming of the epigenome (altered DNA methylation and histone 
modifications) in various cell types such as leukocytes, vascular endothelial cells (EC) and 
vascular smooth muscle cells (vSMC) [30, 31]. 
TRAINED INNATE IMMUNITY
Although cells of the innate immune system are traditionally considered incapable of building 
an immunological memory, plants and invertebrates that lack an adaptive immune system 
are protected against reinfection with pathogens, suggesting that the response of the innate 
immune system can be modified by previous encounters [10]. Trained innate immune 
responses were confirmed in human monocytes ex vivo by showing that monocytes can adopt 
a long-term pro-inflammatory phenotype after brief exposure to various micro-organisms or 
microbial products, including the bacille Calmette-Guérin (BCG) vaccine, Candida albicans, 
or its cell wall component β-glucan [32, 33]. This phenomenon could also be shown in 
humans in vivo by demonstrating that BCG vaccination in healthy human subjects induced an 
increased production of pro-inflammatory cytokines when isolated monocytes were exposed 
ex vivo to various unrelated microbial metabolites [32]. This enhanced pro-inflammatory 
phenotype of the monocyte could be detected even three months after the first vaccination 
suggesting that trained innate immune responses can persist for relatively long periods. The 
powerful immunologic effects of this phenomenon are illustrated by the findings in scid 
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mice, which lack T and B lymphocytes, where BCG vaccination provided robust protection 
against a subsequent lethal dose of C. albicans. In humans, BCG vaccination prior to influenza 
vaccination results in a more pronounced increase and accelerated induction of functional 
antibody responses against an influenza vaccine [34]
Importantly, trained innate immunity cannot only be induced by microbial products, but most 
likely also by metabolites that are relevant in the development of metabolic diseases and its 
complications. In the context of atherosclerosis, innate immune training might occur in a high 
fat and high cholesterol environment occurring within the plaque and potentially elsewhere, 
such as in the gut, liver or bone marrow. We postulate that long-term epigenetically 
reprogrammed myeloid precursor cells that are characterized by a hyper-inflammatory 
phenotype may contribute to a sustained disease progression [35] (Figure 1).
HUMAN IN VITRO STUDIES
In an in vitro model in human isolated monocytes, we found that trained innate immunity 
can be induced by modified LDL (oxLDL as well as acetylated LDL), but not by native LDL [36]. 
Twenty-four hour exposure of human monocytes to low concentrations of oxLDL resulted in 
Figure 1: Cellular stressors can influence the epigenetic landscape of innate immune cells. 
Depending on the chromatin modification the outcomes lead to different immune responses 
of the cells towards secondary stimuli, a concept that has been termed ‘innate immune 
memory’, with alternative fates being polarization, cell death or increased proliferation.
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an increased production of pro-atherogenic cytokines and chemokines (including IL-6, TNFα, 
IL-8, and MCP-1) upon re-stimulation of the cells 7 days later with TLR4 or TLR2 agonists. 
Additionally, IL-18, MMP2, and MMP9 mRNA-expression was significantly higher in the 
trained monocytes and increased foam cell formation with higher expression of the scavenger 
receptors CD36 and SR-A and decreased expression of the cholesterol efflux transporters 
ABCA1 and ABCG1 was found. Importantly, oxLDL-induced trained macrophages showed no 
significant differences in expression of TLR4, TLR2 and nitric oxide synthase (‘M1’ markers); 
arginase1 and CD163 (‘M2’ markers); and HLA-DR (human leukocyte antigen-DR), DC-SIGN 
(dendritic cell-specific intercellular adhesion molecule-3-grabbing nonintegrin), and CD83 
expression (DC markers). These data illustrate that the trained innate immune phenotype 
does not merely represent skewing of the cells into the classical ‘M1’ but rather represents a 
unique pro-inflammatory phenotype. Pathway analysis revealed that oxLDL-induced training 
is dependent on TLR2 and TLR4 activation, and activation of extracellular regulated kinase 
(ERK) and phosphoinositide 3 kinase (PI3K) [36]. 
IN VIVO STUDIES
Corroborating the human in vitro data, it has previously been reported that subcutaneous 
immunization of cholesterol-fed New Zealand White rabbits with a human dose of BCG 
enhanced peripheral leukocyte activation, aortic monocyte recruitment and atherogenesis 
[37]. Although this finding fits within the concept that trained innate immunity contributes 
to atherogenesis, a contributory role for the adaptive immune system cannot be excluded in 
these experiments. In addition, several papers provide evidence that glucose can also induce 
a persistent immunological memory in various cell types that are relevant in the context of 
atherosclerosis, including EC, vSMC, and monocytes. In a mouse model of diabetes, long-term 
activation of several key inflammatory genes in isolated vSMC was described, which correlated 
with increased H3K4 methylation and suppressed H3K9 di- and tri-methylation at the nuclear 
factor κB (NF-κB) subunit p65 promoter, which persisted even after ex vivo cell culturing 
[38, 39]. Also, brief exposure to high-glucose medium in cultured EC induced a persistent 
pro-inflammatory phenotype, even after reversal to normoglycemic conditions. This was 
associated with enrichment of the activating mark H3K4me1 in the NF-κB subunit p65 [40]. 
These results highlight the surprisingly long-lasting effects that short-term hyperglycemic 
spikes can execute on vascular cells, suggesting the idea of memory formation as a result 
of methyl-writing and methyl-erasing histone modifications [41]. In line, the concept of 
epigenetically mediated metabolic memory was recently also illustrated in patients from the 
Diabetes Control and Complications Trials (DCCT). Isolated monocytes from patients without 
diabetic microvascular complications, that had received intensive diabetes regulation in the 
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past, showed overall hyperacetylation of H3K9 compared to patients with microvascular 
complications who had received less-intensive diabetes regulation in the past [42]. A link 
to glucose induced alterations in the bone marrow niche has recently been illustrated by 
the observation that a high-glucose environment induces stable intrinsic pro-inflammatory 
changes in HSC in mice [43].
Further in vitro and in vivo studies are required to corroborate the concept of trained 
innate immunity due to persistent epigenetic changes in response to ‘epigenetically toxic’ 
nutrient and/or microbial metabolites such as high fat, high cholesterol or high glucose in the 
context of metabolic diseases and its complications including atherosclerosis. Nevertheless, 
one supporting issue in the theory of epigenetic reprogramming and development of a 
trained memory is the trans-generational transmission of epigenetic traits, independently of 
genetically inherited risk factors [44]. In this regard, several studies in humans and experimental 
animal models have shown that parental adverse diet feeding (under- or over-nutrition) not 
only influences the individuals environment, but can also influence the metabolic phenotype 
in the offspring thereby raising metabolic and cardiovascular disease susceptibility [45-48]. 
However, dissecting the effects induced by an unfavorable intra uterine environment to which 
fetus is exposed to during gestation from direct effects on the parental germ line remains a 
challenging task. To determine whether epigenetic information can be transmitted through 
the germ line, multiple animal studies have tested the question of whether the offspring 
responded to changed paternal diet conditions. Indeed, paternal low-protein diet induced 
an up-regulation of genes involved in lipid and cholesterol biosynthesis in both male and 
female offspring, which was associated with a changed DNA methylation pattern in enhancer 
regions of peroxisome proliferator-activated receptors (PPAR) a [49].  Likewise, chronic HFD 
feeding of male rats led to altered expression of genes involved in glucose metabolism due 
to a changed DNA methylation pattern, subsequently impairing glucose tolerance as well 
as insulin sensitivity in female offspring [50]. A recently published study demonstrates that 
a high-fat/high-fructose diet, starting at young age, leads to the development of obesity 
and to the progression of metabolic syndrome, accompanied by altered DNA methylation 
patterns in male and female Wistar rats [51]. HFD feeding was shown to affect 5-mC levels 
differently in both genders with a 20% reduction in males and a 15% increase in females. 
Interestingly, DNA methylation patterns were modified as well in the F1 generation, thus 
proposing that HFD-induced epigenetic modifications – as mediator of metabolic memory 
- can be transmitted to the next generation, subsequently increasing the susceptibility for 
disease development. Three recent studies support the idea of epigenetic inheritance by 
the paternal germ line in demonstrating that nutritional change can directly remodel the 
epigenetic signature of spermatozoa. A comprehensive profiling of the sperm epigenome 
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showed that mal-nutrition as well as over-nutrition altered small RNA levels, including tRNA 
fragments, and DNA methylation patterns, indicating that sperm (as the direct transducer of 
genetic information) is vulnerable to environmental changes [52-54]. Whether epigenetic 
changes in the myeloid lineage can be transmitted to offspring remains unanswered yet. 
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THE POTENTIAL MECHANISMS LEADING TO TRAINED INNATE IMMUNITY
The more prone pro-inflammatory phenotype that characterizes trained innate immune cells 
is critically dependent on a complex integration of epigenetic reprogramming and a change 
in the intracellular immuno-metabolism. 
Epigenetic reprogramming
Epigenetic modulation denotes the regulation of gene transcription independent of the 
DNA sequence. Epigenetic regulation can occur at the level of DNA methylation, histone 
modifications, or involves RNA-based mechanisms. Whereas DNA methylation is associated 
with a condensed chromatin structure that prevents binding of transcription factors and 
gene silencing, histone acetylation is associated with activation of gene transcription. Histone 
methylation can either activate or repress gene transcription, depending on the exact location 
of the methylated lysine residue and on the number of bound methyl groups (mono-, di-, or 
trimethylation). Macrophage differentiation, polarization, and activation can all be influenced 
by epigenetic reprogramming, which is reviewed in detail elsewhere [55-57]. 
A distinguishing hallmark of a trained innate immune cell is its ability to exhibit a quantitatively 
and qualitatively modified - usually more intense - inflammatory response upon re-challenge 
with danger signals that differ from the priming stimulus. The underlying molecular basis 
has thus far only partially been resolved and involves changes in chromatin organization 
(loosening and stringent accessibility to the transcriptional machinery), but might also 
comprise alterations in DNA methylation and RNA functionality (miRNAs, lncRNAs, tRNAs) 
caused by a certain primary stimulus [58, 59]. Two recent studies support the concept of 
trained innate immunity in that they evidenced latent or de novo enhancer formation in 
stimulated macrophages [60, 61]. TLR4-induced NF-kB activation in macrophages resulted in 
binding of the transcription factors (TF) PU.1/ C/EBP to an appropriate enhancer element. TF 
binding was accompanied by recruitment and binding of the NF-kB-p65 subunit and histone 
acetyltransferases, and subsequent RNA polymerase II binding and elongation. Finally, 
histone methyltransferases MLL1, MLL2/4 and MLL3 were recruited, being responsible 
for H3K4 monomethylation and fully active enhancer formation. Notably, de novo formed 
enhancer elements remained stable (H3K4me1) upon loss of stimulus, and re-stimulation of 
macrophages resulted in faster and stronger responses.
For oxLDL-induced trained immunity in isolated human monocytes, epigenetic reprogramming 
at the level of histone methylation is crucial. Brief stimulation of human monocytes with 
oxLDL leads to the acquirement of a ‘trained innate memory’, which was associated with a 
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pro-atherogenic and pro-inflammatory phenotype, and was characterized by enriched H3K4 
trimethylation – a prototypical long-term activating epigenetic mark - on the promoters of 
pro-inflammatory cytokines and chemokines [36]. Moreover, trained innate immunity was 
completely prevented by co-incubation with a nonspecific histone methyltransferase inhibitor. 
For training with β-glucan, an unbiased genome-wide experimental approach revealed 
changes in the activating H3K4me3 levels on promoters, H3K4me1 levels on enhancers, and 
H3K27ac levels on promoters and enhancers. Indeed, most dynamic promoters showed an 
enrichment of these marks [62]. Moreover, pathway analysis of the promoters that were 
potentiated by β–glucan identified several innate immune and signaling pathways upregulated 
in trained cells that are responsible for the induction of trained immunity. 
Immuno-metabolism and epigenetic programming
Epigenetic modifications are indispensable in cell reprogramming, however, it still remains 
an open question which cellular processes act to initiate or maintain these modifications. 
Increasing evidence supports a close connection between systemic and cellular metabolic 
processes and epigenetic reprogramming with a crucial role for cellular metabolites, e.g. 
S-adenosylmethionine (SAM), flavin adenine dinucleotide (FAD), b-hydroxybutyrate (b-OHB), 
acetyl-CoA, NAD+, a-ketoglutarate, and adenosine triphosphate (ATP) as co-modifiers for 
epigenetic ‘writing’ (DNA and histone methyltransferases, lysine acetyltransferases) and 
‘erasing’ (DNA demethylases, histone deacetylases, lysine demethylases) enzymes [63, 64]. 
The metabolic state of an immune cell represents a highly dynamic process and changes 
between homeostasis and immune activation (tolerance versus inflammation), all of which 
has been documented in different macrophage phenotypes. Generally, resting macrophages 
and the ‘M2’ phenotype (involved in tissue repair and wound healing) utilize energetically 
efficient processes including an intact Krebs cycle with ATP generation via oxidative 
phosphorylation. Upon immune cell activation and a switch towards the ‘M1’ phenotype 
there is a rapid shift towards aerobic glycolysis, which enables de novo lipogenesis, cholesterol 
and amino acid synthesis for subsequent fast cell division and growth, and an increased 
production of inflammatory mediators (eicosanoids, IL-1b, reactive oxygen species) [65, 66]. 
Hence, the cellular transcription machinery and its chromatin associated proteins process 
cellular metabolic signals to regulate gene expression.
The importance of immuno-metabolism in macrophage polarization and reprogramming 
suggests that similar mechanisms take place during the long-term acquirement of a trained 
innate memory phenotype. Indeed, a shift from oxidative phosphorylation towards aerobic 
glycolysis through the AKT-mTOR-HIF-1a pathway, accompanied by changes in histone marks 
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such as H3K4me1, H3K4me3 and H3K27ac, has recently been described to be important for 
training of human monocytes with β-glucan. Pharmacological inhibitors of glycolysis, such 
as 2-deoxy-D-glucose and inhibitors of the mTOR pathway, such as metformin, prevented 
β-glucan-induced trained innate immunity [62, 67]. LPS-priming induced a shift towards 
aerobic glycolysis in murine macrophages, which resulted in the accumulation of the Krebs 
cycle intermediate succinate, which itself induced the expression of the inflammatory 
cytokine IL-1b through the transcription factor HIF-1a [68]. These studies emphasize that 
Krebs cycle metabolites (such as succinate, a-ketoglutarate or NAD+) are important in the 
induction or inhibition of histone-modifying enzymes, thus inducing long-term changes in the 
monocyte or macrophage phenotype. 
How immuno-metabolism is altered under conditions of hyperlipidemia and which 
metabolites potentially contribute to the establishment of a trained myeloid (precursor) cell 
phenotype in atherosclerosis is still ill-defined. Transcription factors such as sterol regulatory 
element binding protein (SREBP; regulation of cholesterol biosynthesis and uptake), liver X 
receptor (LXR; regulation of cholesterol elimination and inflammation) and PPARs (regulation 
of fatty acid oxidation/ energy homeostasis, lipid metabolism and inflammation) strictly 
control the balance between systemic and cellular lipid homeostasis by regulating genes 
involved in lipid uptake, storage, efflux, de novo lipid biosynthesis and catabolism, as well as 
inflammatory processes. Excessive lipid or cholesterol uptake by immune cells has been shown 
to favor inflammatory processes, which accounts for the exacerbated outcome of diseases 
associated with chronic metabolic inflammation (obesity, atherosclerosis). For example, 
overload of modified lipoproteins (oxLDL) in liver Kupffer cells induces a continuous state 
of intracellular stress and promotes a switch towards the pro-inflammatory ‘M1’ phenotype 
[69]. Hyperlipidemia also modulates the immune system by enhancing bone marrow and 
extramedullary hematopoiesis through epigenetic reprogramming of genes crucially involved 
in monocyte proliferation and differentiation [29]. Somewhat unexpectedly, Spann and 
colleagues have recently shown that peritoneal macrophages isolated from Western type 
diet fed Ldlr-/- mice exhibited an overall reduction in pro-inflammatory gene expression 
compared with macrophages from chow fed mice, which was related to the accumulation 
of desmosterol, an intermediate metabolite in the cholesterol biosynthesis pathway and 
activator of LXRs [70]. Desmosterol accumulation in peritoneal foam cell macrophages might 
be explained by impaired functionality of desmosterol reductase, the metabolic enzyme for 
desmosterol degradation. Together, these data clearly illustrate that firstly a tight interplay 
between the different lipid sensing nuclear receptors is important to balance intracellular 
lipid and cholesterol homeostasis and to control immune signaling pathways, such as NF-kB, 
or Nlrp3. Secondly, the specific environment crucially contributes to metabolic processes, 
198
Chapter 8
which critically influences inflammatory responses in different myeloid subsets.
NUTRITIONAL CONTROL OF IMMUNITY
Diet and its components can activate cells of the innate immune system, thus profoundly 
influencing immune responses, and potentially inducing long-term epigenetic modifications 
and a ‘trained innate memory’, especially within the gut resident myeloid subsets. In line, 
the gut microbiota plays an important role in the development and maintenance of the 
immune system. The microbiota affects immune cell metabolism and function either through 
metabolites derived from its enzymatic machinery, such as short chain fatty acids (SCFA), 
bile acid, or trimethylamine (TMA), or through particular microbial molecules, such as innate 
immune receptor activating ligands [71-73]. Maternal and early-life dietary habits already 
play an important role in the development of the immune system, and the prevention of 
immunological disorders later in life [74]. The composition (quantity and quality) of free fatty 
acids and lipids (and their oxidative metabolites) in the diet is crucial in maintaining immune 
cell homeostasis and influences both innate and adaptive immune cell responses. Changes 
in dietary habits such as increased intake of energy-dense processed food enriched in sugars, 
fat, phosphatidylcholine (PC) and L-carnitine instead of nutrient-rich foods, induce a shift 
from commensal to more pathogenic bacterial strains within the gut. 
These changes in enteric microbiome composition correlate with an increased incidence of 
immunological disorders, such as asthma, cancer, allergies, autoimmune and cardiovascular 
diseases [75, 76]. In the contrary, diets enriched in complex carbohydrates and high fibers, 
such as found in vegetables, fruits and fish, promote gut homeostasis. These diets can 
beneficially influence amongst others the production of antimicrobial peptides and mucus, 
maintenance of epithelial integrity and tissue repair, production of anti-inflammatory 
cytokines and maintenance of immune tolerance. Mechanistically, the microbial enzyme 
machinery can process these fiber-rich food into SCFA, including n-butyrate, propionate and 
acetate, and can influence the production of other end products including idole-3-aldehyde, 
niacin and omega-3 fatty acids. Besides their function as energy sources, these metabolites 
control gut homeostasis by signaling through different receptors, e.g. the Aryl hydrocarbon 
receptor (AhR) and G-protein coupled receptors (GPCR), expressed on innate lymphoid cells, 
innate immune cells and Tregs. Food-induced epigenetic reprogramming in innate immune 
cells has been supported by a recent study, in which the SCFA n-butyrate led to the down-
regulation of LPS-induced pro-inflammatory mediators, including nitric oxide, IL-6, and IL-
12 [77]. These effects were independent of TLR-signaling or activation of GPCRs, but were 
due to inhibition of histone deacetylases by n-butyrate. Overall, this rendered lamina propria 
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macrophages hypo-responsive and maintained a tolerogenic environment.
Western type diets are enriched in poly-unsaturated fatty acids, associated with dysbiosis, a 
state of low-grade chronic inflammation in the intestines through activation of NF-kB and the 
Nlrp3 inflammasome, and increased intestinal permeability resulting in endotoxemia [78]. 
Indeed, studies in humans and animal models have shown that an accumulation of lipids and 
cholesterol, and an impaired lipid clearance in myeloid cells are associated with worse septic 
shock outcome due to increased TLR2 and 4 activation [79]. A systemic-wide metabolomics 
approach has recently shown that metabolites (choline, TMA, betaine) derived from the 
dietary phospholipid PC or L-carnitine represent risk factors for cardiovascular diseases. 
Indeed,  increased systemic levels of these metabolites correlate with more aggravated CVD 
phenotype [80, 81]. Consistent with these observations, ApoE-/- mice fed a diet enriched 
in PC or L-carnitine, exhibited worsened atherosclerotic disease outcome [80, 81]. PCs 
and L-carnitine, enriched in red meat, eggs, milk and certain fish, are processed by the gut 
microbial enzymatic machinery to choline and TMA, which is further metabolized to TMA 
n-oxide (TMAO) by the hepatic flavin mono-oxygenase (FMO). TMAO has been shown to 
increase the expression of the scavenger receptors CD36 and SR-A1 on macrophages, 
subsequently promoting foam cell formation. Additionally, it adversely affects reverse 
cholesterol transport; both processes that promote atherosclerosis.
The above-summarized data illustrate the complex network between food composition, the 
microbiota and host’s metabolism linked to immune homeostasis. Consequently, a balanced 
diet, rich in fibers, keeps a balanced microbiota and an intact intestinal barrier function, 
which is a requirement for a regulated metabolism and immune homeostasis (Figure 2). It 
still remains to be resolved how systemic to cellular immune-metabolic crosstalk, impacted 
by the gut microbial composition, is working, and how this can lead to a long-term epigenetic 
reprogramming.
THERAPEUTIC INTERVENTIONS IN ATHEROSCLEROSIS AND POTENTIAL 
CLINICAL RELEVANCE
Targeting LDL/ cholesterol levels and inflammation in atherosclerosis
So far, statins are still used as the main drug treatment in CVDs to lower plasma cholesterol 
levels, thus decreasing disease burden. However, despite the LDL lowering effect up to > 50%, 
a significant residual burden of CVDs remains. Alternatively, ApoA-I containing high density 
lipoprotein (HDL) is being developed as a therapeutic agent to remove excess cholesterol from 
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peripheral tissue, and to dampen inflammation [82-85]. Studies in different animal models 
as well as in humans have shown the beneficial effect of HDL administration in reducing 
atherosclerotic plaque size [86-88]. Notwithstanding, infused HDL in two randomized 
controlled clinical trials in human have not reached the expected beneficial effects on 
atherosclerosis [89, 90].
In the last years scientists have searched for more intelligent ways of drug delivery, but 
also for novel therapeutic targets to dampen atherosclerotic lesion progression. The use 
of nanoparticles seems to be an attractive therapeutic tool to deliver anti-inflammatory 
drugs to specific cell types with the aim to impair immune actions in certain cell subsets e.g. 
restricting myeloid cell differentiation and migration of pro-inflammatory Ly6Chigh monocytes 
to the plaque, dampening plaque macrophage immune signaling and increasing macrophage 
efflux. Some recent preclinical studies have successfully been proposed [91, 92]. 
Epigenetic remodeling as a potential therapeutic approach for CVD
The recent insights into possible mechanistic links between epigenetic cellular reprogramming 
and pathophysiology of atherosclerosis could lead to novel strategies to lower CVD risk [93, 
Figure 2: Schematic representation of the hypothesis that diet can have long lasting effect on 
the systemic host response via epigenetic reprogramming by microbiome-derived PAMPs and 
metabolites.
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94]. Moreover, epigenetic modifications (DNA methylation pattern, modified histone marks) 
might evolve into useful predictors for disease stage [95] and have recently been linked 
to atherosclerosis in humans [30, 96]. Wierda and colleagues evaluated global H3K27me3 
levels, as well as levels of histone-modifying enzymes (EZH2, BMI1 and JMJD3) in vessels 
representing different stages of atherosclerotic plaque development. Overall, they notified a 
global decrease in H3K27me3 in the media of more advanced atherosclerotic plaques, which 
might reflect the dynamic pattern of vSMC differentiation and proliferation associated with 
atherosclerotic disease [30].
Co-modifying metabolites as well as ‘writing’ and ‘erasing’ enzymes are amenable to 
pharmacological modulations, and could potentially turn into novel therapeutic targets. A 
few nonselective HDAC inhibitors are already used in regular patient care in cancer treatment 
[97]. In addition, nonselective HDAC inhibitors have shown beneficial effects in animal models 
for arthritis, septic shock and inflammatory bowel disease [98]. Preclinical studies in mice 
support the idea that ‘epigenetic drugs’ may also be a potential tool in the treatment of 
atherosclerosis [99]. Administration of the nonselective HDAC inhibitor trichostatin A (a lysine 
deacetylase inhibitor) into Ldlr-/- mice induced a more exacerbated neointima formation by 
increasing CD36 mRNA, protein and surface expression levels thus increasing macrophage 
foam cell formation. 
Histone demethylases can also induce a pro-inflammatory macrophage phenotype. For 
example, Jmjd3, UTX and Uty (which are H3K27 demethylases) are induced upon TLR 
engagement and are linked to the expression of inflammatory genes [100]. Targeting of 
Jmjd3 and Utx H3K27 demethylases with small molecule inhibitors impaired inflammatory 
responses in human primary macrophages, which is of high pharmacological interest 
[101]. However, Jmjd3 also plays an important role in the ‘M2’ polarization in the context 
of helminth infection, illustrating its dual role dependent on stimulus and environmental 
context [102]. Selective HDAC inhibitors may be used to dampen inflammatory responses 
within plaque macrophages. Three recent studies illuminated a functional role for certain 
HDACs in the context of atherosclerosis. Myeloid deletion of HDAC3, a histone deacetylase 
which promotes ‘M1’ polarization [103], was shown to augment lesion size, but lesions 
showed a more stable phenotype characterized by a collagen-rich fibrous cap, reduced lipid 
content and reduced numbers of plaque macrophages. The more stable plaque phenotype 
was associated with increased collagen formation by vSMC due to increased TGF-b release by 
HDAC3 deleted myeloid cells [104]. In addition, a genome-wide association study illustrated 
the association between HDAC9 modifications and atherosclerosis development. In fact, 
certain HDAC9 transcripts are more related to coronary artery disease susceptibility [105]. 
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Consistent with these data, Cao and colleagues revealed a correlation between HDAC9 
deletion in bone marrow cells and limited atherosclerosis development in the Ldlr-/- mouse 
atherosclerosis model. HDAC9 deletion in macrophages was linked to an increased expression 
of the cholesterol efflux transporters ABCA1 and ABCG1, reduced inflammation, and a switch 
towards the ant-inflammatory ‘M2’ phenotype [106].
The above-mentioned studies support the impact of epigenetic remodeling in the 
pathophysiology of atherosclerosis, thus encouraging the development of epigenetic tools 
for beneficial lesion remodeling. Nevertheless, it has to be noted that different isoforms of 
histone modifying enzymes might have opposing effects within the same cells, but also in 
different cell types. Additionally, enzymes might function differently in healthy versus acute 
versus chronic disease stages of atherosclerosis. A tremendous challenge within the next 
years will be to better understand epigenetics in the pathophysiology of CVDs and to design 
cell-specific epigenetic drugs that target cell subsets which only detrimentally contribute to 
disease progression. Another important challenge will be the correct timing of therapeutic 
intervention.
In addition to specific epigenetic inhibitors, further elucidation of the immune-metabolic 
basis of trained innate immunity, such as the metabolic shift that occurs, might provide 
alternative novel drug targets. Drugs that interfere with glycolysis (such as metformin, direct 
mTOR inhibitors, glycolysis inhibitors) prevent the occurrence of trained immunity in in vitro 
settings [67]. In animal models of neovascularization it has been revealed that glycolysis 
inhibition limits neovessel formation [107]. A number of small studies in patients with 
atherosclerosis have evidenced the systemic anti-inflammatory effect of metformin [108]. 
In addition, metformin inhibited monocyte to macrophage differentiation, and reduced 
pro-inflammatory cytokine production [109]. However, a real anti-atherosclerotic effect by 
metformin administration has not been proven yet. Although metformin treatment reduces 
cardiovascular morbidity and mortality in patients with diabetes compared to alternative 
glucose-lowering agents with similar glycemic control [110], metformin could not limit the 
intima media thickening in a recent trial in patients without diabetes [111].
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CONCLUSION
There is accumulating evidence that many cardiovascular risk factors, both traditional and 
non-traditional (e.g. nutrients, microbiota), induce a long-term (epigenetic) reprogramming 
of cells of the innate immune system, which in turn may provoke a condition of continuous 
innate immune cell activation. It still remains an open question, which cellular processes 
act to initiate or maintain these alterations. An increasing number of studies support the 
idea of a close connection between systemic and cellular metabolic processes and epigenetic 
reprogramming in the induction of trained innate immunity. These findings pave the road 
for the identification of novel drug targets. Further mechanistic insights on the induction of 
trained innate immunity are necessary to make beneficial use in future clinical therapeutic 
applications. Especially, unraveling the mechanisms in the various stages of atherosclerosis 
will be a challenging task within the next years. Nevertheless, epigenetic remodeling and the 
use of ‘epigenetic drugs’ are a promising tool for future treatment of atherosclerosis.
204
Chapter 8
REFERENCES
1.  Mozaffarian D, Benjamin EJ, Go AS, 
Arnett DK, Blaha MJ, Cushman M, et al. 
Heart Disease and Stroke Statistics-2016 
Update: A Report From the American 
Heart Association. Circulation 
2016;133:e38-e360.
2.  Thompson RC, Allam AH, Lombardi GP, 
Wann LS, Sutherland ML, Sutherland 
JD, et al. Atherosclerosis across 4000 
years of human history: the Horus study 
of four ancient populations. Lancet 
2013;381:1211-22.
3.  Hansson GK, Hermansson A. The immune 
system in atherosclerosis. Nat Immunol 
2011;12:204-12.
4.  Virchow R. Cellular pathology. As based 
upon physiological and pathological 
histology. Lecture XVI--Atheromatous 
affection of arteries. 1858. Nutr Rev 
1989;47:23-5.
5  Rosenfeld ME, Campbell LA. Pathogens 
and atherosclerosis: update on the 
potential contribution of multiple 
infectious organisms to the pathogenesis 
of atherosclerosis. Thromb Haemost 
2011;106:858-67.
6.  Corrales-Medina VF, Musher DM, 
Shachkina S, Chirinos JA. Acute 
pneumonia and the cardiovascular 
system. Lancet 2013;381:496-505.
7.  Dutta P, Courties G, Wei Y, Leuschner F, 
Gorbatov R, Robbins CS, et al. Myocardial 
infarction accelerates atherosclerosis. 
Nature 2012;487:325-9.
8.  Nahrendorf M, Swirski FK. Innate immune 
cells in ischaemic heart disease: does 
myocardial infarction beget myocardial 
infarction? Eur Heart J [Epub ahead of 
print].
9.  De Rosa V, Galgani M, Santopaolo M, 
Colamatteo A, Laccetti R, Matarese 
G. Nutritional control of immunity: 
Balancing the metabolic requirements 
with an appropriate immune function. 
Semin Immunol 2015;27:300-9.
10.  Netea MG, Quintin J, van der Meer 
JW. Trained immunity: a memory for 
innate host defense. Cell Host Microbe 
2011;9:355-61.
11.  Ensan S, Li A, Besla R, Degousee N, 
Cosme J, Roufaiel M, et al. Self-renewing 
resident arterial macrophages arise from 
embryonic CX3CR1(+) precursors and 
circulating monocytes immediately after 
birth. Nat Immunol 2016;17:159-68.
12.  Hansson GK, Libby P. The immune 
response in atherosclerosis: a double-
edged sword. Nat Rev Immunol 
2006;6:508-19.
13.  Robbins CS, Hilgendorf I, Weber GF, 
Theurl I, Iwamoto Y, Figueiredo JL, 
et al. Local proliferation dominates 
lesional macrophage accumulation in 
atherosclerosis. Nat Med 2013;19:1166-
72.
14.  Boring L, Gosling J, Cleary M, Charo IF. 
Decreased lesion formation in CCR2-
/- mice reveals a role for chemokines in 
the initiation of atherosclerosis. Nature 
1998;394:894-7.
15.  Potteaux S, Gautier EL, Hutchison SB, 
van Rooijen N, Rader DJ, Thomas MJ, et 
al. Suppressed monocyte recruitment 
drives macrophage removal from 
atherosclerotic plaques of Apoe-/- mice 
during disease regression. J Clin Invest 
2011;121:2025-36.
16.  Moore KJ, Sheedy FJ, Fisher EA. 
Macrophages in atherosclerosis: a 
dynamic balance. Nat Rev Immunol 
2013;13:709-21.
17.  Duewell P, Kono H, Rayner KJ, Sirois 
CM, Vladimer G, Bauernfeind FG, et al. 
NLRP3 inflammasomes are required for 
atherogenesis and activated by cholesterol 
crystals. Nature 2010;464:1357-61.
18.  Shah PK. Mechanisms of plaque 
vulnerability and rupture. J Am Coll 
Cardiol 2003;41:15S-22S.
19.  Colin S, Chinetti-Gbaguidi G, Staels 
B. Macrophage phenotypes in 
atherosclerosis. Immunol Rev 
2014;262:153-66.
20.  Swirski FK, Libby P, Aikawa E, Alcaide 
P, Luscinskas FW, Weissleder R, et 
al. Ly-6Chi monocytes dominate 
hypercho lestero lemia-assoc iated 
monocytosis and give rise to macrophages 
in atheromata. J Clin Invest 2007;117:195-
205.
21.  Tacke F, Alvarez D, Kaplan TJ, Jakubzick 
C, Spanbroek R, Llodra J, et al. Monocyte 
subsets differentially employ CCR2, 
CCR5, and CX3CR1 to accumulate within 
atherosclerotic plaques. J Clin Invest 
2007;117:185-94.
22.  Kaynar AM, Yende S, Zhu L, Frederick DR, 
Chambers R, Burton CL, et al. Effects of 
intra-abdominal sepsis on atherosclerosis 
in mice. Crit Care 2014;18:469.
23.  Tabas I. Macrophage death and 
defective inflammation resolution 
in atherosclerosis. Nat Rev Immunol 
2010;10:36-46.
24.  Tall AR, Yvan-Charvet L. Cholesterol, 
inflammation and innate immunity. Nat 
Rev Immunol 2015;15:104-16.
25.  Murphy AJ, Akhtari M, Tolani S, Pagler 
205
Long term activation of the innate immune system in atherosclerosis
8
T, Bijl N, Kuo CL, et al. ApoE regulates 
hematopoietic stem cell proliferation, 
monocytosis, and monocyte 
accumulation in atherosclerotic lesions in 
mice. J Clin Invest 2011;121:4138-49.
26.  Westerterp M, Gourion-Arsiquaud S, 
Murphy AJ, Shih A, Cremers S, Levine 
RL, et al. Regulation of hematopoietic 
stem and progenitor cell mobilization by 
cholesterol efflux pathways. Cell Stem Cell 
2012;11:195-206.
27.  Yvan-Charvet L, Pagler T, Gautier EL, 
Avagyan S, Siry RL, Han S, et al. ATP-
binding cassette transporters and HDL 
suppress hematopoietic stem cell 
proliferation. Science 2010;328:1689-93.
28.  Seijkens T, Hoeksema MA, Beckers 
L, Smeets E, Meiler S, Levels J, et al. 
Hypercholesterolemia-induced priming 
of hematopoietic stem and progenitor 
cells aggravates atherosclerosis. FASEB J 
2014;28:2202-13.
29.  van Kampen E, Jaminon A, van 
Berkel TJ, Van Eck M. Diet-induced 
(epigenetic) changes in bone marrow 
augment atherosclerosis. J Leukoc Biol 
2014;96:833-41.
30.  Wierda RJ, Geutskens SB, Jukema JW, 
Quax PH, van den Elsen PJ. Epigenetics in 
atherosclerosis and inflammation. J Cell 
Mol Med 2010;14:1225-40.
31.  Wierda RJ, Rietveld IM, van Eggermond 
MC, Belien JA, van Zwet EW, Lindeman 
JH, et al. Global histone H3 lysine 27 triple 
methylation levels are reduced in vessels 
with advanced atherosclerotic plaques. 
Life Sci 2015;129:3-9.
32.  Kleinnijenhuis J, Quintin J, Preijers F, 
Joosten LA, Ifrim DC, Saeed S, et al. 
Bacille Calmette-Guerin induces NOD2-
dependent nonspecific protection from 
reinfection via epigenetic reprogramming 
of monocytes. Proc Natl Acad Sci U S A 
2012;109:17537-42.
33.  Quintin J, Saeed S, Martens JH, 
Giamarellos-Bourboulis EJ, Ifrim DC, 
Logie C, et al. Candida albicans infection 
affords protection against reinfection via 
functional reprogramming of monocytes. 
Cell Host Microbe 2012;12:223-32.
34.  Leentjens J, Kox M, Stokman R, Gerretsen 
J, Diavatopoulos DA, van Crevel R, 
et al. BCG Vaccination Enhances the 
Immunogenicity of Subsequent Influenza 
Vaccination in Healthy Volunteers: A 
Randomized, Placebo-Controlled Pilot 
Study. J Infect Dis 2015;212:1930-8.
35.  Bekkering S, Joosten LA, van der Meer 
JW, Netea MG, Riksen NP. Trained innate 
immunity and atherosclerosis. Curr Opin 
Lipidol 2013;24:487-92.
36.  Bekkering S, Quintin J, Joosten LA, van 
der Meer JW, Netea MG, Riksen NP. 
Oxidized low-density lipoprotein induces 
long-term proinflammatory cytokine 
production and foam cell formation 
via epigenetic reprogramming of 
monocytes. Arterioscler Thromb Vasc Biol 
2014;34:1731-8.
37.  Lamb DJ, Eales LJ, Ferns GA. Immunization 
with bacillus Calmette-Guerin vaccine 
increases aortic atherosclerosis in the 
cholesterol-fed rabbit. Atherosclerosis 
1999;143:105-13.
38.  Brasacchio D, Okabe J, Tikellis C, 
Balcerczyk A, George P, Baker EK, et 
al. Hyperglycemia induces a dynamic 
cooperativity of histone methylase 
and demethylase enzymes associated 
with gene-activating epigenetic marks 
that coexist on the lysine tail. Diabetes 
2009;58:1229-36.
39.  Villeneuve LM, Reddy MA, Lanting LL, 
Wang M, Meng L, Natarajan R. Epigenetic 
histone H3 lysine 9 methylation in 
metabolic memory and inflammatory 
phenotype of vascular smooth muscle 
cells in diabetes. Proc Natl Acad Sci U S A 
2008;105:9047-52.
40.  El-Osta A, Brasacchio D, Yao D, Pocai A, 
Jones PL, Roeder RG, et al. Transient 
high glucose causes persistent epigenetic 
changes and altered gene expression 
during subsequent normoglycemia. J Exp 
Med 2008;205:2409-17.
41.  El-Osta A. Glycemic memory. Curr Opin 
Lipidol 2012;23:24-9.
42.  Miao F, Chen Z, Genuth S, Paterson A, 
Zhang L, Wu X, et al. Evaluating the role 
of epigenetic histone modifications in the 
metabolic memory of type 1 diabetes. 
Diabetes 2014;63:1748-62.
43.  Bannon P, Wood S, Restivo T, Campbell L, 
Hardman MJ, Mace KA. Diabetes induces 
stable intrinsic changes to myeloid cells 
that contribute to chronic inflammation 
during wound healing in mice. Dis Model 
Mech 2013;6:1434-47.
44.  Rando OJ, Simmons RA. I’m eating for 
two: parental dietary effects on offspring 
metabolism. Cell 2015;161:93-105.
45.  Alkemade FE, van Vliet P, Henneman P, 
van Dijk KW, Hierck BP, van Munsteren JC, 
et al. Prenatal exposure to apoE deficiency 
and postnatal hypercholesterolemia 
are associated with altered cell-specific 
lysine methyltransferase and histone 
methylation patterns in the vasculature. 
Am J Pathol 2010;176:542-8.
46.  Lillycrop KA, Slater-Jefferies JL, Hanson 
MA, Godfrey KM, Jackson AA, Burdge GC. 
Induction of altered epigenetic regulation 
of the hepatic glucocorticoid receptor 
in the offspring of rats fed a protein-
restricted diet during pregnancy suggests 
that reduced DNA methyltransferase-1
206
Chapter 8
 and changes in histone modifications. Br J 
Nutr 2007;97:1064-73.
47.  Lumey LH, Stein AD, Kahn HS, van der 
Pal-de Bruin KM, Blauw GJ, Zybert PA, 
et al. Cohort profile: the Dutch Hunger 
Winter families study. Int J Epidemiol 
2007;36:1196-204.
48.  Patti ME. Intergenerational programming 
of metabolic disease: evidence from 
human populations and experimental 
animal models. Cell Mol Life Sci 
2013;70:1597-608.
49.  Carone BR, Fauquier L, Habib N, Shea 
JM, Hart CE, Li R, et al. Paternally 
induced transgenerational environmental 
reprogramming of metabolic 
gene expression in mammals. Cell 
2010;143:1084-96.
50.  Ng SF, Lin RC, Laybutt DR, Barres R, 
Owens JA, Morris MJ. Chronic high-
fat diet in fathers programs beta-cell 
dysfunction in female rat offspring. 
Nature 2010;467:963-6.
51.  Sanchez I, Reynoso-Camacho R, Salgado 
LM. The diet-induced metabolic 
syndrome is accompanied by whole-
genome epigenetic changes. Genes Nutr 
2015;10:471.
52.  Chen Q, Yan M, Cao Z, Li X, Zhang Y, 
Shi J, et al. Sperm tsRNAs contribute 
to intergenerational inheritance of an 
acquired metabolic disorder. Science 
2016;351:397-400.
53.  Donkin I, Versteyhe S, Ingerslev LR, Qian 
K, Mechta M, Nordkap L, et al. Obesity 
and Bariatric Surgery Drive Epigenetic 
Variation of Spermatozoa in Humans. Cell 
Metab doi: 10.1016/j.cmet.2015.11.004. 
[Epub ahead of print].
54.  Sharma U, Conine CC, Shea JM, Boskovic 
A, Derr AG, Bing XY, et al. Biogenesis and 
function of tRNA fragments during sperm 
maturation and fertilization in mammals. 
Science 2016;351:391-6.
55.  Gosselin D, Glass CK. Epigenomics of 
macrophages. Immunol Rev 2014;262:96-
112.
56.  Ivashkiv LB. Epigenetic regulation of 
macrophage polarization and function. 
Trends Immunol 2013;34:216-23.
57.  Schmidt SV, Krebs W, Ulas T, Xue J, Bassler 
K, Gunther P, et al. The transcriptional 
regulator network of human 
inflammatory macrophages is defined by 
open chromatin. Cell Res 2016.
58.  Smale ST, Natoli G. Transcriptional control 
of inflammatory responses. Cold Spring 
Harb Perspect Biol 2014;6:a016261.
59.  Smale ST, Tarakhovsky A, Natoli G. 
Chromatin contributions to the regulation 
of innate immunity. Annu Rev Immunol 
2014;32:489-511.
60.  Kaikkonen MU, Spann NJ, Heinz S, 
Romanoski CE, Allison KA, Stender JD, et 
al. Remodeling of the enhancer landscape 
during macrophage activation is coupled 
to enhancer transcription. Mol Cell 
2013;51:310-25.
61.  Ostuni R, Piccolo V, Barozzi I, Polletti S, 
Termanini A, Bonifacio S, et al. Latent 
enhancers activated by stimulation in 
differentiated cells. Cell 2013;152:157-
71.
62.  Saeed S, Quintin J, Kerstens HH, Rao 
NA, Aghajanirefah A, Matarese F, et al. 
Epigenetic programming of monocyte-
to-macrophage differentiation and 
trained innate immunity. Science 
2014;345:1251086.
63.  Donohoe DR, Bultman SJ. 
Metaboloepigenetics: interrelationships 
between energy metabolism and 
epigenetic control of gene expression. J 
Cell Physiol 2012;227:3169-77.
64.  Gut P, Verdin E. The nexus of chromatin 
regulation and intermediary metabolism. 
Nature 2013;502:489-98.
65.  Ganeshan K, Chawla A. Metabolic 
regulation of immune responses. Annu 
Rev Immunol 2014;32:609-34.
66.  Pearce EL, Pearce EJ. Metabolic pathways 
in immune cell activation and quiescence. 
Immunity 2013;38:633-43.
67.  Cheng SC, Quintin J, Cramer RA, 
Shepardson KM, Saeed S, Kumar V, et al. 
mTOR- and HIF-1alpha-mediated aerobic 
glycolysis as metabolic basis for trained 
immunity. Science 2014;345:1250684.
68.  Tannahill GM, Curtis AM, Adamik J, 
Palsson-McDermott EM, McGettrick AF, 
Goel G, et al. Succinate is an inflammatory 
signal that induces IL-1beta through HIF-
1alpha. Nature 2013;496:238-42.
69.  Bieghs V, Walenbergh SM, Hendrikx T, van 
Gorp PJ, Verheyen F, Olde Damink SW, et 
al. Trapping of oxidized LDL in lysosomes 
of Kupffer cells is a trigger for hepatic 
inflammation. Liver Int 2013;33:1056-61.
70.  Spann NJ, Garmire LX, McDonald JG, 
Myers DS, Milne SB, Shibata N, et al. 
Regulated accumulation of desmosterol 
integrates macrophage lipid metabolism 
and inflammatory responses. Cell 
2012;151:138-52.
71.  Dorrestein PC, Mazmanian SK, Knight 
R. Finding the missing links among 
metabolites, microbes, and the host. 
Immunity 2014;40:824-32.
72.  Sharon G, Garg N, Debelius J, Knight R, 
Dorrestein PC, Mazmanian SK. Specialized 
metabolites from the microbiome 
in health and disease. Cell Metab 
2014;20:719-30. 
207
Long term activation of the innate immune system in atherosclerosis
8
73.  Thorburn AN, Macia L, Mackay CR. 
Diet, metabolites, and “western-
lifestyle” inflammatory diseases. 
Immunity 2014;40:833-42.
74.  Palmer AC. Nutritionally mediated 
programming of the developing immune 
system. Adv Nutr 2011;2:377-95.
75.  Hildebrandt MA, Hoffmann C, Sherrill-
Mix SA, Keilbaugh SA, Hamady M, 
Chen YY, et al. High-fat diet determines 
the composition of the murine gut 
microbiome independently of obesity. 
Gastroenterology 2009;137:1716-24 e1-
2.
76.  Walker AW, Ince J, Duncan SH, Webster 
LM, Holtrop G, Ze X, et al. Dominant and 
diet-responsive groups of bacteria within 
the human colonic microbiota. ISME J 
2011;5:220-30.
77.  Chang PV, Hao L, Offermanns S, Medzhitov 
R. The microbial metabolite butyrate 
regulates intestinal macrophage function 
via histone deacetylase inhibition. Proc 
Natl Acad Sci U S A 2014;111:2247-52.
78.  Pendyala S, Walker JM, Holt PR. A high-fat 
diet is associated with endotoxemia that 
originates from the gut. Gastroenterology 
2012;142:1100-1 e2.
79.  Chien JY, Jerng JS, Yu CJ, Yang PC. Low 
serum level of high-density lipoprotein 
cholesterol is a poor prognostic factor 
for severe sepsis. Crit Care Med 
2005;33:1688-93.
80.  Koeth RA, Wang Z, Levison BS, Buffa JA, Org 
E, Sheehy BT, et al. Intestinal microbiota 
metabolism of L-carnitine, a nutrient in 
red meat, promotes atherosclerosis. Nat 
Med 2013;19:576-85.
81.  Wang Z, Klipfell E, Bennett BJ, Koeth 
R, Levison BS, Dugar B, et al. Gut flora 
metabolism of phosphatidylcholine 
promotes cardiovascular disease. Nature 
2011;472:57-63.
82.  Cockerill GW, Rye KA, Gamble JR, 
Vadas MA, Barter PJ. High-density 
lipoproteins inhibit cytokine-induced 
expression of endothelial cell adhesion 
molecules. Arterioscler Thromb Vasc Biol 
1995;15:1987-94.
83.  De Nardo D, Labzin LI, Kono H, Seki R, 
Schmidt SV, Beyer M, et al. High-density 
lipoprotein mediates anti-inflammatory 
reprogramming of macrophages via 
the transcriptional regulator ATF3. Nat 
Immunol 2014;15:152-60.
84.  Vaisar T, Pennathur S, Green PS, Gharib 
SA, Hoofnagle AN, Cheung MC, et al. 
Shotgun proteomics implicates protease 
inhibition and complement activation in 
the antiinflammatory properties of HDL. J 
Clin Invest 2007;117:746-56.
85.  Vickers KC, Palmisano BT, Shoucri BM, 
Shamburek RD, Remaley AT. MicroRNAs 
are transported in plasma and delivered 
to recipient cells by high-density 
lipoproteins. Nat Cell Biol 2011;13:423-
33.
86.  Badimon JJ, Badimon L, Fuster V. 
Regression of atherosclerotic lesions by 
high density lipoprotein plasma fraction 
in the cholesterol-fed rabbit. J Clin Invest 
1990;85:1234-41.
87.  Plump AS, Scott CJ, Breslow JL. Human 
apolipoprotein A-I gene expression 
increases high density lipoprotein 
and suppresses atherosclerosis in the 
apolipoprotein E-deficient mouse. Proc 
Natl Acad Sci U S A 1994;91:9607-11.
88.  Rubin EM, Krauss RM, Spangler EA, 
Verstuyft JG, Clift SM. Inhibition of 
early atherogenesis in transgenic mice 
by human apolipoprotein AI. Nature 
1991;353:265-7.
89.  Nissen SE, Tsunoda T, Tuzcu EM, 
Schoenhagen P, Cooper CJ, Yasin M, et al. 
Effect of recombinant ApoA-I Milano on 
coronary atherosclerosis in patients with 
acute coronary syndromes: a randomized 
controlled trial. JAMA 2003;290:2292-
300.
90.  Tardif JC, Gregoire J, L’Allier PL, Ibrahim R, 
Lesperance J, Heinonen TM, et al. Effects 
of reconstituted high-density lipoprotein 
infusions on coronary atherosclerosis: 
a randomized controlled trial. JAMA 
2007;297:1675-82.
91.  Duivenvoorden R, Tang J, Cormode DP, 
Mieszawska AJ, Izquierdo-Garcia D, Ozcan 
C, et al. A statin-loaded reconstituted high-
density lipoprotein nanoparticle inhibits 
atherosclerotic plaque inflammation. Nat 
Commun 2014;5:3065.
92.  Kamaly N, Fredman G, Subramanian 
M, Gadde S, Pesic A, Cheung L, et al. 
Development and in vivo efficacy of 
targeted polymeric inflammation-
resolving nanoparticles. Proc Natl Acad 
Sci U S A 2013;110:6506-11.
93.  Bekkering S, Joosten LA, van der Meer 
JW, Netea MG, Riksen NP. The epigenetic 
memory of monocytes and macrophages 
as a novel drug target in atherosclerosis. 
Clin Ther 2015;37:914-23.
94.  Loscalzo J, Handy DE. Epigenetic 
modifications: basic mechanisms and role 
in cardiovascular disease (2013 Grover 
Conference series). Pulm Circ 2014;4:169-
74.
95.  Seligson DB, Horvath S, McBrian MA, 
Mah V, Yu H, Tze S, et al. Global levels of 
histone modifications predict prognosis 
in different cancers. Am J Pathol 
2009;174:1619-28.
208
Chapter 8
96.  Yamada Y, Nishida T, Horibe H, Oguri M, 
Kato K, Sawabe M. Identification of hypo- 
and hypermethylated genes related 
to atherosclerosis by a genome-wide 
analysis of DNA methylation. Int J Mol 
Med 2014;33:1355-63.
97.  Nebbioso A, Carafa V, Benedetti R, Altucci 
L. Trials with ‘epigenetic’ drugs: an 
update. Mol Oncol 2012;6:657-82.
98.  Shakespear MR, Halili MA, Irvine KM, 
Fairlie DP, Sweet MJ. Histone deacetylases 
as regulators of inflammation and 
immunity. Trends Immunol 2011;32:335-
43.
99.  Choi JH, Nam KH, Kim J, Baek MW, Park JE, 
Park HY, et al. Trichostatin A exacerbates 
atherosclerosis in low density lipoprotein 
receptor-deficient mice. Arterioscler 
Thromb Vasc Biol 2005;25:2404-9.
100.  De Santa F, Narang V, Yap ZH, Tusi BK, 
Burgold T, Austenaa L, et al. Jmjd3 
contributes to the control of gene 
expression in LPS-activated macrophages. 
EMBO J 2009;28:3341-52.
101.  Kruidenier L, Chung CW, Cheng Z, Liddle J, 
Che K, Joberty G, et al. A selective jumonji 
H3K27 demethylase inhibitor modulates 
the proinflammatory macrophage 
response. Nature 2012;488:404-8.
102.  Satoh T, Takeuchi O, Vandenbon A, 
Yasuda K, Tanaka Y, Kumagai Y, et al. The 
Jmjd3-Irf4 axis regulates M2 macrophage 
polarization and host responses against 
helminth infection. Nat Immunol 
2010;11:936-44.
103.  Mullican SE, Gaddis CA, Alenghat T, Nair 
MG, Giacomin PR, Everett LJ, et al. Histone 
deacetylase 3 is an epigenomic brake in 
macrophage alternative activation. Genes 
Dev 2011;25:2480-8.
104.  Hoeksema MA, Gijbels MJ, Van den 
Bossche J, van der Velden S, Sijm A, Neele 
AE, et al. Targeting macrophage Histone 
deacetylase 3 stabilizes atherosclerotic 
lesions. EMBO Mol Med 2014;6:1124-32.
105.  Consortium UIG, Barrett JC, Lee JC, 
Lees CW, Prescott NJ, Anderson CA, et 
al. Genome-wide association study of 
ulcerative colitis identifies three new 
susceptibility loci, including the HNF4A 
region. Nat Genet 2009;41:1330-4.
106.  Cao Q, Rong S, Repa JJ, St Clair R, Parks JS, 
Mishra N. Histone deacetylase 9 represses 
cholesterol efflux and alternatively 
activated macrophages in atherosclerosis 
development. Arterioscler Thromb Vasc 
Biol 2014;34:1871-9.
107.  Schoors S, De Bock K, Cantelmo 
AR, Georgiadou M, Ghesquiere B, 
Cauwenberghs S, et al. Partial and 
transient reduction of glycolysis by 
PFKFB3 blockade reduces pathological 
angiogenesis. Cell Metab 2014;19:37-48.
108.  Xu W, Deng YY, Yang L, Zhao S, Liu J, 
Zhao Z, et al. Metformin ameliorates 
the proinflammatory state in patients 
with carotid artery atherosclerosis 
through sirtuin 1 induction. Transl Res 
2015;166:451-8.
109.  Vasamsetti SB, Karnewar S, Kanugula 
AK, Thatipalli AR, Kumar JM, Kotamraju 
S. Metformin inhibits monocyte-to-
macrophage differentiation via AMPK-
mediated inhibition of STAT3 activation: 
potential role in atherosclerosis. Diabetes 
2015;64:2028-41.
110.  Riksen NP, Rongen GA. Preface. 
Novel targets and drugs to prevent 
atherogenesis and its consequences. Eur 
J Pharmacol 2015;763:1-2.
111.  Riksen NP, Tack CJ. The cardiovascular 
effects of metformin: lost in translation? 
Curr Opin Lipidol 2014;25:446-51.
209
Long term activation of the innate immune system in atherosclerosis
8

General discussion
Nederlandse samenvatting
Dankwoord
List of publications
Curriculum Vitae

CHAPTER 9
GENERAL CONCLUSION, DISCUSSION AND FUTURE 
PERSPECTIVES
214
Chapter 9
Despite the discovery of several new and effective lipid-lowering drugs, cardiovascular disease 
(CVD) is still the leading cause of death worldwide1. The main underlying pathological process 
of CVD is atherosclerosis. This has long been considered a vascular lipid storage disease, but 
is now characterized as a chronic inflammatory disorder of the arterial vessel wall. Ultimately, 
atherosclerosis can lead to complete vascular occlusion, myocardial infarction or stroke2,3. 
There is a strong need to better understand the inflammatory mechanisms in atherosclerosis, 
to identify novel drug targets that can be used in the prevention and treatment of 
atherosclerosis. Therefore, in this thesis, we aimed to explore a possible hypothesis for the 
cause of persistent inflammation in atherosclerosis. A recent groundbreaking discovery in 
immunology is that cells of the innate immune system are also able to build a long-term 
immunological memory. This phenomenon has been named ‘trained immunity’. In this thesis 
we propose that trained immunity contributes to the development of atherosclerosis and 
provide several lines of evidence to confirm this hypothesis.
The general view that only the adaptive immune system can build an immunological memory 
has recently been challenged4. In organisms lacking adaptive immunity such as plants 
and invertebrates, the innate immune system can build up resistance against reinfection. 
Interestingly, recent studies have shown that also in vertebrates, innate immune cells display 
persistent adaptive characteristics leading to non-specific memory, which has been termed 
‘trained immunity’5,6. It is likely that in evolution, trained immunity evolved as a primitive form 
of immune memory, aimed to provide additional protection of the host against reinfection. 
This could increase survival, especially in the newborn, who lacks a mature and functional 
adaptive immune system. However, there may also be a dark side to the reprogramming 
of innate immunity, in which increased inflammatory responses towards exogenous or 
endogenous stimuli could have deleterious effects, such as atherosclerosis7. 
This thesis describes a series of in vitro and in vivo experiments in which the role of trained 
innate immunity in atherosclerosis is explored. First of all, we used a well-established in vitro 
model of trained immunity to investigate whether endogenous pro-atherogenic substances, 
such as oxLDL and lp(a) can induce trained immunity. Secondly, the role of trained immunity 
was explored in two in vivo studies of patients with or without atherosclerosis. We translated 
our findings of oxLDL training in vitro to an in vivo study of patients with elevated levels of 
lipoprotein(a), a carrier of oxidized phospholipids in the circulation. Next, we studied the 
inflammatory and epigenetic phenotype of patients with symptomatic and asymptomatic 
atherosclerosis and matched healthy controls. Thirdly, we studied the role of the cholesterol 
synthesis pathway in trained immunity in vitro and pharmacological inhibition of this pathway 
using statins, a well-known drug for the treatment of CVD. 
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Part One: In vitro trained innate immunity and atherosclerosis
In chapter 3, we validated an in vitro model of trained immunity. We observed that 24 
hours of training and 6 days of resting is the most optimal condition for inducing a trained 
immunity phenotype in monocyte-derived macrophages. We used this model in chapter 4, 
where we showed that trained immunity can be induced by modified LDL (oxLDL as well 
as acetylated LDL), but not by native LDL8. Twentyfour hour exposure of human monocytes 
to low concentrations of oxLDL resulted in an increased production of pro-atherogenic 
cytokines and chemokines (such as IL-6, TNFα, IL-8, and MCP-1) upon re-stimulation of the 
cells 7 days later with TLR4 or TLR2 agonists. Additionally, mRNA expression of these and 
other atherogenic cytokines and proteases was significantly higher in the trained monocytes 
6 days after the initial stimulus. Furthermore, trained monocyte-derived macrophages 
displayed increased foam cell formation with higher expression of the scavenger receptors 
CD36 and SR-A and decreased expression of the cholesterol efflux transporters ABCA1 and 
ABCG1. Pathway analysis revealed that oxLDL-induced training is dependent on TLR2 and 
TLR4 activation, and activation of extracellular regulated kinase (ERK) and phosphoinositide 3 
kinase (PI3K). Further laboratory analyses revealed that oxLDL-induced trained immunity was 
mediated via epigenetic reprogramming at the level of histone methylation. Brief stimulation 
of human monocytes with oxLDL led to long-term enrichment of H3K4 trimethylation, which 
is a prototypical long-term activating epigenetic mark, on the promoters of pro-inflammatory 
cytokines and chemokines. Moreover, oxLDL induced trained innate immunity was completely 
prevented by co-incubation with a nonspecific histone methyltransferase inhibitor. 
For a translation of our observation to patients with atherosclerosis, it is important to consider 
the evidence that oxLDL is present in the circulation of patients with (an increased risk for) 
atherosclerosis. In other words, does oxLDL stimulate monocytes in the circulation in humans 
in vivo? It is generally believed that it is not possible to have high levels of oxLDL in the 
circulation for a long period of time. Main reasons are that the blood is rich in antioxidants, 
and it is rapidly cleared by the liver9. Furthermore, generally all vertebrates have preexisting 
circulating autoantibodies against oxLDL, that rapidly remove any oxLDL in the circulation. On 
the other hand, strong evidence does exist that smaller but detectable levels of modified LDL 
are present in the circulation10, for example in patients with metabolic syndrome, obesity, 
diabetes and CVD11. In obese children and adolescents, serum oxLDL levels are higher than 
in healthy controls, and interestingly, oxLDL levels decrease again upon strong weight loss12. 
In patients with diabetes, circulating levels of oxLDL were significantly higher than in control 
patients without diabetes13. In patients with CVD, the concentration of circulating minimally 
modified LDL (mmLDL) is associated with the severity of CVD. For example, plasma levels of 
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mmLDL are considered as a prognostic indicator of mortality in patients with heart failure14. 
Ehara et al. showed that plasma levels of mmLDL were significantly elevated in patients with 
CAD compared to a matched control group15. Furthermore, Holvoet et al. showed that LDL 
containing oxidation-specific epitopes could differentiate normal patients from patients with 
CAD, transplant atherosclerosis patients and acute coronary syndrome (ACS)16,17,18. More 
importantly, Tsimikas et al. showed that plasma oxLDL levels temporarily rise after an ACS 
with 35% in the first month after the event19. This is of special interest for our hypothesis, 
since a myocardial infarction (MI) is known to increase the risk for future events, by increasing 
the inflammatory response of monocytes and monocyte levels in the circulation20. 
Part Two: In vivo trained innate immunity and atherosclerosis
Although the role for circulating oxLDL in the pathogenesis of atherosclerosis is still a matter 
of debate, this is better established for other circulating lipoproteins which carry oxidized 
phospholipids, such as lipoprotein(a) [lp(a)]. In chapter 5, together with our collaborators 
from the AMC, we conducted a series of in vitro and ex vivo studies to investigate whether 
lp(a) can induce trained innate immunity. We showed that human isolated Lp(a) can induce 
a trained immunity phenotype in vitro in healthy monocytes, using the in vitro trained innate 
immunity method from chapter 3. Ex vivo analysis of circulating monocytes from patients 
with extremely elevated lp(a) levels showed a comparable pro-inflammatory phenotype, 
which is characterized by increased pro-inflammatory cytokine production and increased 
expression of activation markers on the membrane compared to monocytes isolated from 
control patients with normal Lp(a) concentrations. Furthermore, the expression of adhesion 
molecules, such as CCR7, was higher, which was accompanied with an increased binding and 
migration on cultured endothelial cells in vitro. Lp(a) is comprised of an LDL particle, which 
is covalently bound to an apo(a) particle, which subsequently carries oxidized phospholipids. 
Further mechanistic studies showed that not the apoB, but the apo(a) particle of lp(a) induced 
the training effect, and in more detail the oxidized phospholipids. When the oxPLs on apo(a) 
were blocked using a blocking antibody, the trained immunity phenotype was diminished.
Our collaborators from Amsterdam have performed in vivo imaging studies on the subjects 
with elevated lp(a) levels, that clearly demonstrate the potential implications of the pro-
inflammatory monocyte phenotype for atherosclerosis. First, monocytes from patients and 
controls were labeled with 99-Tm and reinfused in the subjects. The cells were tracked in 
vivo by use of SPECT-CT imaging. We showed an increased accumulation of monocytes from 
patients with elevated lp(a) in the arterial wall, whereas monocytes from healthy controls 
did not accumulate in the arterial wall. Finally, we also showed increased arterial wall 
inflammation in patients with elevated lp(a), measured by FDG-PET/CT, both in the aorta and 
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carotid arteries. 
What we didn’t show in chapter 5 is whether this trained innate immunity phenotype is 
dependent on the same epigenetic and metabolic changes as previously shown for oxLDL 
and β-glucan. This will be topic of future studies. An important clinical question that remains 
is whether pharmacological strategies that lower Lp(a), such as antisense oligonucleotides 
targeting apolipoprotein(a) or PCSK9 inhibitors, could reverse the inflammatory phenotype 
of the monocytes. 
The lifespan of monocytes is limited to only hours to days, while the trained immunity 
phenotype persists much longer in the circulation. Therefore, future studies should also 
comprise whether elevated levels of lp(a) can induce changes in the monocyte progenitor 
cells. As shown by van der Valk et al., oxLDL can induce increased myeloid skewing and 
increased CCR2 expression on HSC-derived monocytes21. Whether or not Lp(a) can also 
induce these effects, is currently not known. 
In conclusion, in chapter 3,4 and 5 we have shown that several cardiovascular risk factors 
and pro-inflammatory stimuli can induce trained innate immunity. The next approach 
was to study whether monocytes from patients with established atherosclerosis show a 
trained immunity phenotype, both in terms of cytokine production, as well as in terms of 
epigenetic and metabolic reprogramming. In chapter 6, we selected two groups of patients 
with atherosclerosis, one with symptomatic coronary atherosclerosis, and the other with 
asymptomatic carotid atherosclerosis, together with two matched control groups. We isolated 
circulating monocytes and extensively phenotyped these cells in terms of ex vivo cytokine 
production. We studied both epigenetic changes as well as metabolic reprogramming 
as underlying mechanism for increased inflammation. We demonstrated that circulating 
monocytes of patients with symptomatic atherosclerosis have a pro-inflammatory phenotype. 
This was associated with epigenetic remodeling at the level of histone methylation and 
increased expression of rate limiting enzymes of the glycolysis pathway and the pentose 
phosphate pathway. Interestingly, this pro-inflammatory phenotype was present only in 
patients with severe symptomatic coronary atherosclerosis. Patients with mild asymptomatic 
carotid atherosclerosis did not show a pro-inflammatory phenotype.
We studied the RNA expression profile of immune cells in PAXgene blood, which contains 
all inflammatory cells. In these samples, there was an increase in pro-inflammatory gene 
expression. Interestingly, also the gene expression of important rate-limiting glycolytic 
enzymes was increased, which was correlated to the increased pro-inflammatory response. 
This suggests that not only in plaque macrophages, intracellular metabolism is switched to 
increased glycolysis and correlates to increased inflammation as has been shown before22, 
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but that this could also be detected in circulating cells. Unfortunately, we only stored 
PAXgene tubes for RNA analysis and did not store CD14+ selected monocytes. Therefore, we 
can only speculate on the origin of cells that have both increased glycolysis and increased 
inflammation. In future studies, this will certainly be a topic of interest. 
To our surprise, the analysis of epigenetic marks showed lower H3K4me3 on pro-inflammatory 
genes in patients with established atherosclerosis compared to controls. Lower activating 
marks but higher gene expression could only mean that there should also be lower repressive 
marks present, such as H3K27me3 and H3K9me3. Indeed, analysis of the repressive marks 
H3K27me3 and H3K9me3 showed profound enrichment of these marks on the promoter 
region of TNFα. H3K27me3 on TNFα correlated negatively with TNFα RNA expression, 
whereas there was no correlation with H3K4me3, indicating that repression rather than 
activation marks in these patients drive the pro-inflammatory response. It would be of great 
interest to perform whole genome ChIP-sequencing on these samples to see which pathways 
are up- or down-regulated in levels of activating or repressive histone marks. Also, it would 
be of interest to study more histone marks. Unfortunately, lack of sample prevented us from 
doing this. 
One important fact complicating this story is the difference in medication use between the 
symptomatic patients and controls. Almost all patients were taking statins and controls were 
mostly statin-free. Interestingly, statins are known to decrease the inflammatory response 
(as explained in part three) and these patients still had an elevated inflammatory response. 
Therefore, this will not explain the differences observed regarding cytokine production and 
statins might even dampen the original effect. However, statins are known to induce changes 
in epigenetic marks, such as H3K27Ac but also H3K4me3, H3K27me3 and H3K9me3 23–27. We 
therefore cannot exclude the influence of statins on the results in this study. In future studies, 
we will need to study the effect of statins on epigenetic marks in patients in vivo. 
Although levels of histone methylation and acetylation have been studied in plaques before28–30, 
only two studies have studied the association between histone marks in circulating cells and 
CVD. First, Gómez-Uriz et al. showed that in patients with or without stroke, H3K4me3 and 
H3K9Ac did not significantly differ in the total blood cell population, although there seemed 
to be a trend for increased H3K4me3 in stroke patients compared to control31. More striking 
was the correlation between H3K4me3 and H3K9Ac levels and the levels of circulating TNFα. 
In our study, we found a negative correlation between H3K27me3 and TNFα RNA expression 
levels, as well as a correlation between H3K4me3 and H3K27me3. This indicates that 
epigenetic remodeling in patients with CVD is associated with levels of pro-inflammatory 
markers. Secondly, Shen et al. showed that in patients with acute ischemic stroke, levels 
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of acetylated histone H3 in PBMCs were lower than in healthy controls. Unfortunately the 
authors did not explain any possible mechanism32. Where DNA methylation in circulating 
cells in CVD are widely studied33, there is a great gap in studies to histone modifications in 
circulating cells in relation to CVD. It is believed to be an important epigenetic mechanism 
involved. In the future, we hope to add new insights in this mechanism. We have seen that 
trained immunity in vitro does not completely translate to the in vivo situation in patients 
with atherosclerosis. Different risk factors might induce different epigenetic changes. A 
broader study to histone modifications in all risk factors for atherosclerosis will be necessary. 
When the results of both in vivo studies are combined, we might hypothesize that trained 
immunity does not play a role in the initiation of atherosclerotic plaques, but rather in the 
progression and destabilization. This fits with the observation in previous clinical studies that 
elevated lipoprotein(a) is not associated with early atherosclerotic lesions (e.g. carotid IMT) 
whereas elevated lp(a) is consistently associated with cardiovascular events, which mostly 
result from vulnerable atherosclerotic plaques34–36. We have also shown that in asymptomatic 
subjects with plaques on carotid ultrasound, there is no increased inflammation present in 
plasma or in monocytes. In patients with more severe symptomatic coronary atherosclerosis 
as well as in patients with elevated levels of lp(a), however, a pro-inflammatory phenotype 
can be clearly detected. 
Part Three: Pharmacological intervention and trained innate immunity
The cholesterol synthesis pathway in trained immunity
The induction of trained 
immunity is mediated by 
activation of both immune and 
metabolic pathways that results 
in epigenetic rewiring of cellular 
functional programs7,37,38. Using 
analysis of transcriptomics and 
metabolomics data, several 
pathways were identified as 
indispensable for the induction 
of trained immunity by β-glucan 
in monocytes (Figure 1)39 . 
Interestingly, in b-glucan trained 
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monocytes, the cholesterol synthesis pathway was significantly upregulated. In chapter 7, 
we explored the role of the cholesterol synthesis pathway in trained immunity, using two 
different approaches. First, we inhibited the cholesterol synthesis pathway in the in vitro 
trained immunity model of chapter 3 with statins and other inhibitors of the pathway more 
downstream. In vitro, preincubation of monocytes with fluvastatin before beta-glucan or 
oxLDL training prevented the increased cytokine production upon restimulation on day 6. 
Also, the switch to increased glycolysis as well as the increase in foam cell formation was 
inhibited. Further study revealed that the accumulation of intermediates in this pathway, in 
particular mevalonate, was responsible for inducing the training effects. Transcriptome and 
epigenome analysis showed that incubation of healthy monocytes with mevalonate alone 
mimicked the trained immunity phenotype. This indicates that next to fumarate39, mevalonate 
is an essential factor in the metaboloepigenetics of trained immunity. Secondly, we studied 
monocytes of patients with a genetic deficiency of mevalonate kinase. These patients suffer 
from the Hyper IgD Syndrome (HIDS), one of the many hereditary periodic fever syndromes. 
HIDS patients carry a mutation in mevalonate kinase that is causative for the clinical 
presentation, which is characterized by symptoms as febrile attacks, skin lesions, arthritis and 
lymphadenopathy. The mutation in mevalonate kinase leads to accumulation of mevalonate 
and results in elevated excretion of mevalonic acid during attacks, a process which can be 
diminished by statins. Since patients with HIDS accumulate mevalonate intracellularly, we 
hypothesize that monocytes from these patients could resemble a (partly) trained immunity 
phenotype. RNA sequencing and ChIP sequencing analyses showed that indeed monocytes 
from patients with HIDS also show a trained immunity phenotype, characterized by increased 
cytokine expression as well as an upregulated mTOR and glycolysis pathway. 
The upregulation of the cholesterol synthesis pathway only partly explains the molecular 
mechanisms of trained immunity. Therefore, in inflammatory diseases characterized by a 
trained immunity phenotype, treatment with statins might be a promising pharmacological 
strategy. Statins, HMG-CoA reductase inhibitors, are a widely used drug to treat patients at 
risk for CVD, especially for the treatment of elevated LDL-cholesterol. In addition, statins 
are increasingly prescribed to patients with other systemic inflammatory diseases leading 
to increased arterial wall inflammation, such as elevated levels of remnant cholesterol or 
lipoprotein(a), or for example patients with ankylosing spondylitis. When patients with 
ankylosing spondylitis were treated with statins, the arterial wall inflammation measured by 
FDG-PET/CT significantly decreased upon treatment. Additional treatment to lower the other 
pathways increased in trained immunity would be needed as well as reversing the epigenetic 
changes induced through these pathways.  
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FUTURE PERSPECTIVES
We now know that in vitro, in addition to the previously described PAMPs β-glucan and BCG, 
atherogenic DAMPs such as oxLDL and Lp(a) can induce trained innate immunity. In vivo, 
we have shown that monocytes from patients with elevated lp(a) show a trained immunity 
phenotype and that monocytes from patients with symptomatic atherosclerosis show trained 
immunity by an increased pro-inflammatory phenotype and epigenetic and metabolic 
rewiring. However, the causal role for trained immunity in atherosclerosis still needs to be 
proven. Therefore, animal studies are needed that allow pharmacological modulation of the 
trained phenotype. For example, diet induced trained immunity as described in chapter 8 or 
infection. Also, the onset and progression of atherosclerosis should be studied. When trained 
immunity is indeed inducing increased atherosclerosis, the search for proper intervention 
will start. 
Furthermore, the role of trained immunity in atherosclerosis in humans in vivo needs to be 
explored in the context of other traditional and non-traditional CV risk factors. Traditional 
risk factors should include diet and lipid-driven disorders, such as low levels of HDL, high 
triglycerides and elevated levels of LDL or other traditional risk factors such as previous 
events40,20. Examples of non-traditional risk factors comprise of chronic inflammatory diseases 
such as rheumatoid arthritis (RA), gout, ankylosing spondylitis, diabetes, HIV and other 
chronic or acute infections, which might share the common mechanism trained immunity41. 
A third layer in future studies to trained immunity in atherosclerosis will be the role of the 
bone marrow. As mentioned before, a trained immune phenotype can still be observed in 
circulating monocytes up to three months after vaccination of healthy subjects with BCG6. 
This period greatly exceeds the half-life of circulating monocytes, strongly suggesting that 
training already occurs at the level of the bone marrow progenitors. Indeed, in preclinical 
studies have already shown that the epigenome of myeloid progenitor cells can be modified 
by diet for prolonged periods of time, leading to increased atherosclerosis in mice42,43. 
Whether this also takes place in humans in vivo is topic of future studies (Figure 2).
Subsequently, the mechanism of trained immunity needs to be elucidated in more detail to 
be able to construct biomarkers that might facilitate personalized medicine and to develop 
novel drugs for treatment or prevention of established atherosclerosis. 
Histone modifications as biomarkers in personalized medicine
How can the increasing knowledge about the role of epigenetic reprogramming in the 
pathophysiology of atherosclerosis be exploited to improve patient care? Recent developments 
in the fields of oncology and hematology offer a glimpse of the various possibilities. For 
example, the presence of specific histone modifications can be used to predict the outcome 
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in selected patient groups. This was first described for patients with prostate carcinoma44,45, 
but recently also in much more cancer types46. Here we can learn from the oncology field, 
since the amount of studies to the role of histone modifications in disease and as biomarker 
is greatly higher than the amount of studies in the cardiovascular field. In future, one can 
dream about being able to study patterns in the epigenetic marks and predict outcome based 
on histone modifications and design a personalized treatment strategy, making use of a wide 
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Figure 2: the induction of trained immunity by traditional and non-traditional risk factors for CVD 
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range of epigenetic drugs available.
 
Pharmacological intervention
Most importantly when studying epigenetic remodeling is that the enzymes that act as 
the ‘writers’ (DNA and histone methylases and acetylases) and ‘erasers’ (DNA and histone 
demethylases and deacetylases) of the epigenetic code are amenable to pharmacological 
modulation. This offers a potentially important novel target for pharmacotherapy47,48. 
A few nonselective inhibitors of HDAC’s and of DNA methyltransferases are already in use 
in regular patient care in oncology and haematology47,48. In preclinical studies, nonselective 
HDAC inhibitors have been shown to reduce inflammation and disease severity in animal 
models, for example for arthritis, septic shock and inflammatory bowel disease 64. Preclinical 
proof of the concept that ‘epigenetic drugs’ can also affect the development of atherosclerosis 
was provided by Choi et al in LDLr-/- mice 65. Treatment with the nonselective HDAC inhibitor 
trichostatin A increased atherosclerotic lesion size, and increased macrophage accumulation 
in aortic sinus 65. This finding contradicts the beneficial effects of myeloid HDAC3 deletion 
on atherosclerosis formation 58 and highlights two important issues in epigenetic drug 
development. Firstly, most writers and erasers have many difference isoforms that can 
have opposite effects. Secondly, similar isoforms can have opposing effects in different 
cell types: genetic deletion of HDAC3 in myeloid cells is associated with larger, but more 
stable atherosclerotic lesions 20, whereas deletion of this similar isoform in endothelial cells 
enhances atherosclerosis development 55. Therefore, techniques that enable cell-specific or 
plaque specific targeting of drugs, such as nanoparticles, will facilitate optimal future use of 
epigenetic drugs 66-68. For example, Duivenvoorden et al used reconstituted HDL particles 
to directly target the atherosclerotic plaque macrophage and increase the potency of anti-
inflammatory statin therapy 69. They showed that statin-loaded recombinant HDL particles 
accumulate in atherosclerotic lesions in which they specifically target plaque macrophages, 
and thereby inhibit inflammation and plaque progression. Now we know how important the 
role of the cholesterol synthesis pathway is in trained immunity, locally delivering statins to 
plaques becomes even more attractive. Very recently, Zheng et al have performed preliminary 
studies to the therapeutic options of treatment in humans in vivo with this nanoparticle. 
In humans in vivo, labeled rHDL targets the plaques in the arterial wall, whereas plaque-
free areas were free of rHDL49. These clinical findings may guide future nanomedicine 
development using HDL particles for drug delivery in atherosclerosis in humans.
Next to the difficulties in developing specific histone acetylation inhibitors, targeting histone 
methylation is an even greater challenge. To date, 28 lysine methyltransferases have been 
identified that catalyze histone methylation 62. These enzymes generally target specific lysine 
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residues and can either promote or repress gene transcription, depending on the specific 
lysine residue involved. In contrast to HDAC inhibitors and DNA methyltransferase inhibitors, 
(selective) histone methyltransferase inhibitors are not yet available for use in humans. 
Therefore, one of the challenges of the next decade is the development of more specific 
inhibitors of epigenetic writers and erasers, as well as reliable techniques that allow for 
targeting of specific cell types, such as monocytes and macrophages. Only with the availability 
of these methodologies it will be possible to use the exciting properties of trained immunity 
to optimize pharmacotherapeutic strategies for patients with (risk factors for) cardiovascular 
diseases.
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Atherosclerose, ofwel aderverkalking
Atherosclerose, vroeger aderverkalking genoemd, is een chronische ontstekingsziekte van de 
vaatwand. Atherosclerose ontstaat doordat witte bloedcellen cholesterol opeten. De witte 
bloedcellen kunnen dit niet goed verwerken, waardoor ze gaan plakken aan de binnenkant 
van de bloedvaten. De witte bloedcellen zorgen dan voor een ontsteking. Ze produceren 
stoffen die nog meer witte bloedcellen aantrekken, waardoor ze zich gaan stapelen. Er 
ontstaat een plaque (figuur 1). 
We weten dat witte bloedcellen die rondzwemmen in het bloed bij patiënten met 
atherosclerose veel actiever zijn dan witte bloedcellen van gezonde mensen. Deze witte 
bloedcellen gaan makkelijker door de wand van de bloedvaten heen. Ook maken ze sneller 
en meer ontstekingsstoffen. In mijn thesis heb ik onderzocht hoe de witte bloedcellen nu 
precies actiever worden en of we deze activiteit kunnen remmen. 
Twee immuunsystemen
Er zijn heel veel verschillende soorten witte bloedcellen (figuur 2). De witte bloedcellen die 
cholesterol eten heten monocyten of macrofagen en horen bij het aangeboren immuunsysteem. 
Zoals de naam al zegt, heb je deze cellen al vanaf je geboorte, ze zijn aangeboren. Deze cellen 
werken niet heel specifiek, maar ruimen alles op wat lichaamsvreemd is. Ook hebben we een 
aangeleerd immuunsysteem met een geheugen. Dat geheugen bouw je elke keer op als je 
ziek bent of bijvoorbeeld met een vaccinatie. Dan krijg je een klein beetje ziekteverwekker, 
waarvan je niet ziek wordt, maar die je aangeleerde immuunsysteem wel onthoudt. Je 
lichaam maakt een geheugencel aan. De volgende keer dat je deze ziekteverwekker krijgt, 
ruimt je lichaam deze sneller op en word je minder ziek.  
Monocyten met geheugen
Tot vier jaar geleden dacht men dat cellen van het aangeboren immuunsysteem geen 
geheugen konden hebben. Nu blijkt dat anders te zijn: als monocyten een klein beetje 
lichaamsvreemde stof tegenkomen, gaan ze zich hierna anders gedragen, hyperactief. Dit 
is al aangetoond voor een aantal vaccins, die hierdoor beschermen tegen meer dan alleen 
Plaque
Figuur 1: overzicht van de verschillende fases van atherosclerose ©Siroon Bekkering
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de ziekteverwekker waarvoor het vaccin gemaakt is. Dit geheugen is niet specifiek, zoals bij 
het aangeleerde immuunsysteem, maar de cellen gaan zich actiever gedragen tegenover alle 
nieuwe indringers. 
Mijn hypothese en onderzoek in het lab
In mijn thesis vroeg ik me nu af: ‘Zien monocyten sommige vormen van cholesterol bijvoorbeeld 
als lichaamsvreemd en ontwikkelen ze hierdoor een vergelijkbare hyperactiviteit?’ In de 
afgelopen jaren onderzocht ik deze hypothese op verschillende niveaus. Het eerste level 
is in het lab, in vitro noemen we dat. Ik gebruikte hiervoor monocyten uit het bloed van 
gezonde mensen, bijvoorbeeld van de bloedbank. Ik bracht monocyten van gezonde mensen 
in contact met verschillende vormen van cholesterol. Daarna keek ik of deze cellen zich dan 
anders gingen gedragen dan monocyten die in hun ‘gewone’ groeimedium werden gehouden, 
zonder cholesterol. Ik keek of ze meer ontstekingsstofjes gingen maken, en of de cellen dus 
hadden onthouden dat ze een paar dagen eerder met cholesterol in contact waren gekomen. 
En inderdaad, 6 dagen na het eerste contact met cholesterol waren de cellen nog steeds 
hyperactief. Ze maakten meer ontstekingsstoffen als ze daarna een bacterie tegenkwamen 
en gingen ook meer cholesterol opeten. Het leek wel alsof ze een geheugen hadden: na 
hun eerste ontmoeting met cholesterol leken ze in het volgende contact veel agressiever te 
reageren. 
Monocyten en Macrofagen
T cel
B cel
Antilichamen
Aangeboren Immuunsysteem Aangeleerd Immuunsysteem
Bacterie
Alarm!
Bacterie
+
Geheugencel
Geheugencel
B-cel
Geheugencel
Uren Dagen
Figuur 2: Twee immuunsystemen werken verschillend in specificiteit en snelheid: het aangeboren 
immuunsysteem werkt snel (binnen een paar uur) maar aspecifiek: het ruimt alles op wat 
lichaamsvreemd is. Het aangeleerde immuunsysteem werkt via antilichamen, die worden gemaakt 
door B en T-cellen. Nadat deze cellen voor de eerste keer een antilichaam hebben gemaakt, wordt 
er een geheugencel gemaakt, die sneller werkt bij de volgende keer dat je ziek wordt ©Siroon 
Bekkering.
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Vlaggetjes op het DNA
Je kan het geheugen zien als een soort vlaggetjes op het DNA. Er staan groene vlaggetjes op 
het DNA bij processen die aan staan in de bloedcel en rode vlaggetjes bij processen die uit 
staan (figuur 3). Zo weet de dirigent van de cel wat er wel en niet gemaakt moet worden. 
Maar als er te veel vlaggetjes staan, of als ze op de verkeerde plek staan, kan de cel hyperactief 
worden. Dan maakt het bijvoorbeeld te veel ontstekingsstoffen. De aanraking met cholesterol 
zorgt in deze monocyten voor het plaatsen van veel meer groene vlaggetjes. Dit betekent dat 
er veel meer eiwitten voor ontsteking in de cel gemaakt worden. Gelukkig zitten de vlaggetjes 
niet vastgelijmd, maar kunnen ze er ook weer afgehaald worden. Onderzoek hiernaar is dus 
veelbelovend, want er kunnen ook medicijnen worden gemaakt. 
Onderzoek in patiënten
In het tweede deel van mijn thesis ging ik ook kijken naar de monocyten van patiënten met 
hart- en vaatziekten. Dit deed ik in twee verschillende patiëntengroepen: in de eerste studie 
onderzocht ik patiënten die al veel plaques in hun aderen hebben en gezonde controles 
die dat niet hebben. Uit het bloed van deze mensen haalde ik de witte bloedcellen en ik 
onderzocht de (hyper)activiteit: hoeveel ontstekingsstofjes maken de witte bloedcellen 
van mensen met en zonder plaques? Daarna onderzocht ik het vlaggetjespatroon van de 
witte bloedcellen. Ik ontdekte dat er verschillen waren tussen de patiënten en de gezonde 
controles. Een eerste hint dus dat dit geheugen en de vlaggetjes misschien wel een rol spelen 
in het verloop van de ziekte. 
Een speciaal soort cholesterol: lipoprotein(a)
De tweede patiëntenpopulatie die ik bestudeerde waren patiënten met verhoogd 
lipoprotein(a). Dit is een speciaal soort cholesterol, waarvan we weten dat het kan zorgen 
voor activatie van de monocyten. Maar hoe dit precies werkt, en of dit misschien ook werkt 
DNA
DNA
Aan
UitMonocyte
Figuur 3: Vlaggetjes op het DNA in een cel bepalen of het gen aan staat (groene vlaggetjes) of uit 
(rode vlaggetjes). Zo kan de dirigent van de cel weten welke eiwitten er gemaakt moeten worden en 
welke niet ©Siroon Bekkering.
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via de vlaggetjes, dat wisten we nog niet. Ik bekeek hoe monocyten van gezonde mensen 
reageerden als ze met dit lipoprotein(a) in aanraking kwamen. Net als in het eerste gedeelte 
van mijn thesis gingen de monocyten zich hyperactief gedragen. En in de patiënten was dit 
net zo! De monocyten kropen eerder door de vaatwand en zorgden voor meer ontsteking. 
We zijn helaas nog niet toegekomen aan het onderzoeken van het vlaggetjespatroon in deze 
patiënten, dus ik hoop dat dat snel in de toekomst gaat gebeuren!
In het derde deel van mijn thesis dook ik meer in de mechanismen van dit hele proces: hoe 
werkt dit? Wat is nou anders in deze cellen met hyperactiviteit? Welke processen spelen 
hierbij een rol? Daarop zal ik verder nu niet in gaan. 
Het toekomstplaatje
Uiteindelijk is het natuurlijk de droom om een persoonlijk vlaggetjespatroon te kunnen 
ontdekken in verschillende patiënten die risico hebben op hart- en vaatziekten. Hopelijk kan 
de patiënt dan persoonlijke medicijnen krijgen om de cellen weer in normale staat te krijgen, 
om het teveel aan vlaggetjes te verwijderen. Want dat is het mooie: je wil niet de functie van 
de witte bloedcellen helemaal platleggen, omdat zij ons eigenlijk moeten beschermen tegen 
allerlei lichaamsvreemde stoffen zoals bacteriën. Als je het teveel aan vlaggetjes eraf haalt, 
haal je alleen het hyperactieve deel weg, en blijft de cel alsnog zijn werk doen. Je drukt als 
het ware op de resetknop! 
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Johanneke, Katharina, Kathrin T, Lily, Lisa, Marije, Mariska, Mark S, Marlies, Michelle, 
Monique, Quirijn, Reinout, Rinke, Rob H, Ruud, Sanne, Tania, Thalijn, Theo, Wouter, 
Yvette, Valerie, Vesla, and I sincerely hope I didn’t forget anyone. Thanks for being the best 
collegues one can imagine. The atmosphere on the lab is really friendly and helpful. 
Lieve collega’s uit het AMC, in het bijzonder ‘Erik’s Amazing Group’. We hebben heel wat 
bijzonders opgezet samen, een samenwerking die echt heel veel potentie heeft. Keep it 
going! Ook de collega’s van G1 bedankt! Met een onmogelijke structuur aan wie voor wie 
werkt, zijn jullie toch een hechte groep, echt heel fijn. 
Lieve Hanne en Marjon, mijn balletvriendinnetjes, maar zoveel meer. Bedankt voor jullie 
eeuwige luisterend oor, jullie kritische blik en het feit dat jullie er altijd voor me zijn. Ik 
hoop dat we nog jaren lekker samen koken en elkaar scherp houden. Hanne, je bent een 
geweldige tekenares, en ik wilde niemand anders dan jouw werk voor mijn voorkant! 
Marjon, ik mis onze logeerdates nog steeds, maar ik geniet nu van onze gesprekken op de 
kookdates. You rock! 
Lieve Iris, we go way back! Ik ben blij dat we al meer dan 10 jaar vriendinnetjes zijn en 
zoveel gemeenschappelijke delers hebben! Ik hoop dat we nog lang onze liefde voor 
Scandinavie kunnen delen en vintage markten en lindyhop en wetenschapscommunicatie 
en Haruki Murakami en dropchocola en… en… 
Lieve superbetas, Daan, Sander, Wouter, Arne, Renee, Inge en Marije jullie zijn me een 
stelletje. Ik geniet ervan hoe verschillend we allemaal zijn, en het is inspirerend hoeveel 
kanten je op kunt met 1 en dezelfde studie. Maar meer geniet ik ervan hoe we elkaar elk 
jaar weer opzoeken, dit jaar wat meer door alle promoties. Ik hoop dat we dit volhouden tot 
we later groot zijn en met grote families in een Landall greenpark huisje moeten gaan zitten. 
Lieve MMBers, Ivo, Lisette, Gerdien, Sanne, Janneke, Dennis en Andrea, met jullie deelde 
ik een jaar stage, maar wat een toffe groep! Ik hoop altijd op elk lab waar ik kom dat de 
studenten het net zo goed met elkaar kunnen vinden als wij, want het was echt een super 
leuk jaar. Ik ben blij dat we elkaar (al dan niet op afstand) nog steeds volgen!
Lieve Kenza, toen we 15 waren en in de bus naar Italië zaten met het superman poppetje 
werden we vriendinnetjes omdat we allebei echt iets super stoms heel grappig vonden. Ik 
ben zo blij dat we weer in dezelfde stad wonen en de draad weer konden oppakken! 
I love onze koffiedates en bioscoopdates en dubbeldates en vooral goede gesprekken! 
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Dankwoord
Lieve Lisette, jij inspireert me doordat je keuzes maakt die moeilijk zijn en die niet iedereen 
durft. Ik vind het super fijn om de moeilijkheden in het werk te delen en aan de andere kant 
alle gezellige dingen in de stad. Ik ben vet trots op je.
Lieve Viva, als er iemand inspirerend is, dan ben jij het! Maar het is dan ook terecht je baan 
;) Ik ben blij dat ik jou ook kan inspireren en dat we samen enorm hebben genoten om te 
wonen op de Willem van Noort. Ik ben blij dat je niet heel ver weg bent gegaan nu en dat 
we onze gesprekken met wilde ideeën en reisuitwisselingen voort kunnen zetten. 
Lieve familie, jullie zijn me dr eentje (dit wordt een lange alinea ;)). Het is nooit saai, maar 
we blijven altijd dichtbij, het ene moment zien we elkaar veel, het andere wat minder. 
Maar jullie zijn er altijd voor me en dat bewonder ik echt enorm. Pap en mam, bedankt 
dat jullie me hebben gestimuleerd als kind om nerdy te zijn en me door het leven hebben 
geleerd dat je nooit te oud bent om te leren. Lieve broers en zussen, van jong naar oud. 
Lieve Leah, bedankt dat je me zo goed begrijpt en dat we zo hetzelfde denken. Je inspireert 
me doordat je zo volwassen bent en ik heb helemaal niet door dat we 8 jaar verschillen. 
Lieve Rowan, al vroeger tijdens onze strijd om spelletjes die jij altijd won, wist ik dat jij een 
goede onderhandelaar zou worden. Dat je nu de economie in gaat verbaast me dan ook 
niets en maakt me heel trots op jou! Lieve Avner, het is zo fijn dat we zo dicht bij elkaar 
wonen en altijd bij elkaar terecht kunnen. Bedankt voor je wijze woorden altijd en je hebt 
me zelfs aan het sporten gekregen! ;) Lieve Persis, wij zitten zo dicht op elkaar, zoals we al 
zeiden hadden we vroeger al weinig vrienden nodig, want we hadden elkaar. Ik vind het 
super inspirerend dat je schrijver bent en ik zal altijd tegen je op kijken. Vergeet niet dat 
Utrecht stiekem best dichtbij is! Lieve Renzo, er is heel veel moed en kracht voor nodig wat 
jij allemaal meemaakt. Dat bewonder ik! Lieve Ezra, je inspireert me door hoe je je leven 
inricht met je kids en jezelf. Je bent super lief en altijd positief, fijn dat we zo dicht bij elkaar 
wonen! Lieve Jarno, als er iemand hard kan werken, ben jij het. Gaaf wat jij allemaal hebt 
bereikt door zelf iets heel graag te willen! Aan allemaal, onder andere om jullie ben ik weer 
in Utrecht komen wonen. Ik vind het een heerlijk gevoel om af en toe bij elkaar op de koffie 
te kunnen, en elkaar in ieder geval dichtbij te hebben. En dat jullie ook altijd heel erg druk 
zijn, waardoor ik niet de enige ben ;)
Lieve Ad, Roos en Megan, jullie kreeg ik er als schoonfamilie bij en ik voel me enorm thuis 
in jullie gezin! Bedankt dat ik in jullie hechte familie wordt opgenomen, en ik hoop dat we 
nog veel avonturen mogen beleven samen! 
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Lieve lieve Thom. Wat moet ik zonder jou. Ik leer van je rust en je wijze woorden, maar 
bovenal geniet ik van al onze 100 hobbies samen. Door jou heb ik Lindyhop leren kennen, 
wat me de grootste smile geeft als wij samen dansen. Bedankt dat je er voor mij bent in al 
mijn ups en downs (en PhD life kent er nogal wat), en dat we nu samen verder genieten van 
het leven in Utrecht. Ik hou van jou!
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CURRICULUM VITAE
Siroon Bekkering werd op 26 augustus 1988 geboren in Houten. Na het behalen van 
haar Gymnasium-diploma aan het Stedelijk Gymnasium te Utrecht in 2005, deed ze een 
oriëntatiejaar aan de Evangelische Hogeschool in Amersfoort. Dat was maar goed ook: vóór 
dit oriëntatiejaar was zij van plan Griekse en Latijnse taal en cultuur te gaan studeren. Na het 
oriëntatiejaar wilde zij liever de bèta kant op. 
In 2006 begon zij aan de studie Scheikunde aan de Radboud Universiteit in Nijmegen, maar 
na een half jaar switchte ze naar Moleculaire Levenswetenschappen (MLW). Tijdens haar 
bachelor deed ze een stage op de afdeling Experimentele Urologie onder supervisie van 
Gerald Verhaegh en behaalde haar bachelor in 2009. Tussen haar bachelor- en master-studie 
deed zij een bestuursjaar bij de Nijmeegse Studentenvereniging de Navigators (NSN). 
In 2010 ging zij verder met haar master Molecular Life Sciences, specialisatie research. Haar 
eerste stage deed zij op de afdeling Laboratorium voor Kindergeneeskunde en Infectieziekten 
(LKI) op het Radboudumc onder supervisie van Dimitri Diavatopoulos, in samenwerking 
met de afdeling Medische MicroBiologie (MMB) op het UMC Utrecht onder supervisie van 
Susan Rooijakkers. Hier deed zij onderzoek naar ontsnapping aan het immuunsysteem van 
de bacterie Streptococcus Pneumoniae. Haar tweede stage deed zij in Kopenhagen in het 
Rigshospitalet onder supervisie Niels Borregaard, naar de localisatie van het eiwit ADAM8 in 
de neutrofiel. In 2012 studeerde zij cum laude af. 
Na haar studie begon zij aan haar PhD op de afdeling Interne Geneeskunde van het 
Radboudumc. Haar onderzoek is in deze thesis beschreven en gepresenteerd op vele nationale 
en internationale congressen. Haar onderzoek besloeg laboratorium werk, gecombineerd met 
patiëntenstudies. Siroon werkte samen met vele andere ziekenhuizen voor deze doeleinden, 
onder andere met het Academisch Medisch Centrum (AMC) te Amsterdam, het Erasmus MC 
te Rotterdam, het Leiden Universitair Medisch Centrum (LUMC) en het Canisius Wilhelmina 
Ziekenhuis (CWZ) te Nijmegen. Ze treinde het hele land door voor samples. 
Na haar PhD ging zij begin 2016 aan de slag als post-doc bij de afdeling Vasculaire Geneeskunde 
in het AMC onder begeleiding van prof. Erik Stroes. Zij continueert hier haar onderzoek uit 
haar PhD naar de rol van geheugen in het aangeboren immuunsysteem bij mensen met hart- 
en vaatziekten. De samenwerking met het Radboudumc is nog steeds nauw. 
Siroon woont samen met Thom in Utrecht.
